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Abstract 
The prevalence of overweight (BMI >25 kg/m²) and obesity (BMI >30 kg/m²) are increasing on a global 
scale, and as a consequence, obesity among women of reproductive age has also increased within the 
last decades. Obesity before and during pregnancy is associated with a higher risk for the mother and 
the unborn child to develop pregnancy related complications, including gestational diabetes and 
disturbed fetal growth. Abnormal fetal growth has been linked to placental dysfunction and can translate 
into childhood and adolescence health issues, resulting in high socio-economic costs.  
Obesity and pregnancy are both linked to a state of increased inflammation and oxidative stress, which 
in case of pregnancy may be relevant to initiate the birth process at the end of pregnancy, but 
concomitant with obesity, can also attribute to placental dysfunction. The placenta provides essential 
tasks during pregnancy in both oxygen and nutrient supply, as well as waste removal and contributes 
to the success of pregnancy also by the production of hormones. In order to properly fulfill its function, 
placental cell homeostasis, structure and vascularization are of tremendous importance. However, it is 
still not fully understood how maternal obesity (MO) affects placental cells and processes like 
vascularization and placental transfer capacity. Therefore, we aimed to decipher the effects of MO on 
the placental feto-maternal transfer zone which constitutes the interface for transport of oxygen, 
nutrients and removal of waste products between maternal and fetal circulation. 
In order to address these questions, we induced obesity in C57BL/6N mice via feeding a high fat diet 
(HFD) after weaning until the end of the experiment and collected serum, placentas and epigonadal 
white adipose tissue (egWAT) for analyses at various gestation days (E11.5, E15.5 and E18.5). Lean 
mice, receiving a standard diet (SD), served as control.  
We discovered that in obese dams, gestation was prolonged for about 1 day compared to lean dams, 
and speculate that this might be due to a reduced leukocyte-infiltration of placentas and pro-
inflammatory factor expression in egWAT of obese dams compared to lean dams shortly before 
parturition (E18.5). Furthermore, in our mouse model of maternal obesity, embryos of obese dams 
developed an intrauterine growth restriction (IUGR) at the beginning of the third trimester of gestation 
(E15.5). At the same time, protein and mRNA level of endothelial cell (EC) marker were reduced in 
placentas, and stereological analysis revealed impaired vascularization in placentas of obese dams. 
This was accompanied by increased EC senescence in the transfer zone of placentas under MO. We 
also found elevated interleukin-6 (IL-6) level in maternal serum and observed a trend towards an 
increase in IL-6 mRNA and protein level in egWAT of obese dams compared to controls, suggesting 
this tissue as the source of elevated circulating IL-6 level. In cell culture assays using human placental 
EC, we then confirmed that stimulation with IL-6 can induce senescence, suggesting a link between 
elevated serum IL-6 level, placental EC senescence and impaired placental vasculature.  
Based on the findings regarding IL-6 induced EC senescence in vitro and altered placental 
vascularization in vivo, we subjected obese dams to an anti-IL-6 signaling antibody therapy. We found 
that under this therapy, placental IL-6 protein level were elevated and down-stream signaling marker 
level seemed reduced, which indicates successful IL-6 signaling blockade. However, antibody therapy 
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did not prevent lower fetal weight at E15.5, and placental vascular marker level were reduced compared 
to obese controls without antibody therapy. In summary, anti-IL-6 signaling therapy may not alleviate 
HFD-induced defects in placental vascularization and IUGR, and warrants further investigation with 
additional dosing. 
Proteomic profiling of the feto-maternal transfer zone moreover revealed a reduced level of the adherens 
junctions (AJ) marker E-cadherin in obese compared to lean dams at E15.5. This was confirmed in 
whole placenta lysates of obese compared to lean dams concomitant with a strong tendency towards 
reduced β-catenin level, an intracellular adaptor protein of AJ. These changes persisted until the end of 
pregnancy (E18.5) in placentas of obese dams, while at mid-gestation (E11.5) we could not observe 
altered AJ marker level. In addition, it was found that at E15.5 the ultrastructure and cell homeostasis in 
the transfer zone were affected by MO, as demonstrated by defective syncytial fusion and a disrupted 
basement membrane. In functional assays we then showed that passive transfer across the placenta 
was significantly increased under MO, while active glucose transport was unaltered at E15.5. Moreover, 
our in vitro studies suggest that fatty acids, present in excess in our HFD, can alter trophoblast cell layer 
permeability and cause reduced β-catenin level. Collectively, these findings strongly suggest that MO 
causes disruptions in the feto-maternal transfer zone via disturbed EC and trophoblast homeostasis, 
leading to a “leaky” placental barrier while embryos develop an IUGR.  
A healthy lifestyle with limited intake of fatty acids and prevention of obesity in women of childbearing 
age could therefore, in case of pregnancy, support proper placental function and reduce the risk of fetal 
growth restriction. 
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Zusammenfassung 
Die Prävalenz von Übergewicht (BMI >25 kg/m²) und Adipositas (BMI >30 kg/m²) haben in der 
Bevölkerung weltweit deutlich zugenommen, und infolgedessen sind über die letzten Jahrzehnte auch 
immer mehr Frauen im gebärfähigen Alter von Übergewicht betroffen. Übergewicht und Adipositas vor 
und während der Schwangerschaft sind mit einem höheren Risiko für die Mutter und das ungeborene 
Kind verbunden Schwangerschafts-Komplikationen wie beispielsweise Gestationsdiabetes und ein 
gestörtes fötales Wachstum zu entwickeln. Anormales fötales Wachstum wird dabei oft mit einer 
Funktionsstörung der Plazenta in Verbindung gebracht und kann zu langfristigen gesundheitlichen 
Problemen bis ins Erwachsenenalter führen, was hohe sozioökonomische Kosten zur Folge hat. 
Übergewicht und Schwangerschaft sind jeweils mit einem Zustand erhöhter systemischer Inflammation 
und oxidativem Stress verbunden, die, im Fall einer Schwangerschaft allein, für das Einsetzen des 
Geburtsvorgangs von Bedeutung sein können, doch in Verbindung mit Übergewicht auch zu einer 
plazentaren Dysfunktion führen können. Die Plazenta erfüllt wesentliche Aufgaben, insbesondere die 
Versorgung des Fötus mit Sauerstoff und Nährstoffen sowie den Abtransport von Abfallstoffen und trägt 
durch die Produktion von Hormonen und anderen Faktoren zu einer gesunden Schwangerschaft bei. 
Für eine optimale Funktion der Plazenta sind Faktoren wie die Homöostase der plazentaren Zellen 
sowie die Vaskularisierung und der korrekte Aufbau der plazentaren Struktur von enormer Bedeutung. 
Es ist jedoch noch nicht hinreichend bekannt, wie mütterliches Übergewicht (MÜ) die Zellen und 
Gefäßentwicklung der Plazenta nebst der plazentaren Transferkapazität beeinflusst. 
Aus diesem Grund ist es Ziel der vorliegenden Arbeit, die Effekte des MÜ auf die plazentare feto-
maternale Transferzone, welche die entscheidende Schnittstelle für den Transfer von Sauerstoff, 
Nährstoffen und Abfallstoffen zwischen mütterlichem und fötalem Kreislauf darstellt, zu entschlüsseln. 
Zur Erforschung dieser Fragestellung wurde mütterliches Übergewicht mittels Hochfett-Diät (HFD) in 
C57BL/6N-Mäusen induziert, um Blutserum, Plazenten und epigonadales weißes Fettgewebe (egWAT) 
von verschiedenen Trächtigkeitstagen (E11.5, E15.5, E18.5) für Analysen zu gewinnen. 
Normalgewichtige Mäuse, die eine Standard-Diät (SD) erhielten, dienten als Kontrollgruppe. 
Wir konnten feststellen, dass sich, verglichen mit schlanken Kontrolltieren, in übergewichtigen 
Muttertieren die Trächtigkeit um einen Tag verlängerte. Unsere Daten lassen den Schluss zu, dass eine 
verminderte Leukozyten-Infiltration der Plazenten sowie eine verminderte Expression pro-
inflammatorischer Faktoren im egWAT übergewichtiger Muttertiere kurz vor Ende der Trächtigkeit 
(E18.5) als Ursache für diese Beobachtung in Frage kommen.  
Embryos der übergewichtigen Muttertiere zeigten zu Beginn des letzten Trimenon der Trächtigkeit 
(E15.5) eine intrauterine Wachstumsretardierung (IUGR). Zeitgleich waren Protein- und mRNA-Level 
von Endothelzellmarker herunterreguliert und stereologische Analysen zeigten eine gestörte 
Gefäßentwicklung in Plazenten übergewichtiger Muttertiere. Dies wurde begleitet von erhöhter 
Endothelzell (EC)-Seneszenz in der plazentaren feto-maternalen Transferzone. Wir fanden ebenso 
erhöhte Interleukin-6 (IL-6) Level im mütterlichem Serum und konnten einen deutlichen Trend hin zu 
erhöhten IL-6 mRNA- und Protein-Leveln im egWAT der übergewichtigen Muttertiere, verglichen mit 
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schlanken Kontrolltieren, erkennen. Dies deutet auf das egWAT als Quelle der erhöhten IL-6 Level in 
übergewichtigen Muttertieren hin. Wir konnten ferner bestätigen, dass eine Stimulation von humanen 
plazentaren EC mit IL-6 eine Seneszenz induziert, was eine Verbindung zwischen erhöhten IL-6 
Serumlevel, plazentarer EC-Seneszenz und gestörter Gefäßentwicklung suggeriert.  
Ausgehend von diesen Ergebnissen, dass IL-6 in EC eine Seneszenz in vitro herbeiführen kann und 
die plazentare Gefäßbildung in vivo gestört erscheint, wurde mittels Antikörper-Therapie eine Blockade 
des IL-6-Signalwegs in übergewichtigen Muttertieren induziert. Wir konnten zeigen, dass unter dieser 
Therapie die plazentare IL-6-Proteinmenge signifikant anstieg und nachgeschaltete Signalwege 
beeinträchtigt waren, was auf eine erfolgreiche Blockade des IL-6-Signalwegs hindeutet. Jedoch kam 
es auch unter der Antikörper-Therapie zu einem verringerten Körpergewicht der Föten an E15.5, und 
plazentare Gefäßmarker-Level waren im Vergleich zu den nicht-therapierten, übergewichtigen HFD-
Kontrolltieren reduziert. Insgesamt deutet dies darauf hin, dass die Antikörper-Therapie die HFD-
induzierten Schädigungen in der plazentaren Gefäßentwicklung nicht abschwächen kann und es 
weiterhin zu einer IUGR kommt, so dass weitere Untersuchungen mit alternativen Dosierungen 
angebracht sind. 
Eine Proteom-Analyse der feto-maternalen Transferzone zeigte darüber hinaus, dass eine Reduktion 
des Adherens Junction (AJ)-Markers E-cadherin in Plazenten übergewichtiger Tiere, verglichen mit 
schlanken Kontrolltieren, an E15.5 vorliegt, was wiederum auf eine Destabilisierung der AJ hinweist. 
Die Reduktion von AJ-Markern wurde in Analysen von Gesamtplazenta-Lysaten übergewichtiger 
Muttertiere gegenüber Kontrolltieren bestätigt. Außerdem zeigte sich eine starke Tendenz hin zu einem 
reduzieren β-catenin Level, einem intrazellulären Adapterprotein der AJ. Diese Veränderungen wurden 
ebenso in Plazenten von übergewichtigen Muttertieren kurz vor Ende der Trächtigkeit gemessen 
(E18.5), während zur Mitte der Trächtigkeit hin (E11.5) keine Veränderungen der AJ-Marker Level 
festgestellt wurden. Ferner zeigte sich, dass an E15.5 die Ultrastruktur und Zell-Homöostase der 
Transferzone unter MÜ verändert sind, wie anhand der defekten „Synzytialfusion“ und der geschädigten 
Basalmembran zu erkennen ist. Wir konnten anhand funktionaler Untersuchungen zeigten, dass an 
E15.5 unter MÜ der passive Transfer über die Plazenta signifikant zunahm, während ein aktiver 
Glukose-Transport unverändert blieb. Ebenso lassen in vitro-Studien vermuten, dass Fettsäuren, die 
auch in der HFD im Übermaß vorhanden sind, die Durchlässigkeit der Trophoblasten-Zellschicht 
verändern sowie zu erniedrigten β-catenin Level führen können. Dies deutet darauf hin, dass MÜ über 
die vermehrte Aufnahme von Fettsäuren zu einer gestörten Integrität der feto-maternalen Transferzone 
beitragen könnte. Insgesamt lassen unsere Ergebnisse vermuten, dass MÜ die Transferzone durch 
Störung der EC-Homöostase und Trophoblasten-Differenzierung schädigt und es zu einer 
durchlässigeren Plazentabarriere kommt, während Föten eine IUGR entwickeln.  
Ein gesunder Lebensstil mit einer begrenzten Aufnahme von Fettsäuren sowie die Prävention von 
Übergewicht und Adipositas könnten dementsprechend zu einer uneingeschränkten Plazentafunktion 
und einem geringeren Risiko einer IUGR beitragen. 
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1. Introduction 
 
1.1 Development and function of the placenta 
At the beginning of mammalian, rodent and all human life occurs conception, the fusion of gametes from 
male and female which is the initiation of development of one or multiple new organisms [1]. Subsequent 
to this fertilization event, the development of a zygote starts which can divide by mitosis into a multi-
cellular blastomere. During this process in humans, the blastomere travels towards the uterus which is 
the implantation site, and implantation takes place at about day 5 after conception in the form of a 
blastocyst. The attachment and subsequent implantation of the blastocyst into the endometrial tissue 
are crucial events for gestation and the development of a placenta to occur. During this process, cells 
of the trophectoderm, the outer cell layer of the blastocyst, anchor to the endometrium and give rise to 
the developing placenta, while the inner cell mass of the blastocyst gives rise to the embryo [2, 3]. 
Though the mammalian placenta is an impermanent organ only required during development of the 
conceptus in utero, its formation and function are tightly regulated and pivotal for a healthy development 
of the embryo [2].  
In humans, just about 2 days after the blastocyst reaches the endometrium, trophoblast cells which are 
cells of the outer cell layer of the blastocyst, invade maternal tissue with finger-like formations. These 
trophoblast cells ultimately reach maternal blood vessels by migrating through extracellular matrix 
(ECM), a prerequisite to establish blood supply to the forming placenta and therefore the embryo [4, 5]. 
Trophoblast invasion during implantation and placenta development is crucial and if impaired, it may 
cause stress during early pregnancy which can lead to placental dysfunction later and result in maternal 
and fetal complications [6]. Alterations in the endometrial lining as a consequence of blastocyst adhesion 
and trophoblast invasion lead to the formation of a decidual structure which is only present during 
pregnancy. Decidualization, as the formation of this structure from the endometrium between maternal 
and fetal tissues is called, limits trophoblast invasion, protects the endometrium and myometrium from 
invasion by trophoblasts, and permits preliminary supply for the developing embryo. Later, the maternal 
portion of the placenta consists of the decidua basalis (Db) which harbors a vascular network of spiral 
arteries that are invaded by the trophoblast cells to enable blood supply of the placenta [2]. These tightly 
controlled steps are very similar in human and murine placental development, and many studies in 
murine animal models have contributed substantially to the understanding of molecular and genetic 
aspects of placental development [7, 8]. Since both fetal and maternal cells are involved in the 
development of the placenta, it is considered a feto-maternal organ. A schematic overview of the human 
and murine placenta is shown in Figure 1.1.1. 
Mouse strains used in the laboratory have proven valuable, even if gestation takes only about 20 days 
in these animals, to study gene function, embryogenesis and placental development; and it is especially 
the genetic manipulation that also revealed placental defects often as cause of lethality of the embryo. 
While about one in three knock-outs of individual genes cause fetal death, it is not known how many of 
those are due to placental defects, and the contribution of the placenta to lethality could thus frequently 
be underestimated or even misinterpreted [9-11]. The placenta in mice starts to form at about day 4 of 
1. INTRODUCTION 
 
 
6 
embryonic development (day 0.5 being the next morning when mating takes place overnight) as seen 
by the formation of extraembryonic cell lineages and the yolk sac. At embryonic day 8.5 (E8.5) 
chorioallantoic fusion which forms the placenta has occurred, branching morphogenesis starts taking 
place and highlights in full materno-fetal material exchange at around E12.5 [12, 13]. Roughly 2 days 
later, at E14.5, placental development and peak velocity of the vitelline artery have reached their 
maximum. At the same time, the exponential embryo weight-gain reaches the steepest phase as the 
organogenesis is completed. Technically, the embryo would from then on be called “fetus”, however it 
is convention to refer to the fetus as embryo also after E14.5 or use both terms interchangeably from 
E14.5 onwards [12]. 
The growing embryo requires nutrients and oxygen during its development, and the placenta is 
responsible for the transfer of such nutrients and oxygen additional to the removal of carbon dioxide 
(CO2) and other waste products from fetal metabolism. This is achieved by supplying the embryo with 
oxygenized blood through the umbilical vein and removing waste-containing deoxygenized blood 
through two umbilical arteries. Both arteries spiral around the larger vein, and these three vessels 
together form the umbilical cord. In the umbilical cord, the vessels are embedded in what is called 
Wharton’s jelly. The vessels reach the placenta and enter into the chorionic plate where the arteries 
branch and ultimately form an arteriovenous system [2]. This system and thus the interior 
compartmentalization of the placenta differs among mammalian species and shows distinct 
architectures in human and mice [3, 14]. In murine placentas, trophoblasts of chorionic origin begin 
differentiation and fuse to give rise to the multinucleated syncytiotrophoblast (SynT), organized in two 
layers, which engulfs fetal endothelium of capillaries. A forth cell layer is situated on the other side of 
the SynT, i.e. the mononuclear trophoblast which is in contact with maternal blood sinuses carrying the 
oxygenated blood. In total, these 4 cell layers form the placental transfer barrier with markedly branched 
villi, giving the murine placenta its labyrinthine appearance (Figure 1.1.1 G). This interface for material 
exchange and transfer zone of the murine placenta is therefore called the labyrinth zone (Lz) [7, 8]. In 
humans, the transfer zone corresponds to the villous part of the placenta and comprises a 
multinucleated SynT, followed by a layer of villous mononuclear cytotrophoblast. Each of the so-formed 
floating villi can contain multiple fetal capillaries (Figure 1.1.1 D). In both human and mice, maternal 
blood on one side of the placental barrier and fetal blood in the fetal capillaries flow counter-currently to 
increase nutrient transport in the transfer zone, making both murine and human placentas hemochorial. 
Another similarity of murine and human placentas is the discoid shape (Figure 1.1.1 A & E) which adds 
to the value of mouse models to study the placenta and extrapolate to human placentas.  In contrast, 
horse and pig have a diffuse epitheliochorial placenta, and cats, dogs and other carnivores have a 
zonary endotheliochorial placenta [14]. The flow characteristics within the transfer zone of the placenta 
underpin that adequate vascularization is necessary for appropriate nutrient and oxygen transfer [15, 
16]. As a consequence, disturbances in trophoblast differentiation and defects in Lz or human villous 
development can severely impact on embryonic development and even lead to pregnancy termination 
[4, 17]. 
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In both humans and mice, regulation of material exchange in the placenta is achieved by a variety of 
mechanisms and can be divided in passive and active transfer. In murine placentas, the SynT expresses 
specific nutrient transporters for glucose, amino acids, free fatty acids and other molecules, therefore 
actively mediating supply across the placental barrier to the fetus. Regarding glucose, the transporters 
GLUT1, GLUT3 and GLUT4 are found in the murine transfer zone and facilitate active glucose transport 
towards the fetal circulation [8, 18]. Additionally, fetal growth depends on the ability of the placenta to 
provide glucose, and for periods of glucose shortage the placenta can utilize glycogen which is stored 
in clusters within the murine placenta [19]. Passive transfer of substances without active carriers or 
transporters mediates oxygen supply and also transfer of predominantly hydrophobic molecules with a 
size of 600 Da or less. As pregnancy progresses, increased placental blood flow, increased transfer 
zone surface area and reduction in the SynT cell layer thickness lead to enhanced passive transfer [20]. 
Transporter expression on the surface of SynT and fetal endothelial cells (EC) determine active carrier-
mediated transport. These placental cells also form junctions between each other, which have been 
implicated in vascular permeability and intestinal barrier function and thus in the transfer of substances 
[21, 22]. However, to best of our knowledge, the influence of these junctions on placental passive 
transfer capacity has not been described. 
A third tissue layer in murine placenta, the so called junctional zone (Jz), is present between the maternal 
Db and the Lz consisting of spongiotrophoblasts and trophoblast glycogen cells, as well as arterial and 
venous channels of trophoblastic origin, but the Jz contains no fetal blood (vessels). The 
spongiotrophoblast layer is analogous to the placental column cytotrophoblasts in humans [8]. 
Spongiotrophoblasts and (trophoblast) glycogen cells are collectively forming the Jz of the murine 
placenta. The glycogen cells probably derive from spongiotrophoblasts and form clusters that can be 
seen from the second trimester of murine gestation in the Jz. Though the precise function of this zone 
and its inhabitant cells are not fully understood today, it is known that the Jz produces hormones and is 
absolutely required for placental function and successful pregnancy [3]. Primary trophoblast giant cells, 
originating from mural trophectoderm, do not contribute to the mature placenta, however a secondary 
trophoblast giant cell layer which derives from polar trophectoderm is located at the boundary between 
the Jz and the Db. Furthermore, the relative extent of the three layers, Lz, Jz and Db change during the 
course of gestation to meet fetal demands. This includes an increase in the size of the Lz for example, 
concomitant with enhanced complexity to allow exponential fetal growth towards the end of pregnancy. 
Exponential fetal growth similarly requires a drastic increase in nutrient transfer capacity by upregulation 
of transporters and morphological changes to enhance passive transfer [3, 23]. Conversely, the Jz starts 
decreasing in size from the third trimester onwards and has its maximum size before this time-point [24, 
25]. 
 
1.2 The placental transfer zone 
As mentioned above, the murine placental transfer zone consists of various cell types: the mononuclear 
trophoblasts which are in contact with maternal blood; the two layered SynT which lies beneath 
mononuclear trophoblasts and is in contact with the basement membrane (BM). Opposite of the BM is 
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the fetal endothelium with EC that are in contact with fetal blood, and the development of all these cell 
layers is precisely regulated (Figure 1.1.1) [7, 24]. The SynT can be described as a form of epithelium 
in human placentas which separates maternal and fetal blood while being heavily involved in transport 
of substances, oxygen and waste products in addition to producing certain hormones [8, 26, 27].  
 
 
Figure 1.1.1: Comparative appearance of the human and murine placenta. (A) Photograph of a human placenta 
at term from a cesarean section. (B) Schematic drawing of the human placenta showing a villous tree in the black 
frame (close up in C) perfused by maternal spiral arterial blood. The FV are surrounded by a continuous layer of 
SynT that is in contact with maternal blood, and the extravillous trophoblasts invade from AV in order to anchor the 
villi within the decidua. (D) The human hemodichorial transfer zone with SynT towards maternal blood, vCTB 
underneath, and fetal EC of capillaries containing fetal blood. (E) The murine placenta has a disc-like shape similar 
to human placentas, however the placental layers are distinct as there is a labyrinth of villi (F). The black frame in 
(F) is shown in (G) and highlights the Lz, over which the Jz can be seen with its boundary of trophoblast giant cells. 
Additionally, the murine hemotrichorial transfer zone of maternal trophoblasts, two layers of SynT and fetal EC 
becomes evident in (H). AV: anchoring villi; FV: floating villi; iCTB: invasive cytotrophoblast; vCTB: villous 
cytotrophoblast; SpT: spongiotrophoblasts; TGC: trophoblast giant cell. Adapted and modified from Maltepe et al. 
[7]. 
 
The SynT and EC in the transfer zone are interconnected by adhesion molecules to the BM, but also to 
other SynT or EC, respectively, by the formation of adherens junctions (AJ). AJ contain molecules of 
the cadherin family of proteins to form cell-cell adhesions. In contrast, cell-BM or cell-ECM contact is 
mediated by other forms of adhesion, e.g. integrin binding and focal adhesion. The epithelial cadherin, 
E-cadherin, is mostly found on epithelial cells but also on villous trophoblasts in human placentas. 
1. INTRODUCTION 
 
9 
Already before the definitive placenta is formed, cells of the trophectoderm rely on the formation and 
distribution of AJ [7]. In the placenta and other organs, vascular cells, like fetal EC, rather express 
vascular endothelial cadherin, VE-cadherin [28, 29]. The cadherin molecules in EC and epithelial cells 
establish polarity of cells by forming AJ and creating cell-cell contacts which are required for vascular 
lumen formation and permeability regulation by EC [30, 31]. VE-cadherin clusters in human placentas 
on EC have been reported to co-localize and then bind to β-catenin, which is an intracellular adaptor 
molecule. Catenins are important anchoring proteins for cadherins to peri-junctional actin and thus, the 
cytoskeleton [32]. It has been shown that β-catenin knock-out specifically in EC can lead to altered 
vascularization in the placenta and embryos, and that in vitro β-catenin knock-out led to disorganized 
junctions in EC [33]. Furthermore, catenins can be released from these junctions and are then involved 
in regulation of transcription in the nucleus [32]. In this regard, β-catenin is part of canonical Wnt 
signaling which plays a relevant role in trophoblast development and other reproductive functions. 
Impaired Wnt signaling has been associated with infertility and placental defects, however there is still 
much to be discovered in pathological circumstances regarding involvement of β-catenin [34].  
As mentioned above, EC and SynT together form an important barrier in the transfer zone to regulate 
material exchange between mother and fetus. Both cell layers express transport molecules that 
influence resource allocation. The placenta’s ability to alter efficiency of resource allocation due to 
environmental conditions has been suggested to maintain fetal growth with consequences for the health 
of the offspring after birth [23]. This concept of inadequate fetal supply during intrauterine development, 
mediated by the placenta for a great part, has been termed fetal programming and affects not only 
metabolic health [35, 36], but also e.g. cardiovascular pathology [37] in later life.  
 
1.3 Maternal obesity and placental pathologies 
Since healthy fetal development requires a proper functioning placenta and the placenta is partially 
made up of maternal tissue and transports maternal blood, maternal health translates to placental 
physiology and ultimately fetal health. Numerous studies of the past decades have looked into factors 
of maternal origin and their influence on development and function of the placenta on the one hand, as 
well as perinatal outcome and offspring health on the other hand [4, 38-40]. Among those factors 
associated with adverse consequences on the placenta and fetal health is maternal obesity (MO), i.e. 
obesity before and during pregnancy. In Germany and worldwide, numbers of women at child-bearing 
age with overweight, defined by the World Health Organization by a body mass index (BMI) ≥25 kg/m², 
or obesity, defined by a BMI ≥30 kg/m², have increased since the 1990s [41, 42]. Depending on the 
severity of obesity, the associated complications for mothers differ and fall into a spectrum of 
pathologies, including decreased probability of conception, increased relative risk for preeclampsia and 
gestational diabetes mellitus (GDM), but also the risk for intrauterine death of the fetus [38, 43, 44]. 
Moreover, research in recent years showed that maternal nutrition and its effect on offspring health 
extent beyond pregnancy by fetal programming. Fetal programming occurs for example as a 
consequence of epigenetic changes in the offspring and may contribute to an increased obesity 
prevalence. Various tissues in the offspring can be affected by epigenetic changes, leading to an 
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involvement of multiple organs and the development of diabetes and the metabolic syndrome [45]. In 
the US as well as Europe, the increase in such diseases linked to obesity from an early age has been 
estimated to cost the health care systems between $100 billion to $200 billion per year [46]. Additionally, 
diagnosed obesity among pregnant women is associated with longer hospitalization and impacts the 
hospitalization costs [47]. These findings show the relevance for understanding and limiting adverse 
factors for maternal health before and during pregnancy to improve offspring health and reduce the 
potential burden on healthcare systems. The concept of developmental origins for/of health and disease 
(DOHaD) has reached many disciplines of biomedical science and has generated novel insight from 
many research fields to further public leadership for healthier life-style [48]. As a result, it is often 
collectively advised for obese women to adapt a healthy lifestyle before and during pregnancy to mitigate 
potential negative effects of obesity. However, it is still a matter of debate how this can be achieved 
most effectively, and many studies are difficult to compare due to variations in e.g. diets and study 
endpoints [49, 50]. Furthermore, such cohort studies provide limited insight into the direct effect on 
placental function and mechanisms of placental defects. As a result, studies with established and novel 
animal models are required to decipher mechanisms of placental function under MO.  
Intrauterine growth restriction (IUGR) is occurring in approximately 3% to 8% of human pregnancies 
worldwide and the defined growth potential at a certain gestational age is not reached by fetuses 
suffering from IUGR. IUGR is, amongst others, associated with preeclampsia, a serious hypertensive 
disorder occurring during pregnancy [51] and can be caused by various factors like embryo genetics 
combined with maternal factors. In the majority of cases, it is assumed that placental dysfunction is the 
leading cause of IUGR, where the nutrient supply to the fetus is inadequate despite sufficient maternal 
nutrition [52-56]. Not only IUGR has been associated with insufficient placental function and 
vascularization, MO itself was associated with negatively affected placental vascular development in 
humans [57, 58], as well as mice [44] and rats [59, 60]. Furthermore, induction of obesity and diabetes 
in mice through feeding of a specific diet led to a reduction in placental trophoblast and EC density 
resulting in vascular changes [44] which could also affect the Lz development.  
The effects of MO on the placenta are manifold and comprise exaggerated saturated fatty acid profiles 
that can e.g. cause inflammatory responses in the placenta and altered mitochondrial function which in 
turn may lead to oxidative stress in the placenta. Moreover, the metabolic environment in the placenta 
of obese mothers probably affects the epigenome of placental cells, thereby influencing placental 
function [36]. Additionally, human and primate studies have shown excessive macrophage accumulation 
and reduced blood flow in placentas of obese individuals [61, 62]. In obese mice, elevated placental 
cytokine level and macrophage infiltration were described in placentas [63]. Regarding inflammatory 
responses, obesity and pregnancy are both associated with systemic inflammation of low grade, which 
may constitute the underlying mechanism of adverse placenta function [63, 64]. Longitudinal studies 
have reported that level of pro-inflammatory cytokines, like Interleukin-6 (IL-6), are elevated during 
pregnancy concomitant with higher BMI especially after the first half of pregnancy [65-67]. IL-6 is a 
cytokine that can have both pro-inflammatory and anti-inflammatory effects which are dependent on 
either classic IL-6 receptor (IL-6R)-mediated signaling or trans-signaling, respectively. The trans-
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signaling is dependent on coupling of a soluble IL-6R (sIL-6R) with the membrane-bound gp130 receptor 
for its pro-inflammatory activities on cells of various types, e.g. EC [68, 69]. Furthermore, trans-signaling 
of IL-6 could also affect placental EC via gp130 receptor. It has been shown that IL-6 stimulation of EC 
is associated with lower VE-cadherin level and reduced AJ expression [70], and IL-6 may regulate AJ 
in breast cancer cells [71]. Other inflammatory markers, like IL-1β and TGF-β have been suggested to 
affect placental tight junctions and weaken the placental barrier by regulating the tight junction marker 
occludin [72, 73]. Under obesity, such systemic pro-inflammatory factors like IL-6 are elevated, may 
arise from adipose tissue and be secreted into the circulation to reach and affect different organs 
including the placenta [64, 74]. The placenta is highly vascularized and molecules of many kinds that 
are found in the circulation of the mother will pass the vasculature and thus, may reach and affect cells 
within the placenta. Adipokines and hormones, like leptin and insulin, are associated with MO and could 
play important regulatory roles in the placenta, since they can be produced both here and in adipose 
tissue from which they reach the placenta via the circulation. These substances affect signaling in 
placental cells such as Stat3 and Akt/mTOR pathway activation which translates to regulation of 
placental nutrient transport and ultimately fetal supply and growth [75]. However, in pregnant mice it 
was shown that leptin was not involved in inflammatory responses in the placenta [76]. Nevertheless, it 
could be important to further investigate mechanisms of placental function mediated by inflammatory 
molecules. 
The chain of evidence more and more pinpoints towards placental dysfunction under MO as a cause for 
maternal and fetal health consequences, which makes it worthwhile to study placenta function and 
develop strategies to mitigate adverse effects of MO on the placenta. Studies on the mechanisms of 
placental dysfunction in many contexts, including MO, have however, not yielded sufficient results to 
elucidate the precise origin of IUGR and other complications under MO. As a consequence, further 
studies are required on placental dysfunction. 
 
1.4 Study aims and hypothesis 
The association of MO with placental dysfunction, together with possible implications for fetal health and 
development, permit investigations into the mechanisms behind these clinically relevant effects. 
Previous studies of our group showed that it is possible to induce MO by feeding a high fat diet (HFD) 
after weaning [76, 77]. Herein, we aimed to advance our insight into placental dysfunction and the 
placenta-associated programming effects on offspring health under MO. 
The inflammatory responses in adipose tissue and the placenta during pregnancy in obese women are 
still not understood in great detail and we aimed to elucidate the inflammatory response in adipose 
tissue and the placenta of both obese and lean mice before the onset of parturition.  
Since the placenta is a highly vascularized organ and its main function is the exchange of nutrients and 
waste via blood circulation to ensure proper fetal growth, we aimed to elucidate the effects of MO on 
placental vascularization together with EC homeostasis. Based on previous reports and preliminary data 
from our group, we hypothesize that MO affects maternal serum level of the pro-inflammatory marker 
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IL-6 and in this study we aimed to clarify the effects of IL-6 on placental EC. To this end, obese dams 
were also assigned to an antibody therapy in order to block IL-6 signaling and study potentially positive 
effects on the placenta under MO. An obese mouse model in which IL-6 was genetically knocked-out 
was used to gain further insight into IL-6 signaling related processes in placental and fetal development 
under MO. 
Previous studies suggest that HFD consumption could cause reduced expression level of cell junction 
markers [21, 22] which might also translate to placental cells and therefore affect integrity and function 
of the transfer zone. We hence aimed to analyze the proteome of the transfer zone to find new hints 
regarding altered marker level of cell junctions and AJ. Moreover, localization of such markers was 
investigated, and the morphology and ultrastructure of the transfer zone was studied in detail. We 
furthermore hypothesized that morphological and molecular changes in the transfer zone could have an 
impact on materno-fetal transfer of substances and aimed to determine the transfer capacity across the 
placental barrier in obese dams. 
Collectively, it is assumed that MO can disrupt the placental transfer zone and cause structural and 
molecular changes in the cells of the transfer zone, resulting in adverse placental function and impaired 
fetal development.  
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2. Materials 
 
2.1 Chemicals, materials and reagents 
Table 2.1: Chemicals, materials and reagents used in this work. 
Chemical / material / reagent Company 
1-tetradecanoic acid-d27 Sigma-Aldrich, Steinheim, Germany 
2-Chloroacetamide Sigma-Aldrich, Steinheim, Germany 
2-mercaptoethanol Carl Roth, Karlsruhe, Germany 
2N H2SO4 Carl Roth, Karlsruhe, Germany 
4′,6-diamidino-2-phenylindole, DAPI Sigma-Aldrich, Steinheim, Germany 
6-, 24- and 96-well plates Sarstedt, Nümbrecht, Germany 
Acetic acid Carl Roth, Karlsruhe, Germany 
Aceton Carl Roth, Karlsruhe, Germany 
Acetonitril, 80%, 20% water with 0.1% formic acid, Optima 
LC/MS (Puffer B) 
Fisher Scientific, Waltham, Massachusetts, USA 
Acrylamide (30%) and bisacrylamide (0.8%) mix 
ROTIPHORESE® Gel 30 (37.5:1) 
Carl Roth, Karlsruhe, Germany 
AdipoRed reagent Lonza, Walkersville, Maryland, USA 
Agarose Sigma-Aldrich, Steinheim, Germany 
Albumin bovine fraction V, BSA SERVA Electrophoresis GmbH, Heidelberg, 
Germany 
Ammonium persulfate, APS Sigma-Aldrich, Steinheim, Germany 
Antibody diluent DAKO Agilent, Santa Clara, California, USA 
Aprotinin from bovine lung Sigma-Aldrich, Steinheim, Germany 
Aqueous mounting medium, Fluoromount™ Sigma-Aldrich, Steinheim, Germany 
Bepanthen® Bayer Vital GmbH, Leverkusen, Germany 
Biosol National Diagnostics, Atlanta, Georgia, USA 
Buprenorphine Bayer Vital GmbH, Leverkusen, Germany 
CellStain®, from ECM642 Merck, Darmstadt, Germany 
Chloroacetamide, CAA AppliChem, Darmstadt, Germany 
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Chloroform Merck, Darmstadt, Germany and Sigma-Aldrich, 
Steinheim, Germany 
Citrate buffer pH 6, target retrieval solution DAKO, Glostrup, Denmark 
cOmplete EDTA-free Protease Inhibitor Cocktail Roche, Basel, Schweiz 
Deoxycholic acid sodium salt Carl Roth, Karlsruhe, Germany 
Diethyl pyrocarbonate, DEPC ≥ 97% Sigma-Aldrich, Steinheim, Germany 
Dithiothreitol, DTT AppliChem, Darmstadt, Germany 
D-Mannitol, [1-14C]-250 µCi, 14C-mannitol Hartmann Analytic, Braunschweig, Germany 
DNA ladder Thermo Scientific, Vilnius, Lithuania 
dNTP mix for genotyping and RT-qPCR (10 mM) Thermo Scientific, Vilnius, Lithuania 
(Genotyping) 
Thermo Scientific, Massachusetts, USA (RT-
qPCR) 
Dulbecco’s phosphate-buffered saline (1X and 10X), D-
PBS, Ca2+/Mg2+-free 
Gibco, Life Technologies Ltd. Paisley, UK 
ECL™ Prome Western Blot Detection Reagent GE Healthcare, Solingen, Germany 
Eosin G-solution 0.5% Carl Roth, Karlsruhe, Germany 
Ethanol ≥ 99.8% Carl Roth, Karlsruhe, Germany 
Ethanol absolute Merck, Darmstadt, Germany 
Ethylenediaminetetraacetic acid disodium salt dehydrate, 
EDTA 
Sigma-Aldrich, Steinheim, Germany 
Fetal calf serum, FBS Biochrom GmbH, Berlin, Germany 
Fibronectin from bovine plasma Sigma-Aldrich, Steinheim, Germany 
Flexi Green (5X) Promega, Madison, Wisconsin, USA 
Fludeoxyglucose ((18)F), 18F-FDG Life Radiopharma GmbH, Bonn, Germany 
Formaldehyde, phosohate-buffered 
Roti®-Histofix 4% 
Carl Roth, Karlsruhe, Germany 
Formic acid, puriss. p.a., ≥ 98% Sigma-Aldrich, Steinheim, Germany 
Gelatin, G1393 Sigma-Aldrich, Steinheim, Germany 
Glutaraldehyde, 50% Electron Microscopy Sciences, Hatfield, 
Pennsylvania, USA 
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Glycerol Carl Roth, Karlsruhe, Germany 
Glycine Carl Roth, Karlsruhe, Germany 
goTaq polymerase (5 u/µL) Promega, Madison, Wisconsin, USA 
Heparin, 5000 IE/mL B. Braun Melsungen AG, Melsungen, Germany 
Hexane Sigma-Aldrich, Steinheim, Germany 
Hoechst 33342 stain Fisher Scientific, Waltham, Massachusetts, USA 
HPLC 
Water for chromatography LiChrosolv® 
Merck, Darmstadt, Germany 
Hydrogen chloride Sigma-Aldrich, Steinheim, Germany 
Hydrophobic pen, Liquid Blocker Daido Sangyo Co. Ltd., Japan 
hyperIL-6, recombinant human IL-6/IL-6R Chimera, #8954-
SR 
R&D Systems, Minneapolis, Minnesota, USA 
IGEPAL® CA-630 Sigma-Aldrich, Steinheim, Germany 
Inserts 0.4 µm for 24-well plates Sarstedt, Nümbrecht, Germany 
Isoflurane Primal Healthcare, Northumberland, UK 
Isopropyl alcohol (2-Propanol) 
≥ 99.95% 
Carl Roth, Karlsruhe, Germany 
Leupeptin, ≥ 90% Sigma-Aldrich, Steinheim, Germany 
Linoleic acid sodium salt Sigma-Aldrich, Steinheim, Germany 
Liquid nitrogen Linde AG, Köln, Germany 
Lysyl Endopeptidase, Lys-C WAKO, Neuss, Germany 
Matrigel, growth factor reduced #356230 BD Biosciences, Bedford, Massachusetts, USA 
Mayer’s hematoxylin Carl Roth, Karlsruhe, Germany 
Methanol, ≥99.8% VWR, Radnor, Pennsylvania, USA 
Methanol, 250 ppm BHT 
(equals 0.025%) 
Sigma-Aldrich, Steinheim, Germany 
MgCl2 ≥98,5% (water-free) Carl Roth, Karlsruhe, Germany 
MgCl2, 25 mM Promega, Madison, Wisconsin, USA 
Micro(µ-)slide angiogenesis, #81506 Ibidi GmbH, Graefelfing, Germany 
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Midori Green Advance DNA Stain Nippon Genetics Europe GmbH, Düren, 
Germany 
Milk powder, non-fat Carl Roth, Karlsruhe, Germany 
M-MLV Reverse Transcriptase (200 U/µL) Promega, Mannheim, Germany 
M-MLV RT 5X Buffer Promega, Mannheim, Germany 
Moloney Murine Leukemia Virus Reverse Transcriptase (M-
MLV RT), DNA polymerase 
Promega, Mannheim, Germany 
N,N,N’,N’-Tetramethylethylendiamin, TEMED Sigma-Aldrich, Steinheim, Germany 
Neo-Clear® Sigma-Aldrich, Steinheim, Germany 
Neo-Mount® Sigma-Aldrich, Steinheim, Germany 
Nitrocellulose Blotting Membrane GE Healthcare, Solingen, Germany 
Oil Red O Sigma-Aldrich, Steinheim, Germany 
Oligo-dT primer Eurofins Genomics, Ebersberg, Germany 
PEN-Membrane slides (No. 11600288) Leica, Herborn, Germany 
PenStrep Sigma-Aldrich, Steinheim, Germany 
Pepstatin A ≥ 75% Sigma-Aldrich, Steinheim, Germany 
Phalloidin, fluorescein isothiocyanate labeled, P5282 Sigma-Aldrich, Steinheim, Germany 
Phenylmethylsulfonyl fluoride, PMSF ≥ 98.5% Sigma-Aldrich, Steinheim, Germany 
Phosphate-buffered saline, PBS Biochrom GmbH, Berlin, Germany 
Platinum® qPCR SuperMix-UDG with ROX Invitrogen, Carlsbad, California, USA 
Ponceau S Carl Roth, Karlsruhe, Germany 
Procaine hydrochloride Merck, Darmstadt, Germany 
Protein ladder, PageRuler™ Thermo Scientific, Vilnius, Lithuania 
Proteinase K Thermo Scientific, Vilnius, Lithuania 
Random primer Roche, Basel, Switzerland 
RNasin® Ribonuclease Inhibitors (40 U/µL) Promega, Mannheim, Germany 
RQ1 DNase 10X Reaction Buffer Promega, Mannheim, Germany 
RQ1 DNase Stop Solution (20 mM EGTA) Promega, Mannheim, Germany 
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RQ1 RNase-Free DNase 
(1 U/µL) 
Promega, Mannheim, Germany 
Sea Blocking buffer Thermo Fisher, Rockford, Illinois, USA 
Sodium chloride 0.9% solution Fresenius Kabi Deutschland GmbH, Bad 
Homburg Germany 
Sodium chloride, NaCl Carl Roth, Karlsruhe, Germany 
Sodium dodecyl sulfate, SDS Carl Roth, Karlsruhe, Germany 
Sodium fluoride, NaF ≥ 99% Sigma-Aldrich, Steinheim, Germany 
Sodium oleate Sigma-Aldrich, Steinheim, Germany 
Sodium orthovanadate, Na3VO4 ≥ 99% Sigma-Aldrich, Steinheim, Germany 
Sodium palmitate Sigma-Aldrich, Steinheim, Germany 
Streptavidin-HRP R&D Systems, Minneapolis, Minnesota, USA 
SYBR® Green Master Mix Thermo Scientific, Vilnius, Lithuania 
Tissue-Tek® OCT Sakura Finetek, California, USA 
TMB substrate solution Sigma-Aldrich, Steinheim, Germany 
Toluidine blue Sigma-Aldrich, Steinheim, Germany 
TRI Reagent® Sigma-Aldrich, Steinheim, Germany 
Triethylammonium bicarbonate, TEAB Sigma-Aldrich, Steinheim, Germany 
TRIS (hydrochloride) Carl Roth, Karlsruhe, Germany 
Trypan blue Sigma-Aldrich, Steinheim, Germany 
Trypsin (1 µg/µL) Serva, Heidelberg, Germany 
Trypsin-EDTA Sigma-Aldrich, Steinheim, Germany 
Tween 20 Sigma-Aldrich, Steinheim, Germany 
Urea ≥ 99.5% Sigma-Aldrich, Steinheim, Germany 
Urea-hydrogen peroxide (tablets) Carl Roth, Karlsruhe, Germany 
Water with 0.1% Formic Acid (v/v), Optima LC/MS Grade 
(Puffer A) 
Fisher Scientific, Waltham, Massachusetts, USA 
ZytoChem Plus HRP One-Step Polymer anti-
Mouse/Rabbit/Rat 
Zytomed Systems, Berlin, Germany 
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2.2 Buffers, gels and solutions 
Table 2.2: Buffers made in lab and used in this work. 
Buffer Ingredients Amount/Concentration 
10X Laemmli 
pH 8.3 
TRIS-Hydrochloride 
Glycerine 
SDS 
Water (de-ionized) 
0.184 M 
1.564 M 
34.7 mM 
 
5X Western blot loading 
buffer 
Stacking gel buffer 
SDS 
Bromphenol blue 
Glycerol 
2- mercaptoethanol 
Water (de-ionized) 
16.4% (v/v) 
2.06% (v/v) 
2.6% (v/v) 
10% (v/v) 
25% (v/v) 
 
Main gel buffer 
pH 8.8 
TRIS 
Water (de-ionized) 
1.5 M 
 
Modified RIPA TRIS-Hydrochloride 
NaCl 
IGEPAL® 
Deoxycholic acid sodium salt 
EDTA 
Aprotinin  
Pepastatin A 
Leupeptin 
PMSF 
NaF  
Na3VO4 
50 mM 
150 mM 
1% (v/v) 
0,25% (v/v) 
1 mM 
1 µg/mL 
1 µg/mL 
1 µg/mL 
1 mM 
1 mM 
1 mM 
SP3 lysis buffer SDS 
PBS 
5% (w/v) 
 
Stacking gel buffer 
pH 6.8 
TRIS 
Water (de-ionized) 
0.5 M 
 
Stripping buffer TRIS 
2-mercaptoethanol 
SDS 
50 mM 
100 mM 
2% (v/v) 
TAE buffer 
pH 8 
TRIS 
EDTA 
Acetic acid 
2 M 
50 mM 
variable, pH-dependent 
Tail lysis buffer 
pH 8 
TRIS 
EDTA 
 
100 mM 
5 mM 
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NaCl 
SDS 
 
200 mM 
0.2% (v/v) 
Towbin buffer TRIS 
Glycin 
Water (de-ionized) 
250 mM 
1.92 M 
 
Urea buffer 
(made by Proteomics 
core facility, CECAD) 
Urea ≥ 99.5% 
TEAB 
8 M 
50 mM 
 
Table 2.3: Gels made in lab and used in this work. 
Gel Ingredients Amount 
Agarose gel Agarose 
Midori Green  
TAE buffer 
1.5% (w/v) 
10% (v/v) 
 
Main gel (SDS-PAGE)  
(8% to 12%) 
Acrylamide mix (30%) 
Main gel buffer 
SDS 
APS 
TEMED 
Water (de-ionized) 
27% to 40% (v/v) 
25% (v/v) 
0.1% (v/v) 
0.1% (v/v) 
0.04% to 0.06% (v/v) 
 
Stacking gel Acrylamide mix (30%) 
Stacking gel buffer 
SDS (10%) 
APS (10%) 
TEMED 
Water (de-ionized) 
5.1% (v/v) 
13% (v/v) 
0.1% (v/v) 
0.1% (v/v) 
0.01% (v/v) 
 
 
Table 2.4: Solutions made in lab and used in this work. 
Solution Ingredients Amount/Concentration 
AdipoRed staining solution AdipoRed reagent 
D-PBS 
0.5% (v/v) 
 
Beta-gal staining solution X-Gal 
Potassium ferricyanide 
Potassium ferrocyanide 
MgCl2 
PBS (pH 6) 
1 mg/mL 
5 mM 
5 mM 
2 mM 
variable amounts 
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EM fixation solution Formaldehyde, phosphate-
buffered 
Glutaraldehyde 
Cacodylate buffer, pH 7.35 
2% (v/v) 
 
2% (v/v) 
0.1 M 
Eosin G staining solution Eosing G-solution 0.5% 
acetic acid 
200 mL 
one drop, approx. 50 µL 
Oil Red O staining solution Oil Red O 
2-Propanol 
0.5% (w/v) 
100 mL 
PBS-T PBS 
Tween20 
9.55 g/L 
0.05% (v/v) 
PCR Mastermix 5X Flexi Green 
25 mM MgCl2 
10 mM dNTP’s 
10 µM oIMR-0212 primer 
10 µM oIMR-0213 primer 
10 µM oIMR-0214 primer 
5 u/µL goTaq DNA polymerase 
Water (de-ionized) 
4 µL per sample 
1.6 µL per sample 
0.4 µL per sample 
1 µL per sample 
1 µL per sample 
1 µL per sample 
0.2 µL per sample 
9.8 µL per sample 
Ponceau S solution Ponceau S 
Trichloroacetic acid 
Water (de-ionized) 
0.2% (w/v) 
3% (v/v) 
 
Pre-perfusion solution Procaine hydrochloride 
Heparin 
Sodium chloride 0.9% solution 
5 g/L 
2 mL/L 
 
TBST 
pH 7.45 
TRIS 
NaCl 
 
Tween20 
Water (de-ionized) 
0.1 M 
1 M 
0.1% (v/v) 
 
Toluidine blue staining solution  Toluidine blue 
Water (de-ionized) 
1% (w/v) 
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2.3 Kits 
Table 2.5: Commercial kits used in this work. 
Kit Company 
Cell Proliferation ELISA, BrdU Roche Diagnostics GmbH, Mannheim, Germany 
IL-6 ELISA kit, EZMIL6 Merck Millipore, Darmstadt Germany 
ImmPACT™ DAB Substrate kit Vector Laboratories, Burlingame, California, USA 
In Situ Cell Death Detection Kit, Fluorescein, 
TUNEL kit 
Roche Diagnostics GmbH, Mannheim, Germany 
Lipid Peroxidation (MDA) assay kit Sigma-Aldrich, Steinheim, Germany 
Mouse SAA2 (Serum Amyloid A2) ELISA kit, 
E-EL-M1349 
Elabscience Biotechnology Inc., Houston, Texas, USA 
Pierce™ BCA Protein Assay Kit Thermo Scientific, Rockford, Illinois, USA 
Tyramide SuperBoost™ kit with AlexaFluor™ Invitrogen, Eugene, Oregon, USA 
Caspase-GLO® 3/7 Assay Systems assay Promega, Madison, Wisconsin, USA 
 
2.4 Antibodies 
Table 2.6: Antibodies used in this work. 
Antibody Isotype/species Company 
BrdU, #5292 mouse Cell Signaling Technology 
Caspase 3, #9661 rabbit Cell Signaling Technology 
CD31, ab28364 rabbit Abcam 
CD45, ab10558 rabbit Abcam 
Cleaved Caspase 3, #9662 rabbit Cell Signaling Technology 
Cy3-conjugated, 111-165-003 (anti-rabbit), 115-
165-003 (anti-mouse) 
goat Jackson Immuno Research 
CyclinD1, ab134175 rabbit Abcam 
DyLight488-conjugated, 115-485-003 (anti-
mouse), 111-485-003 (anti-rabbit) 
goat Jackson Immuno Research 
E-cadherin, #3195 rabbit Cell Signaling Technology 
ERK1/2, #4696 mouse Cell Signaling Technology 
HPRT, ab10479 rabbit Abcam 
2. MATERIALS 
 
 
22 
HRP-conjugated anti-mouse IgG, #7076 horse Cell Signaling Technology 
HRP-conjugated anti-rabbit IgG, #7074 goat Cell Signaling Technology 
IL-6, MAB406 rat R&D Systems 
mMR16-1, anti-IL6R rat Chugai Pharmaceutical Co. Ltd. 
PARP, #9542 rabbit Cell Signaling Technology 
P-cadherin, ab190076 rabbit Abcam 
PCNA, M0879 mouse DAKO 
phospho-ERK1/2, #4370 rabbit Cell Signaling Technology 
phospho-S139-γH2A.X, ab11174 rabbit Abcam 
phospho-Stat3, #9145 rabbit Cell Signaling Technology 
phospho-Y654-β-catenin, E-AB-20830 rabbit Elabscience, Biozol, Eching, Germany 
Rat IgG, isotype control, 10700 rat Thermo Fisher Scientific 
SOCS3, ab16030 rabbit Abcam 
Stat3, #9139 mouse Cell Signaling Technology 
VE-cadherin, ab33168 rabbit Abcam 
β-actin, #3700S mouse Cell Signaling Technology 
β-catenin, #8480 rabbit Cell Signaling Technology 
 
2.5 Apparatus 
Table 2.7: Apparatuses used in this work. 
Apparatus Software Company 
BioDoc Analyze BioDoc Analyze Biometra, Analytik Jena, Germany 
BX43F equipped with DP80 dual 
CCD camera 
cellSens Dimension V1.8 Olympus, Germany 
ChemiDOC™ XRS+ ImageLab v5.2.1 Bio-Rad Laboratories, Munich, Germany 
Cryostat CM3050 S - Leica, Germany 
EASY nLC 1000 - Thermo Scientific™, USA 
EVOS FL Auto2 Evos software, Celleste Thermo Scientific™ Invitrogen™, USA 
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Fully-enclosed tissue processor 
ASP300 
Built-in Leica, Germany 
GloMax® Multi Detection 
System 
Built-in Promega, USA 
Histoscan SCN400 ImageScope 12.3.3 Leica, Germany 
Infinite M200 pro Tecan i-control 2.0 Tecan, Austria 
LMD7000 Leica AVC Standard Leica, Germany 
Meta 510 Zeiss LSM software Zeiss, Jena, Germany 
Microtome RM2 - Leica, Germany 
Mixer mill MM 400 - Retsch GmbH, Germany 
Packard TriCarb 1900 TR Liquid 
Scintillation Analyzer 
Built-in Perkin Elmer, USA 
Paraffin embedding module 
EG1150 H 
- Leica, Germany 
PCR Biometra Tone Built-in Analytik Jena, Germany 
PerfectBlue blot chamber - PeqLab, VWR, Germany 
Q Exactive Plus Orbitrap - Thermo Scientific™, USA 
Sonopuls HD - Bandelin electronic GmbH, Berlin, 
Germany 
Steam heater FS 20 - Braun, Germany 
Taqman 7500 7500 Software v2.0.6 AppliedBiosystems, Life Technologies 
GmbH, Germany 
TCS SP8 LAS X Leica, Germany 
 
2.6 Software 
ImageJ-Fiji version 2011 (“Madison”), ImageLab 5.2, GraphPad Prism 6, Microsoft Paint, Omero web 
v5.4.10, Microsoft Office 2013, QuPath v0.2.0-m8 and EndNote were used for this work. 
 
2.7 Animals 
In this work, C57BL/6N mice from Janvier Labs, La Genest-Saint-Isle, France were purchased and 
animal handling and procedures for this work were performed in accordance with German regulations, 
legal requirements and animal welfare guidelines. Animals were housed at the Department of 
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Pharmacology, University of Cologne, Germany. The project was approved by local authorities, 
Landesamt für Natur, Umwelt und Verbraucherschutz, Nordrhein-Westfalen and the Bezirksregierung 
Köln, Germany under the licenses and identification codes 84-02.04.2014.A057 (project A057, organ 
harvest at E15.5 and E18.5) and 84-02.04.2016.A046 (project A046, organ harvest at E11.5, E15.5, 
E18.5, in vivo studies at E15.5, mMR16-1 or IgG therapy at E15.5 and interleukin-6 knock-out (IL-6-/-) 
on HFD). IL-6-/- BL/6N mice were generated from B6.129S2-IL6tm1Kopf/J mice [78] purchased from 
The Jackson Laboratory, Bar Harbor, Maine, USA which were housed in the Center for Molecular 
Medicine Cologne (CMMC). Since wild type mice for HFD and SD groups were from a BL/6N strain, the 
B6.129S2-IL6tm1Kopf/J were backcrossed over 10 generations with wild type BL/6N mice. Preferably 
male IL-6+/- offspring were mated with wild type females and all offspring were genotyped to confirm 
knock-out of one allele. After 10 generations of backcrossing, IL-6+/- male offspring from one parent pair 
and IL-6+/- female offspring from another parent pair were mated to generate IL-6-/- animals that were 
used for experiments and received HFD. 
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3. Methods 
 
The following sections have been partially published in (Appel, Schulze-Edinghausen, Kretschmer et al. 
2017 [79], Nüsken et al. 2019 [80], Kretschmer et al. 2020 [81] or in revision for publication by 
Kretschmer et al. Biology of Reproduction, 2020). 
 
3.1 Animal models, handling and in vivo studies 
In this work, mice were maintained at 20 – 24°C, 45 – 65% humidity, 12 hours light/dark cycles, at a 
maximum of 4 control diet or 3 HFD mice per cage. Mice either received a control / standard diet (SD, 
R/M-H, Ssnif®, Soest, Germany) or HFD (C1057 modified, Altromin, Lage, Germany) ad libitum from 
week 3 of age and until the end of experiments, schematized in Figure 3.1.1.1. Mice were considered 
obese when they reached a body weight of more than 23.5 g. Male mice for mating were received at 
week 8 of age and kept solely on SD. For mating, one non-obese SD dam lighter than 23.5 g or one 
obese HFD dam was mated overnight (O/N) for approximately 20 hours, with a male mouse, while 
further receiving the respective diet ad libitum. The next morning was considered as E0.5. Dams were 
weighed once per week and before the section day to assess pregnancy, together with visual 
examination of the belly. Several SD and HFD dams (project A046) were allowed to give birth to 
determine pregnancy duration. Pregnant dams were transferred to the experimentation site at 
embryonic day E11.5, E15.5 or E18.5 for sacrifice and organ harvest, or at E15.5 for in vivo studies with 
18F-FDG or 14C-mannitol. One and a half hour before sacrifice for organ harvest, dams from A046 
projects were injected with 10 mg/mL BrdU dissolved in D-PBS. For in vivo studies and sacrifice for 
organ harvest, dams from A046 projects received subcutaneously 0.1 mg/kg bodyweight buprenorphine 
dissolved in sodium chloride 0.9% solution 30 minutes prior to sacrifice. For organ harvest, mice were 
euthanized under CO2 and subsequently blood was drawn by cardiac puncture. The body was then 
opened along the linea alba to perform a caesarian section and retrieve the feto-placental units. 
Additionally, epigonadal white adipose tissue (egWAT) and other organs were collected by one dissector 
and egWAT weight as well as number of alive and resorbed fetuses were documented. At the same 
time, fetuses were removed, decapitated, weighed (only E15.5 and E18.5 fetuses) and collected by 
another dissector. Next, placentas were removed, weighed (if collected in total and removed of amniotic 
and uterus tissue for biochemical analysis) and collected. Some placentas were cut in halves and one 
of the resulting halves was either embedded in Tissue-Tek® OCT on dry ice or fixed in 4% (v/v) 
formaldehyde O/N. From the other placenta half, amnion sac and connective tissue were carefully 
removed and this half was snap frozen in liquid nitrogen. Placentas for stereological analysis were 
removed as a whole, thus undamaged with parts of the uterus and attached tissues, and immediately 
fixed in formaldehyde. After formaldehyde fixation, organs were stored for at least one additional night 
in 70% (v/v) 2-propanol in de-ionized water before paraffin-embedding in an ASP300. 
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3.1.1 In vivo studies involving radioactive tracers 18F-FDG and 14C-mannitol 
For in vivo studies, pregnant dams were transferred to the experimentation site at E15.5 under adequate 
transportation conditions. Positron emission tomography (PET) was performed at the Department of 
Nuclear Medicine, University Hospital of Cologne with the help and under the supervision of PD Dr. 
Heike Endepols. Dams were put under general anesthesia using isoflurane inhalation (1,5 – 5% 
isoflurane, 30% O2 and up to 70% medicinal air) which took place 30 minutes after dams received 
subcutaneously 0.1 mg/kg bodyweight buprenorphine dissolved in sodium chloride 0.9% solution. Mice 
were kept on warm plates (37°C), breathing was visually controlled and Bepanthen® was applied to the 
eyes. Starting with the injection of 125 µL with 10 MBq 18F-FDG dissolved in 125 µL sodium chloride 
0.9% solution via a tail vein catheter and subsequent scanning for 60 minutes. After the emission scan, 
a transmission scan with a 57Co point source was performed for attenuation correction. Afterwards, the 
tail vein catheter was removed while a tourniquet was gently applied to the base of the tail. The resulting 
drop of blood was used to determine blood glucose concentration of dams. After the procedure, dams 
were allowed to wake up and afterwards were kept in their cages for 24 hours to achieve almost 
complete decay of 18F-FDG which has a half-life time of ~110 minutes [82]. On the next day, dams were 
injected with buprenorphine as described above, euthanized by CO2 inhalation and the fetuses were 
subsequently removed and decapitated. 
For 14C-mannitol clearance experiments, dams were relocated to the isotope laboratory of the CMMC 
and handled and anesthetized as described above. A similar procedure was performed as described by 
Sibley [83]. During the procedure, the jugular vein was exposed and injected with 100 µL of 3.5 µCi of 
14C-mannitol. Roughly 3 minutes after injection, the animal was opened along the linea alba to expose 
the uterus and access the inferior vena cava from which blood was drawn 4 to 4.5 minutes after tracer 
injection. Subsequently, feto-placental units were collected, viable and resorbed fetuses counted and 
each decapitated fetus and placenta was weighed. Next, placentas were discarded and fetuses were 
minced in biosol at 56°C O/N. On the next day, 10 mL of scintillation liquid was added to 100 µL of 
maternal serum and to each dissolved fetus. Both were put in a Packard TriCarb 1900 TR Liquid 
Scintillation Analyzer for beta decay counting. Materno-fetal clearance (Kmf) expressed as µL per minute 
per gram of placenta was calculated from collected data on beta decay in maternal serum and minced 
fetuses. 
 
3.1.2 mMR16-1 and IgG interventions 
The antibody mMR16-1, a mousenized anti-IL-6R antibody, was kindly provided by Chugai 
Pharmaceutical Co. Ltd. (Japan), and used according to manufacturer’s suggestions and agreement. 
HFD dams were injected intraperitoneally (i.p.) with concentrations of antibody as suggested by Chugai 
Pharmaceutical and as reported by Wu et al. [84] of 25 mg/kg bodyweight of mMR16-1 at E0.5, E7.5 
and E14.5 or 10 mg/kg bodyweight of rat IgG isotype control (IgG) antibody to investigate the effect of 
IL-6 signaling blockade. Pregnant dams were sacrificed at E15.5 after injection of BrdU and 
buprenorphine, and organs were collected, as described above. 
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Figure 3.1.1.1: Mouse model and interventions used in this work. C57BL/6N wild type mice were randomly 
assigned to SD or HFD after weaning at the age of 3 weeks. Mice were mated at an age of 12 to 16 weeks. When 
obese (body weight > 23.5 g), HFD mice were mated and afterwards for several mice mMR16-1 therapy or control 
IgG therapy were conducted by injections on E0.5, E7.5 and E14.5. SD and HFD dams were dissected at E11.5, 
E15.5 and E18.5 to retrieve blood and organs (placentas, egWAT, etc.). Several SD and HFD dams were allowed 
to give birth to determine pregnancy duration. Further, mMR16-1, IgG and IL-6-/- mice were dissected only at E15.5. 
IL-6-/- mice received HFD after weaning and when obese, they were mated and were dissected only at E15.5 to 
collect blood and organs (placentas, egWAT, etc.). 
 
3.2 Histochemical, immunohistochemical and immunofluorescence methods 
The microscopic analysis of tissues and organs requires the segmentation of these biological specimens 
in micrometer-thin sections. The staining of such sections enables detection of structures and, when 
using epitope-specific antibodies, even the identification of many (macro-)molecules, such as proteins 
[85]. As mentioned above, organs and tissues gathered for this work were embedded either in Tissue-
Tek®OCT or in paraffin after dissection from animals. Paraffin-embedded tissues were molded in blocks 
on a heated EG1140 H and, after hardening, were sectioned on a RM2 microtome at various 
thicknesses, i.e. 7 µm for stereology immunohistochemistry (IHC), 5 µm for other IHC, or 3 µm for 
immunofluorescence (IF). For stereology IHC [81], the tissue blocks were exhaustively sectioned and a 
random section between the first 40 sections was determined. This random section and the following 2 
sections comprised one interval, and every 40th following section of this interval were also collected, e.g. 
sections 17, 18, and 19 (interval 1), then sections 57, 58, and 59 (interval 2), then sections 97, 98, and 
99 (interval 3), and so on until the placenta was completely sectioned. One section from interval 1 and 
all 40th consecutive sections, e.g. sections 17, 57, 97, etc., were stained by hematoxylin and eosin. 
Another section from the first interval and all 40th consecutive sections, e.g. sections 18, 58, 98, etc., 
were stained by IHC with CD31 primary antibody. The use of IHC protocols permits the specific 
identification and localization of epitopes bound by a primary antibody. Staining signals originate after 
incubation with a secondary antibody conjugated with a horseradish peroxidase (HRP) that catalyzes 
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the specific reaction of DAB to a brown-colored staining product at the site of reaction which is thus 
specific to the primary antibody. Staining protocols for histochemical, IHC or IF of paraffin-embedded 
sections always comprised de-waxing in 3 changes of NeoClear® for 15 minutes, 1 change of each 
100%, 96%, 80%, 70% ethanol and de-ionized water for 1 minute each. Subsequently, re-hydrated 
sections were either subjected to a) hematoxylin staining (histochemistry) or b) heat-induced epitope 
retrieval (HIER) for IHC and IF. For a) hematoxylin staining, sections were incubated in Mayer’s 
hematoxylin for 5 minutes, rinsed in de-ionized water, blued under running tap water for 10 minutes and 
rinsed again in de-ionized water. Afterwards, eosin staining was performed in eosin G staining solution 
for 2 minutes. Slides were then rinsed in de-ionized water twice and de-hydrated in ascending 
concentrations of ethanol (70 – 100%) for 1 minute each. Lastly, slides were kept in 2 changes of 
NeoClear® for 5 minutes each and were mounted in NeoMount®. Sections that received b) HIER for 25 
minutes in citrate buffer pH 6 were subsequently cooled for at least 30 minutes. Tissues on the slides 
were outlined with a hydrophobic pen, rinsed in PBS-T and blocked in urea-hydrogen peroxide (1 tablet 
per 5 mL) for 10 minutes. Urea-hydrogen peroxide was discarded and slides were then incubated with 
Sea Blocking buffer for 1 hour. Sea Blocking buffer was discarded and primary antibody (Table 3.1) was 
incubated O/N at 4°C. Next, sections were washed for 5 minutes in PBS-T, 3 changes, and ZytoChem 
Plus HRP One-Step Polymer anti-Mouse/Rabbit/Rat was incubated subsequently for 30 minutes at 
room temperature (R/T). Sections were then washed in PBS-T and treated with ImmPACT™ DAB 
substrate according to manufacturer instructions. Reactions were stopped by immersing sections in de-
ionized water. Then, sections were counterstained with Mayer’s hematoxylin for 2 minutes, rinsed in de-
ionized water and put under running tap water for 10 minutes. After a rinse in de-ionized water, sections 
were de-hydrated in ascending concentrations of ethanol, kept in NeoClear® and mounted in 
NeoMount® as described above. 
 
Table 3.1: Antibody dilutions used in this work for IHC and IF. 
Antibody IHC/IF Dilution (in antibody diluent) 
BrdU IF 1:1000 
CD31 IHC & IF 1:300 
CD45 IHC 1:2000 
Cy3-conjugated IF 1:400 
DyLight488-conjugated IF 1:400 
E-cadherin IHC & IF 1:1000 (IHC), 1:100 (IF) 
HRP-conjugated-goat anti-rabbit 
(Tyramide SuperBoost™) 
IF 1:500 
Lamininγ1 IF 1:100 
P-cadherin IHC & IF 1:1000 (IHC), 1:100 (IF) 
VE-cadherin IHC & IF 1:1000 (IHC), 1:100 (IF) 
β-catenin IHC & IF 1:200 (IHC), 1:100 (IF) 
γH2A.X IF 1:4000 
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IF was performed on sections close to the placental mid-line where the cord was present and sections 
were treated similarly to b) HIER. Briefly, after urea-hydrogen peroxide treatment, sections were 
incubated with 300 mM glycine in de-ionized water for 30 minutes before Sea blocking for 1 hour. 
Primary antibodies (Table 3.1) were incubated O/N at 4°C. Then, sections were washed 3 times in PBS-
T for 5 minutes and the secondary antibody was applied for 1 hour, i.e. either a Cy3-conjugated, 
DyLight488-conjugated, or HRP-conjugated-goat anti-rabbit from Tyramide SuperBoost™ kit according 
to manufacturer instructions. Afterwards, sections were washed in PBS-T and Tyramide SuperBoost™ 
(Table 2.5) treated sections were further treated with working solution and stop solution. For 
multiplexing, Tyramide SuperBoost™ treated sections were again subjected to HIER, blocking, primary 
and secondary antibody incubation as described above. Note that multiplexing with primary antibodies 
of different host species, e.g. rabbit and mouse, was performed without the use of Tyramide 
SuperBoost™ secondary antibodies, but utilized a Cy3-cunjugated secondary antibody against rabbit 
and a DyLight488-conjugated secondary antibody against mouse or vice versa. Sections were 
subsequently washed in PBS-T and nuclear-counterstained with DAPI (1:1000 in antibody diluent). 
Lastly, sections were washed in PBS-T, rinsed in de-ionized water and mounted using Fluoromount™. 
Since paraffin-embedding disposes tissues of lipids that were once inside tissues and cells, 
histochemical staining protocols for lipids, such as Oil Red O staining, are best performed on native 
tissue [85]. To this end, placentas were embedded in Tissue-Tek® OCT immediately after dissection, 
stored at -80°C and sectioned on a Cryostat CM3050 S. For Oil Red O, 5 µm thick non-consecutive 
sections were prepared, transferred on dry ice and fixed promptly in -20°C cold methanol for 1 minute. 
After a short rinse in de-ionized water, sections were treated with 60% (v/v) 2-propanol in de-ionized 
water for 5 minutes at R/T and were subsequently stained in Oil Red O staining solution for 20 minutes 
at R/T. Sections were then rinsed twice in de-ionized water and counterstained with Mayer’s hematoxylin 
as described above before mounting with Fluoromount™. Sections were scanned on a Histoscan 
SCN400. 
 
3.2.1 Quantitation of IHC and IF stained sections 
The analysis and quantitation of IHC and IF stained tissue sections was performed by blinded 
investigators to avoid bias. 
CD45-IHC stained placental and egWAT sections were counted as follows: three or five randomly 
chosen pictures of 343.43 µm by 258.59 µm from placental or egWAT sections, respectively, were used 
for CD45-positive cell counting. Cells were counted in ImageJ Fiji using the cell counter tool. Positive 
cell counts were normalized to the tissue area analyzed and expressed as positive cells per mm². Five 
sections from independent dams per group were stained and analyzed. 
To quantify IF stained BrdU, γH2A.X, TUNEL-positive and EC nuclei in placental sections, scanned 
sections were divided in 10 equally sized frames and 3 frames were manually counted using the cell 
counter tool in ImageJ Fiji. The first frame that was counted originated close to the middle section of the 
Lz, the second frame lied on the distal end of the Lz and the third frame lied in between the other 2 
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frames, schematized in Figure 3.2.1.1. Total cell nuclei number per frame was automatically counted in 
the DAPI channel by Fiji using particle analysis. Positive cell counts were normalized to the total number 
of cell nuclei for CD31 stained EC and expressed as percentage of positive cells. Typically, 6 to 7 
sections from independent dams per group were analyzed. 
 
 
Figure 3.2.1.1: Scheme of framing for cell counting analysis of placenta Lz. This example of a hematoxylin 
and eosin stained placenta visualizes the frame segmentation by 10 equally sized green rectangles of the Lz, of 
which 3 were chosen for cell counting, indicated by black arrows. One frame is on the distal end, one frame is in 
the center of the Lz and the third lies between those other two. For better visualization, a hematoxylin and eosin 
stained placenta is shown, however the framing was applied in the same way on IF stained sections for cell counting. 
 
3.2.2 Quantitation of Oil Red O sections 
Analysis of scanned Oil Red O stained sections was done with QuPath. Using unstained and Oil Red O 
stained placental tissue regions virtually extracted from multiple sections, a random forest pixel classifier 
was trained to predict positive and negative pixels. The labyrinth zone was manually annotated in each 
section and afterwards the classifier was used to detect Oil Red O positive pixels. Subsequently, stain-
positive area fraction per section was calculated and normalized to total placenta area. During the 
procedure, the investigator was blinded for sample affiliation. 
 
3.3 Stereological analysis of the placenta 
The three-dimensional (3D) properties of tissues and organs can be estimated by calculating these 3D-
properties from 2D-histo sections [86]. To this end, placentas and adjacent tissue were stained as 
mentioned above. After sections were digitalized on a Histoscan SCN400, they were processed into 
4096 by 4096 pixel tiles with a scale of 3.96 µm/pixel. Line and point grids were superimposed on these 
tiles and points falling on placental strata, i.e. labyrinth zone (Lz), junctional zone (Jz), decidua or 
chorionic plate, as well as fetal capillary profiles and intersections of a line with fetal capillaries (FC) or 
maternal blood sinuses (MBS) were counted in ImageJ Fiji (see Figure 4.2.2.2 and Figure 4.3.5.1). 
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Densities of volumes, surface area and others were calculated using the following equations published 
by Coan [24]: 
V(Obj) = t × a(p) × Σ P         (1) 
S(structure) = (2 × Σ I(structure)/I(p) × Σ P(reference)) × V(reference)     (2) 
Vv(struc,ref) = P(struc)/P(total)         (3) 
LV(cap) = 2QA          (4) 
d = 2[(VV(struc)/LV(cap))/π]1/2        (5) 
 
Where V(Obj) equals the assumed placental volume, t is the number of sections multiplied by their 
thickness, a(p) is the area attributed to a grid point, Σ I(structure) equals the sum of intersections of the line 
with the structure (MBS or FC), Σ P(reference) is the total number of points on the Lz, I(p) equals the length 
of the line associated with each grid point, Vv(struc,ref) denotes the volume fraction of a placental stratum 
(e.g. Lz, Jz) within the placental reference space, P(struc) equals the number of points attributed to the 
stratum and P(total) is the number of points falling on the reference structure, i.e. the placenta, and the 
respective stratum, QA represents the numerical density of capillaries per unit area of Lz, LV(cap) is the 
length density of fetal capillaries, and d represents the mean diameter of these capillaries. The 
calculated values were then multiplied by the absolute placental volume to generate absolute quantities. 
Values were further weight-averaged for each placenta [81]. 
 
3.4 Laser-capture microdissection and proteomics profiling 
The placental halves embedded in Tissue-Tek® OCT were further used to generate 16 µm thick 
placental sections which were transferred onto PEN-Membrane slides for laser-capture microdissection 
(LCM). This procedure utilizes a LMD7000 microscope equipped with a laser that can be controlled to 
dissect specific fractions of a tissue section. To differentiate between placental Lz which was aimed to 
collect by LCM and other placental zones, sections were stained with toluidine blue. In brief, sections 
were first fixed in 70% (v/v) ethanol in de-ionized water supplemented with cOmplete EDTA-free 
Protease Inhibitor Cocktail at 4°C for 1 minute. Subsequently, sections were rinsed in de-ionized water 
and stained in toluidine blue for 1 minute followed by a rinse in de-ionized water and 70% (v/v) ethanol. 
Sections were then dried for at least 1 hour at R/T before LCM was performed [80]. The settings used 
on the LMD7000 for dissection can be found in Table 3.2. During LCM, between 8 and 12 mm² of 
dissected placental tissues were collected from 3 sections per placenta, 5 placentas per group, 1 
placenta per dam. After collection, SP3 lysis was performed as described by Hughes [87]. In brief, SP3 
buffer was added to each tube at a volume similar to the volume of collected placental tissue. Samples 
were then heated at 95°C for 10 minutes and chromatin degraded in a Diagenode Bioruptor for 10 
minutes (cycle 30/30 seconds) at R/T. Afterwards, DTT was added to a final concentration of 5 mM, 
vortexed and incubated for 30 minutes at 55°C. Then, CAA was added to a final concentration of  
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40 mM, vortexed and incubated for 30 minutes in the dark at R/T. Samples were frozen at -20°C until 
mass spectrometry and proteomics data analysis by the staff of the CECAD Proteomics Facility.  
Table 3.2: Settings on LMD7000 for LCM of placental sections. 
Power 16 – 18 
Aperture 20 
Velocity 7 
Specimen Balance 23 
Head Current 100% 
Pulse Frequency 201 
 
3.4.1 Mass Spectrometry 
To analyze samples, Q Exactive Plus Orbitrap (Thermo Scientific) mass spectrometer coupled to an 
EASY nLC 1000 (Thermo Scientific) was used. Peptides were loaded with solvent A (0.1% (v/v) formic 
acid in de-ionized water) onto an in-house packed analytical column (50 cm — 75 µm I.D., filled with  
2.7 µm Poroshell EC120 C18, Agilent). Chromatographical separation of peptides was done at a 
constant flow rate of 250 nL/minute with the following gradient: 3 – 5% solvent B (0.1% formic acid in 
80% acetonitrile) within 1.0 minute, 5 – 30% solvent B within 119.0 minutes, 30 – 50% solvent B within 
19.0 minutes, 50 – 95% solvent B within 1.0 minute, followed by washing and column equilibration. The 
mass spectrometer was set to data-dependent acquisition mode. The MS1 survey scan was acquired 
from 300 – 1750 m/z at a resolution of 70,000. Isolation of the top 10 most abundant peptides was done 
within a 2.1 Th window and peptides were subjected to HCD fragmentation at a normalized collision 
energy of 27%. A maximum injection time of 60 milliseconds was applied, as the AGC target was set to 
5e5 charges. Product ions were detected at a resolution of 17,500 in the Orbitrap. Dynamic exclusion 
of precursors was set for 25.0 seconds [80]. 
 
3.4.2 Proteomics data analysis 
Maxquant (version 1.5.3.8) with default parameters was utilized to process raw data from mass 
spectrometry. Briefly, MS2 spectra were searched against the Uniprot MOUSE.fasta database with a 
list of common contaminants included. False discovery rates (FDR) on protein and PSM level were 
estimated by the target-decoy approach to 1% (Protein FDR) and 1% (PSM FDR), respectively. A 
minimal peptide length of 7 amino acids was set and carbamidomethylation at cysteine residues was 
considered as a fixed modification. Oxidation (M) and Acetyl (Protein N-term) were included as variable 
modifications. The match-between runs option was enabled. LFQ quantification was enabled using 
default settings. Further analysis was carried out with Perseus (version 1.5.5.3). Briefly, LFQ values 
were log2-transformed, and proteins flagged as “potential contaminants”, “reverse” and “only identified 
by site” were removed from the data set. Only proteins which have been quantified in all samples were 
retained after filtering the data. A two-sample Student’s t test was used to determine statistically 
significant changes [80]. 
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3.5 Electron microscopy 
To obtain placentas for electron microscopy, pregnant dams were perfusion fixated at E15.5. First, dams 
were injected subcutaneously with 0.1 mg/kg bodyweight buprenorphine dissolved in sodium chloride 
0.9% solution 30 minutes prior to perfusion. Then, perfusion was performed in deep isoflurane 
anesthesia as mentioned above under 3.1.1. The animal was opened along the linea alba, the uterus 
was carefully placed outside the belly to ensure perfusion of uterine vessels, and the heart was exposed 
by incision of the thorax and removal of several ribs. A cannula was carefully inserted into the left 
ventricle while pre-perfusion solution (Table 2.4) was running which was placed about 1.2 m above the 
animal. Once the cannula was placed, this solution ran for 2 minutes after which it was switched to 
formaldehyde Roti®-Histofix 4% for another 10 minutes. Successful fixation was determined by 
inspecting the liver, which appeared light brown, and a kidney, which appeared pale with dark stains. 
Next, uteri and feto-placental units were removed to collect placentas. These were cut in 2 mm by 2 mm 
by 2 mm sized tissue cubes from the center of the organ and transferred into EM fixation solution for  
4 hours at 4°C. Afterwards, tissues were transferred to 10X D-PBS until epon-embedding by Mojgan 
Ghilav of the Research Group of Prof. Wilhelm Bloch, at the Department of Molecular and Cellular Sports 
Medicine, Institute of Cardiovascular Research and Sports Medicine, German Sport University Cologne, 
Cologne, Germany. Mrs. Ghilav also prepared semi- and ultra-thin sections for EM at the Department 
of Anatomy I, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 
Germany, which was performed by Tim van Beers.  
 
3.6 Protein isolation and detection 
Approximately 25 mg of placental tissue, that was snap frozen in liquid nitrogen after dissection, was 
manually ground using a 1.5 mL-reaction tube mortar in modified RIPA buffer. Lysed tissues were kept 
on ice and were sonicated for 20 seconds at 50% energy and 3 × 10% cycle on a Sonopuls HD, then 
incubated on ice for 1 hour and subsequently centrifuged at 18,500 g for 5 minutes at 4°C. Supernatants 
were collected and protein concentration was determined using Pierce™ BCA Protein Assay kit 
according to manufacturer instructions on an Infinite M200 pro at 562 nm. For protein detection, 20 to 
30 μg of protein was added to 5X western blot loading buffer and de-ionized water and separated on 
8% to 12% acrylamide SDS-PAGE under reducing conditions, followed by transfer onto a nitrocellulose 
membrane by blotting for 2 hours at 1.3 mA/cm2, and at R/T using Towbin buffer. After blotting, 
membranes were shortly rinsed in de-ionized water and stained for 2 minutes in Ponceau S solution. 
Afterwards, membranes were washed 3 times in TBST and were blocked with 2% BSA, 5% non-fat dry 
milk powder (w/v) in TBST for 1 hour on a shake plate at R/T. Next, membranes were incubated with 
primary antibodies for 30 minutes at R/T followed by incubation O/N at 4°C. On the next day, membranes 
were washed 3 times for 7 minutes in TBST and secondary antibodies against primary antibody species 
were applied for 1 hour at R/T. Membranes were washed in TBST and subsequently incubated for 
detection with ECL for 1 minute. Images were taken on a ChemiDoc XRS+. From those images, 
densitometric analysis was performed using ImageLab software.  
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3.7 Enzyme-linked immunosorbent assays of serum proteins 
 
3.7.1 IL-6 ELISA 
The concentration of IL-6 in undiluted maternal serum from E15.5 was measured by IL-6 ELISA kit 
EZMIL6. Manufacturers’ protocols were followed to perform IL-6 ELISA. Plates were read on an Infinite 
M200 pro at the respective wavelengths. 
 
3.7.2 Serum amyloid A2 (SAA2) ELISA 
SAA2 concentration was measured in undiluted maternal serum, from E15.5 dams from which received 
i.p. injections of mMR16-1 or IgG, by mouse SAA2 ELISA kit in animals. The ELISA was performed 
according to manufacturer instructions and plates were read on an Infinite M200 pro at the respective 
wavelengths. 
 
3.8 Genotyping 
Table 3.3: Genotyping primers used in this work 
Name Type Sequence Company 
oIMR0212 Primer (common) 5’-TTCCATCCAGTTGCCTTCTTGG-3’ Eurofins Genomic 
oIMR0213 Primer (wild type 
reverse) 
5’-TTCTCATTTCCACGATTTCCCAG-3’ Eurofins Genomic 
oIMR0214 Primer (mutant 
reverse) 
5’-CCGGAGAACCTGCGTGCAATCC-3’ Eurofins Genomic 
 
3.8.1 DNA extraction 
Backcrossing of B6.129S2-IL6tm1Kopf/J IL-6+/- to BL/6N background with BL/6N IL-6 wild type mice 
required genotyping of offspring before weaning in order to select IL-6+/- offspring for subsequent 
backcrossing. To this end, ear tags from 3 week old mice were collected and lysed in 500 µL tail lysis 
buffer pH 8 supplemented with 5 µL Proteinase K per sample O/N at 55°C on a shake plate. Next,  
500 µL of 2-propanol was added and incubated for 10 minutes at R/T after which samples were 
centrifuged at 20,000 g for 15 minutes at 4°C. Supernatant was removed and the DNA-pellets washed 
with 500 µL of 70% ethanol of -20°C before repeating centrifugation for 10 minutes. Again, supernatant 
was removed and the DNA-pellets were air-dried for 1 hour before adding 50 µL de-ionized water and 
vortexing thoroughly. Samples were kept at 4°C from that point on. 
 
3.8.2 PCR and agarose gel electrophoresis 
First, an adequate amount of PCR mastermix was made with specific primers (Table 3.3). After mixing, 
1 µL of extracted DNA was added to 19 µL PCR mix. Reaction tubes were placed in a PCR Cycler 
Biometra Tone and the protocol from Table 3.4 was applied. 
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Table 3.4: Steps in the PCR cycling program 
Step Time Temperature 
Denaturation  3 minutes 94°C 
36 cycle Denature 30 seconds 94°C 
Anneal 1 minute 62°C 
Extend 1 minute 72°C 
Extension  10 minutes 72°C 
Cool and hold  indefinitely 4°C 
 
For gel electrophoresis, a 1.5% agarose gel was made with Midori Green. Then, samples were added 
and the electrophoresis was run at 110 V. The gel was removed and imaged on a BioDoc Analyze. An 
example of genotyping can be found in Appendix 6.1 (Figure 6.1.1). 
 
3.9 Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) 
 
3.9.1 qPCR oligonucleotides 
Table 3.5: Oligonucleotides used in this work. IL6 and TNFα primer have been published elsewhere [79, 88], MCP1 
to CAT primer have been published elsewhere [79]. 
Name Type Sequence Company 
E-cadherin 
(CDH1) 
Forward primer 
Reverse primer 
Taqman probe 
5’-CAGTCATAGGGAGCTGTCTACCAAA-3’ 
5’-GGGTACACGCTGGGAAACAT-3’ 
5’-CACCACCACCGCGACCCTGC-3’ 
Eurofins Genomics 
P-cadherin 
(CDH3) 
Forward primer 
Reverse primer 
Taqman probe 
5’-GACATGGATGGAGAGGGCTCTA-3’ 
5’-CTCATACTTCTGCGGCTCAAACT-3’ 
5’-CCTTGATGCCAACGATAACGCTCCG-3’ 
Eurofins Genomics 
VE-cadherin 
(CDH5) 
Forward primer 
Reverse primer 
Taqman probe 
5’-TGGCCAAAGACCCTGACAAG-3’ 
5’-TCGGAAGAATTGGCCTCTGT-3’ 
5’-CTCAGCGCAGCATCGGGTACTCCAT-3’ 
Eurofins Genomics 
β-catenin 
(CTNNB1) 
Forward primer 
Reverse primer 
Taqman probe 
5’-GGACGTTCACAACCGGATTG-3’ 
5’-GGACCCCTGCAGCTACTCTTT-3’ 
5’-CCATTGTTTGTGCAGTTGCTTTATTCTCCC-3’ 
Eurofins Genomics 
β-actin (ACTB) Forward primer 
Reverse primer 
Taqman probe 
5’-TGACAGGATGCAGAAGGAGATTACT-3’ 
5’-GCCACCGATCCACACAGAGT-3’ 
5’-ATCAAGATCATTGCTCCTCCTGAGCGC-3’ 
Eurofins Genomics 
HPRT (HPRT1) Forward primer 
Reverse primer 
Taqman probe 
5’-TGGCCATCTGCCTAGTAAAGCT-3’ 
5’-TAGGCTCATAGTGCAAATCAAAAGTC-3’ 
5’-TTTTTAGAAATGTCAGTTGCTGCGTCCCC-3’ 
Eurofins Genomics 
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GAPDH Forward primer 
Reverse primer 
Taqman probe 
5’-ATGTGTCCGTCGTGGATCTGA-3’ 
5’-TGCCTGCTTCACCACCTTCT-3’ 
5’-CCGCCTGGAGAAACCTGCCAAGTATG-3’ 
Eurofins Genomics 
IL6 Forward primer 
Reverse primer 
Taqman probe 
5‘-ACAAAGCCAGAGTCCTTCAGAGA-3‘ 
5‘-CACTCCTTCTGTGACTCCAGCTTA-3‘ 
5’-AGTCCTTCCTACCCCAATTTCCAATGCTC-3’ 
Eurofins Genomics 
TNFα Forward primer 
Reverse primer 
Taqman probe 
5’-GGCTGCCCCGACTACGT-3’ 
5’-GACTTTCTCCTGGTATGAGATAGCAA-3’ 
5’-CCTCACCCACACCGTCAGCCG-3’ 
Eurofins Genomics 
MCP1 Forward primer 
Reverse primer 
Taqman probe 
5’-GGCTCAGCCAGATGCAGTTAAC-3’ 
5’-CTTGGTGACAAAAACTACAGCTTCTT-3’ 
5’-CCCCACTCACCTGCTGCTACTCATTCA-3’ 
Eurofins Genomics 
CXCL1 Forward primer 
Reverse primer 
Taqman probe 
5’-AGACCATGGCTGGGATTCAC-3’ 
5’-AGCCTCGCGACCATTCTTG-3’ 
5’-CTGCACCCAAACCGAAGTCATAGCCAC-3’ 
Eurofins Genomics 
CXCL10 Forward primer 
Reverse primer 
Taqman probe 
5’-CATCCCTGCGAGCCTATCC-3’ 
5’-CCCTTTTAGACCTTTTTTGGCTAA-3’ 
5’-CCCACGTGTTGAGATCATTGCCACG-3’ 
Eurofins Genomics 
IL1A Forward primer 
Reverse primer 
Taqman probe 
5’-TGGCAACTCCTTCAGCAACA-3’ 
5’-TCGGGAGGAGACGACTCTAAATA-3’ 
5’-TCAGATTCACAACTGTTCGTGAGCGCTC-3’ 
Eurofins Genomics 
IL1B Forward primer 
Reverse primer 
Taqman probe 
5’-TGACAGTGATGAGAATGACCTGTTC-3’ 
5’-GGACAGCCCAGGTCAAAGG-3’ 
5’-ACCCCAAAAGATGAAGGGCTGCTTCC-3’ 
Eurofins Genomics 
CYBA Forward primer 
Reverse primer 
Taqman probe 
5’-CGTCTGGCCTGATTCTCATCA-3’ 
5’-GATAGAGTAGGCGCCGAAATACC-3’ 
5’-CATCGTGGCTACTGCTGGACGTTTCAC-3’ 
Eurofins Genomics 
CYBB Forward primer 
Reverse primer 
Taqman probe 
5’-CCCAACTGGGATAACGAGTTCA-3’ 
5’-TCAGGGCCACACAGGAAAAC-3’ 
5’-ACCATTGCAAGTGAACACCCTAACACCACA-3’ 
Eurofins Genomics 
NCF1 Forward primer 
Reverse primer 
Taqman probe 
5’-CACCTTCATTCGCCATATTGC-3’ 
5’-ACAGGTCCTGCCACTTAACCA-3’ 
5’-CATCCCCAGCCAGCACTATGTGTACATGT-3’ 
Eurofins Genomics 
NCF2 Forward primer 
Reverse primer 
Taqman probe 
5’-CCGATATTCCACCACCTCCTAA-3’ 
5’-CATAGGCACGCTGAGCTTCA-3’ 
5’-TCACCAGGTCACAAGCAAAAAGAGCCC-3’ 
Eurofins Genomics 
NOX4 Forward primer 
Reverse primer 
Taqman probe 
5’-GAAGGTCCCTAGCAGGAGAACA-3’ 
5’-ACTGAAAAGTTGAGGGCATTCAC-3’ 
5’-TCTCAGGTGTGCATGTAGCCGCCC-3’ 
Eurofins Genomics 
GPX Forward primer 
Reverse primer 
Taqman probe 
5’-GACACCAGGAGAATGGCAAGA-3’ 
5’-TTCTCACCATTCACTTCGCACTT-3’ 
5’-TGAATTCCCTCAAGTACGTCCGACCTGG-3’ 
Eurofins Genomics 
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SOD Forward primer 
Reverse primer 
Taqman probe 
5’-GTACCAGTGCAGGACCTCATTTTA-3’ 
5’-GTCTCCAACATGCCTCTCTTCAT-3’ 
5’-CTCACTCTAAGAAACATGGTGGCCCGG-3’ 
Eurofins Genomics 
CAT Forward primer 
Reverse primer 
Taqman probe 
5’-CCATCCTTTATCCATAGCCAGAA-3’ 
5’-GAATCCCTCGGTCACTGAACAA-3’ 
5’-TCGTCCCGAGTCTCTCCATCAGGTTTCT-3’ 
Eurofins Genomics 
 
3.9.2 RNA isolation 
Approximately 100 mg of snap frozen tissue, stored at -80°C, was added to 1.5 mL TRI Reagent® and 
homogenized in a Mixer mill MM 400 at 30 Hz for 30 seconds. Depending on tissue rigidity, 
homogenization was repeated up to 4 times. Then, lysates were incubated for 5 minutes at R/T before 
adding 300 µL of chloroform, vortexing and incubating again for 3 minutes. Subsequently, samples were 
centrifuged at 13,680 g for 15 minutes at 4°C to achieve phase-separation of RNA, DNA and debris. 
The topmost phase containing RNA was transferred to a fresh tube and added with 750 µL 2-propanol 
and mixed. Samples were then incubated on ice for 20 minutes and subsequently centrifuged at  
21,000 g at 4°C for 15 minutes. Afterwards, supernatant was removed and the remaining RNA pellet 
washed 2 times with 75% ethanol with centrifugation in between at 21,000 g at 4°C for 5 minutes. The 
supernatant was removed and the pellet was air-dried after which DEPC-H2O was added to resuspend 
the pellet and stored at -80°C. RNA purity and concentration were determined by spectrophotometry on 
an Infinite M200 pro. RNA has an absorption maximum at an optical density (OD) of 260 nm which was 
used to determine RNA concentration, while protein OD of 280 nm was used to calculate RNA purity by 
dividing OD260/OD280. If this ratio is between 1.8 and 2.0, the purity was high and RNA was used for 
generating cDNA. 
 
3.9.3 Generating cDNA stocks 
RNA was reverse transcribed to double-stranded cDNA from 0.5 µg RNA dissolved in DEPC-H2O. The 
resulting amount of cDNA stocks proved sufficient for the estimated number of qPCR assays required. 
RNA samples were first treated according to manufacturer’s instruction with RQ1 DNAse (1u/µL) plus 
RQ1 DNAse buffer for 15 minutes at R/T after which reactions were stopped with RQ1 DNAse stop 
solution and incubation for 15 minutes at 65°C. Next, oligo-dT and random primer in DEPC-H2O were 
added and heated to 70°C and incubated for 5 minutes before cool-down on ice for 1 minute. As a 
consequence, oligo-dT primers bind to the poly-A tail at the 3’-end of RNA molecules and random 
primers further bind at several random locations on the RNA strand. Then, reverse transcription was 
achieved by adding DNA polymerase, reaction buffer, dNTP mix, RNasin® and DEPC-H2O and 
incubating for 1 hour at 37°C. At the end, the reaction was stopped by incubating samples on ice for  
1 minute. Resulting cDNA stocks were kept at -20°C.  
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3.9.4 RT-qPCR assays 
RT-qPCR assays utilizing cDNA stocks (2.5 µL for Platinum® or 1 µL for SyBR®) and oligonucleotide 
primers (Table 3.5) were prepared with Platinum® qPCR SuperMix-UDG with ROX or SYBR® Green 
Master Mix. qPCR plates were run on a Taqman 7500 using TAMRA quencher and FAM reporter. The 
delta-delta Ct method was used to calculate gene expression fold changes for each assay [89]. For 
normalization, housekeeping genes ACTB, HPRT1 and GAPDH were used. Graphs in the result section 
show results after normalization to the housekeeping gene that was most homogeneously expressed in 
both tested groups. Normalized data were similar among housekeeping genes (data not shown). 
Table 3.6: Platinum ® Taqman temperature and cycling. 
Step Cycles Stage Time Temperature 
Step 1  Holding stage 2 minutes 50°C 
Step 1  Holding stage 10 minutes 95°C 
Step 1 
40 cycles 
Cycling stage 15 seconds 95°C 
Step 2 Cycling stage 1 minute 60°C 
 
Table 3.7: SyBR® temperature and cycling. 
Step Cycles Stage Time Temperature 
Step 1  Holding stage 2 minutes 95°C 
Step 1 
40 cycles 
Cycling stage 15 seconds 95°C 
Step 2 Cycling stage 1 minute 60°C 
Step 1  Melt curve stage 15 seconds 95°C 
 
3.9.5 Lipid peroxidation assay 
A marker for lipid oxidation and thus oxidative stress, malondialdehyde (MDA), was detected utilizing 
the Lipid Peroxidation (MDA) assay kit. In brief, 10 mg of placental tissue were homogenized in MDA 
lysis buffer and processed further according to manufacturer’s instructions. Basically, the assay 
measures the production of a colorimetric product from the reaction of MDA with TBA and this reaction 
product can be quantitated by spectrophotometry at an absorbance maximum of 532 nm, measured on 
Infinite 200 pro.  
 
3.10 Cell culture studies 
Culturing of cells was done in humid incubators at 37°C and 5% CO2. For handling, cells were 
transferred to a cell culture hood with laminar flow which was decontaminated with ethanol and UV-light 
on a daily basis to provide as sterile working conditions as possible. Media were supplemented with 
PenStrep to avoid bacterial contamination, and mycoplasma contamination tests of culture media were 
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regularly performed. All solutions from non-sterile source added to cell cultures were either autoclaved 
or sterile-filtered prior to use. 
 
3.10.1 Cell culture medium 
Table 3.8: Cell culture media purchased and used in this work. 
Medium Company 
DMEM/F12, HEPES #11039-021 Gibco®, Carlsbad, California, USA 
Endothelial cell medium #1001 ScienCell, Carlsbad, California, USA 
 
3.10.2 Cell lines 
Table 3.9: Commercial cell lines used in this work. 
Cell line Company 
BeWo, ACC-No. 458 Deutsche Sammlung von Mikroorganismen und Zellkulturen 
(DSMZ), Braunschweig, Germany 
HPVEC, #7100 ScienCell, Carlsbad, California, USA 
 
3.10.3 Maintenance of cell lines 
Human trophoblast-derived choriocarcinoma cells (BeWo) were purchased from DSMZ and cultured 
according to manufacturer instructions. Briefly, cells were thawed carefully in a 37°C water bath until 
completely thawed and then transferred to 9 mL fresh DMEM/F-12 HEPES medium. This medium was 
supplemented with 1% (v/v) PenStrep and 10% (v/v) FBS. Cells in medium were centrifuged at 125 g 
for 3 minutes, supernatant was removed and cells were resuspended in 1 mL medium before plating in 
flasks. Typically, every 48 hours, the cell medium was changed and cells were split shortly before 
reaching 100% confluence by removing the medium, washing with D-PBS and incubating with trypsin-
EDTA for 3 to 5 minutes at 37°C. Fresh medium with FBS and PenStrep was subsequently added to 
block trypsin-EDTA. Cells in suspension were centrifuged at 125 g for 3 minutes to remove supernatant 
and 1 mL of fresh medium was added to resuspend. Either 1/4 or 1/5 of cell suspension were then plated 
in 75 cm² flasks filled with approximately 10 mL of fresh medium. 
Human placental vein endothelial cells (HPVEC), which are primary placenta cells from one placenta/lot, 
were purchased from ScienCell and cultured in accordance with manufacturer instructions. In brief, cells 
were received at passage one, thawed and then plated in flasks filled with 10 mL fresh endothelial cell 
medium supplemented with 1% (v/v) endothelial cell growth supplements, 5% (v/v) FBS and 1% (v/v) 
PenStrep. Flasks were coated with 0.2% (v/v) gelatin in de-ionized water on the day before plating cells. 
To this end, gelatin was diluted with de-ionized water to 0.2% and 7.5 mL gelatin solution was incubated 
in a 75 cm2 flask for 1 hour. When cells were seeded, the medium was changed 16 hours after first 
plating to remove residual DMSO. From there, medium was changed every 48 hours and cells were 
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split before reaching confluence similar as described above, however, 1/2 of cell suspension was plated 
per 75 cm² flask. After 8 passages, HPVEC were not further split or used for assays, since they are 
primary cells.  
 
3.10.4 Stimulation of cells 
The influence of cytokines or fatty acids on cell behavior and protein expression was studied by applying 
cell medium supplemented with either a dissolved fatty acid or hyperIL-6 (description below) to cells in 
culture. Fatty acids were purchased as sodium palmitate (PA), sodium oleate (OA) and linoleic acid 
sodium salt (LA) and were first dissolved in de-ionized water to a final concentration of 50 mM and mixed 
in a heated shaker at 70°C. For cell stimulation, fatty acids were further diluted in cell medium 
supplemented with 5% (w/v) protease-free and fatty acid-free BSA to a final concentration of 2.5 mM. 
To enhance dissolution, these 2.5 mM stocks were heated to 40°C for 15 minutes on a shake plate. 
Stimulation of cells with IL-6 was done with a fusion protein of IL-6 and its soluble IL-6R. The bioactive 
fusion protein hyperIL-6 is constructed by recombinant human IL-6 (Val30 – Met212) which is ligated to 
a small glycine and serine-rich peptide chain with the sequence ‘GGGSGGGSGGGS’ to the IL-6 
receptor-alpha (Leu20 – Asp358) [90]. HyperIL-6 was received at a concentration of 500 µg/mL and was 
diluted 1:100 in culture medium to generate a stock solution before further diluting to the required final 
concentrations. 
 
3.10.5 Cell culture for protein detection 
Cells were seeded in 6-well plates at a density of 300,000 cells per well. To achieve this density, cells 
were counted in a Neubauer chamber after splitting. After seeding in wells, cells were maintained in 
medium O/N, approximately 16 hours. Then, medium was removed and cells were either stimulated 
with a) medium plus FBS plus PenStrep or b) medium plus FBS plus PenStrep with 5% (w/v) protease-
free and fatty acid-free BSA or c) various concentrations of fatty acids (PA, OA or LA) dissolved in 
medium as described above or d) medium plus FBS plus PenStrep with hyperIL-6. To assess 
phosphorylation of Stat3 after hyperIL-6 stimulation, cells were incubated for 15 minutes with hyperIL-6 
in medium at 37°C. Stimulation with fatty acids was performed for 24 hours at 37°C. After stimulation, 
medium was removed and cells were put on ice after adding 1 mL of 4°C cold PBS. Cells were collected 
in D-PBS, centrifuged at 125 g for 3 minutes, washed in D-PBS twice and supernatant was removed. 
Pellets were then frozen and stored at -80°C. After four repetitions per stimulation, frozen pellets were 
thawed on ice and 40 µL modified RIPA buffer was added, vortexed and incubated on ice for 1 hour. 
Next, samples were centrifuged at 18,500 g for 5 minutes at 4°C and supernatant was transferred to 
fresh tubes. Supernatant was used in a Pierce™ BCA Protein Assay to determine protein abundance in 
duplicate and for protein detection, 20 µg of protein were used as described above (section 3.6). 
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3.10.6 Permeability assay 
BeWo cells were split and seeded in inserts with a pore size of 0.4 µm at a density of 50,000 cells/insert 
in a 24-well plate filled with 800 µL medium per well and 300 µL medium per insert. Typically, medium 
was replaced after 48 hours and cells took 48 to 72 hours to reach confluence which was confirmed by 
staining cells with CellStain® and inspection under a microscope. When confluent, medium was 
removed and cells were treated with fatty acids for 24 hours. Afterwards, medium was carefully removed 
from inserts and inserts were transferred to a fresh 24-well plate filled with 800 µL plain DMEM/F12 
medium (without FBS, PenStrep). Subsequently, 300 µL of Streptavidin-HRP diluted 1:20 in plain 
medium was added to each insert and incubated for 30 minutes at 37°C. Next, inserts were removed 
and 30 µL from each underlying well was transferred on a 96-well plate in triplicates. Then, 50 µL of 
TMB substrate solution was added to each well and incubated for 20 minutes at R/T on a shake plate. 
Reaction was stopped by applying 25 µL of 2N H2SO4 to each well and absorption was subsequently 
measured at 450 nm on an Infinite M200 pro. 
 
3.10.7 AdipoRed assay 
The intracellular accumulation of triglycerides can be quantified by AdipoRed assays. To this end, 
15,000 cells per well were plated in 96-well plates and allowed to sit O/N, approximately 16 hours. Then, 
medium was removed and 100 µL medium plus fatty acids was added as described above and incubated 
for 8 hours. After incubation, medium with fatty acids was removed, cells were rinsed in D-PBS and  
100 µL of AdipoRed staining solution was added to each well and incubated for 10 minutes at 37°C. 
Immediately afterwards, fluorescence was read with excitation/emission 485/572 nm on a GloMax® 
Multi Detection System. 
 
3.10.8 Tube formation assay 
The formation of vessel structures, so called tubes, is a characteristic of several cells and cell lines, like 
HPVEC. In order to assess their tube formation capacity and changes in tube formation due to 
stimulation with hyperIL-6, HPVEC were subjected to this assay. A µ-slide was coated with 10 µL 4°C 
cold, growth factor-reduced matrigel and incubated for 45 minutes to 1 hour at 37°C. Afterwards, 5,000 
HPVEC per well were seeded directly in stimulation (10 ng/mL or 50 ng/mL hyperIL-6) or control medium 
(without hyperIL-6). The seeded µ-slide was placed in an incubator for 1 hour at 37°C after which it was 
transferred to a pre-heated confocal Zeiss Meta 510 microscope equipped with an incubator chamber 
set to 37°C and 5% CO2. After 12 hours of incubation with stimulants or control medium, images of the 
wells were taken to manually count closed tubes using ImageJ Fiji. The number of such tubes was then 
normalized to the total analyzed area.  
 
3.10.9 Caspase-GLO® 3/7 apoptosis assay 
HPVEC apoptosis was detected by a commercial Caspase-GLO® 3/7 assay. After coating a 96-well 
plate with 0.2% gelatin, 15,000 cells per well were seeded and allowed to attach for 12 hours. 
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Afterwards, cells were stimulated without, with 10 ng/mL or 50 ng/mL hyperIL-6 for 12 hours. 
Subsequently, Caspase-GLO® 3/7 assay was used to detect caspase activity following manufacturer’s 
instructions. 
 
3.10.10 Cell proliferation assay with BrdU 
Proliferation of HPVEC was determined by cell proliferation ELISA with BrdU from commercial source. 
To this end, a 96-well plate was coated with 0.2% gelatin and 10,000 cells/well were seeded and cultured 
for 12 hours. Afterwards, cells were stimulated without, with 10 ng/mL or 50 ng/mL hyperIL-6 for  
12 hours before removing stimulants and added fresh stimulation medium with BrdU and incubating for 
24 hours. BrdU incorporation in HPVEC was measured according to manufacturer’s instructions.  
 
3.10.11 Cell senescence by beta-galactosidase assay 
Senescence of HPVEC was assessed by seeding 10,000 cell per well in a gelatin-coated 96-well plate 
after which cells were allowed to attach for 12 hours. Next, cells were stimulated with, i.e. 10 ng/mL or 
50 ng/mL of hyperIL-6, or without hyperIL-6 for 48 hours. Afterwards, the senescence-associated  
beta-galactosidase activity was determined as previously published [91]. In brief, after incubation with 
stimulants for 48 hours, cells were washed twice with D-PBS and fixed in 2% formaldehyde plus 
0.2% glutaraldehyde in D-PBS solution. Next, cells were washed twice with D-PBS and fresh beta-gal 
staining solution was added and incubated O/N at 37°C. On the next day, cells were washed with  
D-PBS and transferred to a BX43F microscope to scan wells and take images (DP80 dual CCD camera 
and cellSens Dimension V1.8 software). Using ImageJ Fiji, blue-colored beta-gal positive cells were 
counted and relative senescence rate was calculated. 
 
3.11 Statistical analyses 
Statistical analyses were performed with GraphPad Prism software. D’Agostino and Pearson test was 
used to determine normality distribution of the data. Sets of normally distributed data were analyzed by 
two-tailed Student’s t test or one-way ANOVA followed by Tukey’s multiple comparison test (indicated 
in figure description) and non-normally distributed data were analyzed by two-tailed Mann-Whitney test 
(indicated in figure description). Significant difference was determined by a p value of <0.05. Graphs of 
data calculated or published before May 2019 are shown as mean ± SEM independent of normal 
distribution or non-normal distribution. Later, after consulting a statistician, graphs of data are shown as 
mean ± SEM if normally distributed and as median ± interquartile range if non-normally distributed. Due 
to the large dataset in proteomics profiling, Student’s t test p values were post-tested by the method of 
Benjamini-Hochberg correction [92] and significant difference after correction was determined by a  
q value of <0.05. Further details are shown in the figure descriptions. 
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4. Results 
 
4.1 The pre-delivery inflammatory reaction is mitigated by MO in C57BL/6N mice 
Note: This part of the results section, i.e. “The pre-delivery inflammatory reaction is mitigated by MO in 
C57BL/6N mice”, was published in the Journal of Reproductive Immunology in the article “Maternal 
obesity attenuates predelivery inflammatory reaction in C57BL/6N mice” [79]. Sarah Appel, Merle 
Schulze-Edinghausen and Tobias Kretschmer contributed equally to this work with the help of several 
others: 
Animal handling and tissue collections was performed by Ruth Janoschek, Inga Bae-Gartz, Marion 
Handwerk and Sarah Appel. The qPCR assays were prepared and performed by Merle Schulze-
Edinghausen, Tobias Kretschmer and Maria Wohlfarth, while data calculation was done by Merle 
Schulze-Edinghausen and Sarah Appel. Histological stainings (IHC for CD45) were performed by 
Tobias Kretschmer, while picture processing for cell counting was done by Merle Schulze-Edinghausen 
and Tobias Kretschmer. Lipid peroxidation assay was performed by Merle Schulze-Edinghausen and 
Maria Wohlfarth. Malte Heykants performed multiplex cytokine assays. Statistical analyses were 
performed by Merle Schulze-Edinghausen, Sarah Appel and Tobias Kretschmer. The project was 
supervised and supported by technical input and advice by Kai-Dietrich Nüsken, Eva Hucklenbruch-
Rother, Esther Mahabir, Jörg Dötsch and Sarah Appel. 
 
4.1.1 Inflammation, leukocyte infiltration and oxidative stress in placental tissue and egWAT 
Two time-points of murine gestation, E15.5 which represents the beginning of the third trimester of 
pregnancy and E18.5 which represents the end of the third trimester shortly before parturition, were 
investigated on placental and egWAT level. While SD dams usually gave birth around E19, HFD dams 
took about an extra day before giving birth (Figure 4.1.1.2 D). Gene expression of IL-6 and TNFα, two 
pro-inflammatory cytokines, was significantly increased in placentas of SD dams on E18.5 compared to 
E15.5. MCP1 and the murine IL-8 homologue CXCL1 were not significantly altered and CXCL10, IL-1α 
and IL-1β were down-regulated without reaching statistical significance (Figure 4.1.1.1 B). On E18.5 in 
placentas of obese dams, TNFα was significantly up-regulated compared to E15.5 and IL-6, MCP1, and 
IL-1β were unaltered in expression. CXCL1, CXCL10 and IL-1α on the other hand appeared down-
regulated, but without reaching statistical significance (Figure 4.1.1.1 C). Concomitantly, with an 
increase in IL-6 and TNFα gene expression at E18.5 compared to E15.5 in SD dams, there was 
significant infiltration of leukocytes (CD45-positive) in the Lz. This increase in leukocytes towards the 
end of pregnancy was not observed in HFD dams (Figure 4.1.1.1 A). Further, in both, SD and HFD 
placentas, lipid peroxidation, a marker for oxidative stress, as assessed by MDA assay was significantly 
increased at E18.5 compared to E15.5, however MDA level were also significantly higher in HFD 
placentas at E18.5 compared to SD (Figure 4.1.1.1 D). Anti-oxidative genes GPX and CAT were 
significantly down-regulated at E18.5 compared to E15.5 in SD placentas, whereas pro-oxidative stress 
genes remained largely unaltered (Figure 4.1.1.1 E).  
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The pro-oxidative genes CYBB, NCF1 and NCF2 were significantly up-regulated in placentas of obese 
dams at E18.5 compared to E15.5 and the anti-oxidative CAT gene expression was significantly reduced 
(Figure 4.1.1.1 F). 
 
 
Figure 4.1.1.1: Inflammation, leukocyte infiltration and oxidative stress measurements in placentas at E15.5 
and E18.5. (A) Quantitation of CD45-positive leukocytes in the Lz of the placenta of obese and lean dams at E15.5 
and E18.5, n = 5 placentas for both groups and both gestations days. (B) Gene expression measurement by qPCR 
of pro-inflammatory factors in placentas of SD dams normalized to ACTB at E15.5 and E18.5. Expression was set 
to 1 for E15.5 and the fold change on E18.5 relative to E15.5 is shown. For SD at E15.5 n = 16 placentas from  
5 dams, at E18.5 n = 25 placentas from 5 dams. (C) Gene expression measurement by qPCR of pro-inflammatory 
factors in placentas of HFD dams normalized to ACTB at E15.5 and E18.5. Expression was set to 1 for E15.5 and 
the fold change on E18.5 relative to E15.5 is shown. For HFD at E15.5 n = 21 placentas from 5 dams, at E18.5  
n = 25 placentas from 5 dams. (D) Lipid peroxidation assay to determine oxidative stress level as assessed by 
change in MDA in placentas of SD and HFD dams at E15.5 and E18.5. For SD n = 11 placentas from 11 dams of 
E15.5 and n = 9 placentas from 9 dams of E18.5. For HFD n = 10 placentas from 10 dams of E15.5 and n = 10 
placentas from 10 dams of E18.5. (E) Gene expression measurement by qPCR of oxidative stress markers in 
placentas of SD dams normalized to ACTB at E15.5 and E18.5. Expression was set to 1 for E15.5 and the fold 
change on E18.5 relative to E15.5 is shown. For SD at E15.5 n = 21 placentas from 5 dams, at E18.5 n = 25 
placentas from 5 dams. (F) Gene expression measurement by qPCR of oxidative stress markers in placentas of 
HFD dams normalized to ACTB at E15.5 and E18.5. Expression was set to 1 for E15.5 and the fold change on 
E18.5 relative to E15.5 is shown. For HFD at E15.5 n = 21 placentas from 5 dams, at E18.5 n = 25 placentas from 
5 dams.  ns = not significant; * p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001, calculated by two-tailed Student’s 
t test (for normally distributed data) or a Mann-Whitney test (for non-normally distributed data). Graphs show  
mean ± SEM. Figure was published in Appel, Schulze-Edinghausen, Kretschmer et al. [79] Figure 1 and was 
modified. 
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We further investigated inflammatory markers in the egWAT of both diet groups and gestation days, 
since we hypothesized that the egWAT might produce higher amounts of inflammatory markers that 
could affect uterine tissues due to its proximity to these tissues. Significantly elevated expression of  
pro-inflammatory genes IL-6, TNFα, CXCL1, CXCL10, MCP1 and IL-1β were measured in egWAT of 
SD dams at E18.5 compared to E15.5 (Figure 4.1.1.2 B). By contrast, these genes remained unaltered 
in egWAT of obese dams (Figure 4.1.1.2 C). Additionally, the amount of leukocytes was not significantly 
altered in egWAT in either diet group at E15.5 or E18.5 (Figure 4.1.1.2 A).  
 
 
Figure 4.1.1.2: Leukocyte infiltration, inflammatory factor expression in egWAT at E15.5 and E18.5, and 
duration of gestation. (A) Quantitation of CD45-positive leukocytes in the egWAT of SD and HFD dams at E15.5 
and E18.5, n = 5 egWAT for both groups and both gestation days. (B) Gene expression measurement by qPCR of 
pro-inflammatory factors in egWAT of SD dams normalized to ACTB at E15.5 and E18.5. Expression was set to 1 
for E15.5 and the fold change on E18.5 relative to E15.5 is shown. For SD at E15.5 n = 8, at E18.5 n = 5. (C) Gene 
expression measurement by qPCR of pro-inflammatory factors in egWAT of HFD dams normalized to ACTB at 
E15.5 and E18.5. Expression was set to 1 for E15.5 and the fold change on E18.5 relative to E15.5 is shown. For 
SD at E15.5 n = 8, at E18.5 n = 8. (D) Duration of gestation expressed as the “birth date at Gx” in SD and HFD 
dams. n = 8 for SD and n = 11 for HFD. ns = not significant; * p <0.05, ** p <0.01, calculated by two-tailed Student’s 
t test (for normally distributed data) or a Mann-Whitney test (for non-normally distributed data). Graphs show  
mean ± SEM. Figure was published in Appel, Schulze-Edinghausen, Kretschmer et al. [79] Figure 1 and was 
modified. 
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4.2 MO affects EC homeostasis and causes elevated IL-6 serum level which could cause EC 
senescence 
Note: This part of the results section, i.e. “MO affects EC homeostasis and causes elevated IL-6 serum 
level which could cause EC senescence”, was recently published in parts in Nutrients in the article 
“Effect of Maternal Obesity in Mice on IL-6 Levels and Placental Endothelial Cell Homeostasis” [81]. 
This work was made possible with the help of several others: 
Animal handling and tissue collections was performed by Eva-Maria Turnwald, Ruth Janoschek, Inga 
Bae-Gartz, Marion Handwerk, Sarah Appel and Tobias Kretschmer. The qPCR assays were prepared 
and performed by Merle Schulze-Edinghausen and Maria Wohlfarth, while data calculation was done 
by Sarah Appel and Tobias Kretschmer. Protein isolation and detection were performed by Maria 
Wohlfarth, densitometric analysis was contributed by Sarah Appel and Tobias Kretschmer. Histological 
stainings (IHC) were performed by Merle Schulze-Edinghausen and Tobias Kretschmer (IHC, IF and 
Stereology), while picture processing for stereology was done by Peter Zentis and analysis of IF and 
stereology sections was conducted by Tobias Kretschmer. The IL-6 ELISA on serum samples was 
conducted by Merle Schulze-Edinghausen. Cell culture assays and analyses (apoptosis, BrdU, 
senescence-associated beta-galactosidase and tube formation assay) were performed by Merle 
Schulze-Edinghausen and Tobias Kretschmer (tube formation assay). Statistical analyses were 
performed by Merle Schulze-Edinghausen, Sarah Appel and Tobias Kretschmer. The project was 
supervised and supported by technical input and advice by Astrid Schauss, Eva Hucklenbruch-Rother, 
Jörg Dötsch and Sarah Appel. 
 
The significant reduction of fetal weight (0.3786 ± 0.004382 g in HFD vs. 0.4482 ± 0.008337 g in SD,  
p < 0.0001) in HFD offspring of this animal cohort (project A057) at E15.5 was previously reported by 
Appel et al. [93]. In this work, fetal IUGR was also observed (Figure 4.4.1.1 B, Figure 4.6.1.1 B). In the 
work of Kretschmer et al. [81], the aim was to elucidate if a defective vascularization of the placenta 
under MO might contribute to the observed IUGR phenotype. 
 
4.2.1 Significant reduction in EC marker expression in placentas under MO 
Gene activity (mRNA expression) and protein level of EC markers in whole placental lysates of E15.5 
were determined to study the effect of MO on vascularization of the placenta (Figure 4.2.1.1). The qPCR 
assays revealed significant down-regulation of the EC markers CD31, vWF and Tie-1 in placentas of 
HFD dams. Expression level were normalized to ACTB and HPRT. Data is shown for normalization to 
HRPT (Figure 4.2.1.1 A). For normalization to ACTB, similar results were obtained (data not shown). 
The marker CD31 is primarily found in the Lz of placentas which harbors the transfer zone for nutrient 
and gas exchange (Figure 4.2.1.1 B). Additionally, CD31 protein level was significantly lower (p 0.03) in 
whole placental lysates from HFD dams. Interestingly, a similar, significant reduction (p 0.0006) in CD31 
protein level was observed in placentas of dams of project A046 (Figure 4.2.1.1 F). Hence, data 
indicates an effect of MO on ECs of the transfer zone. 
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Figure 4.2.1.1: EC marker level under MO. (A) Gene expression in placentas of SD and HFD of vascular EC 
markers CD31, vWF and Tie-1 detected by qPCR and normalized to HPRT; n = 21 placentas from 5 dams in SD, 
n = 21 placentas from 6 dams in HFD group. The p value is indicated above graphs and was calculated by  
Mann-Whitney test. (B) Representative images showing placental sections stained for CD31 by IHC. Left panel 
(scale bar: 200 µm) shows the 3 main zones, Lz, Jz and Db, and CD31 to be primarily expressed in fetal capillaries 
in the Lz as detailed in the right panel (scale bar: 10 µm). (C) Western blot detection of CD31 in SD and HFD 
placentas (project A057). HPRT was detected as loading control. n = 15 placentas from 5 dams for SD and n = 19 
placentas from seven dams for HFD. (D) Densitometric analysis of CD31 signal from western blot in (C) normalized 
to HPRT. (E) Western blot detection of CD31 in SD and HFD placentas (project A046). HPRT was detected as 
loading control. n = 7 placentas, 1 per dam for both SD and HFD. (F) Densitometric analysis of CD31 signal from 
western blot in (E) normalized to HPRT. All graphs show mean ± SEM. The p value is displayed above the graph, 
calculated by Mann-Whitney test. Figure was published in Kretschmer et al. [81], Figure 1 and was modified. 
 
4.2.2 Disturbed EC homeostasis and placental vascular morphology 
Assessing EC homeostasis, i.e. EC proliferation, apoptosis and senescence, was done by means of IF 
staining for BrdU-positive (proliferation), TUNEL-positive (apoptosis) and γH2A.X-positive (senescence) 
EC which were detected specifically by co-staining for the EC marker CD31 (Figure 4.2.2.1 A – C). The 
stainings were performed on sections close to the placental midline and quantitation by cell counting of 
scanned sections in ImageJ Fiji revealed the number of positively stained EC. No difference in BrdU-
positive or TUNEL-positive cell count was observed in the Lz for HFD placentas compared to controls 
(Figure 4.2.2.1 D & E). However, the amount of γH2A.X-positive EC was significantly larger in placentas 
under MO compared to controls (p 0.0262, Figure 4.2.2.1 F). This indicates elevated level of senescence 
in EC as assessed by γH2A.X-positive staining. 
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Figure 4.2.2.1: Placental EC homeostasis under maternal obesity. (A – C) Representative images of placental 
Lz with IF stainings for proliferation marker BrdU (A, green), apoptosis by TUNEL (B, green) and senescence/DNA-
damage marker γH2A.X (C, green). Co-staining was performed for CD31 (red) and nuclei by DAPI (blue). Scale 
bar = 50 µm. (D – F) Quantitation of IF-positively stained EC nuclei by BrdU (D, n = 6 placentas, 1 placenta per 
dam for both groups SD & HFD), by TUNEL (E, n = 6 placentas, 1 per dam for both SD & HFD) and by γH2A.X  
(F, n = 7 placentas, 1 per dam for both SD & HFD). Graphs show mean ± SEM. The p value is denoted above 
graphs in the figure, calculated using Mann-Whitney test. Figure was published in Kretschmer et al. [81], Figure 2 
and was modified. 
 
Vascularization and vessel morphology of the Lz was studied by stereological means and to this end, 
placental section were stained by IHC against CD31 after exhaustive sectioning (Figure 4.2.2.2 A & B). 
Quantitation of FC surface area revealed a significant reduction (p 0.038) in placentas under MO 
concomitant with a significantly decreased total capillary length (p 0.002) and a tendency towards an 
increased capillary diameter (p 0.072) in those placentas compared to controls (Figure 4.2.2.2 C – E). 
These results strongly suggest an impaired vascularization of the placentas in obese dams. 
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Figure 4.2.2.2: Vascular morphology assessed by stereology under MO. (A) Representative image showing 
the Lz in a SD placenta stained with antibodies against CD31 and DAB. A grid for stereological analysis of fetal 
capillary surface area was superimposed on the image. Scale bar = 50 µm. (B) Representative image showing the 
Lz in a SD placenta stained similar to (B) for CD31. A grid was superimposed on the image to assess fetal capillary 
length and diameter. Scale bar = 50 µm. (C – E) Quantitation of fetal capillary surface area (C), fetal capillary length 
(D) and fetal capillary diameter (E) after stereological analyses. Graphs show mean ± SEM. For SD n = 8 placentas 
from 8 dams, for HFD n = 7 placentas from 7 dams, the p values are denoted above graphs in the figure, calculated 
using Mann-Whitney test. Figure was published in Kretschmer et al. [81], Figure 2 and was modified. 
 
4.2.3 Change in level of IL-6 inflammatory marker 
We hypothesized that IL-6 can influence EC homeostasis in placentas of our obese mouse model and, 
as a consequence, determined IL-6 level in the serum of dams at E15.5. Serum IL-6 level was 
significantly elevated (p 0.048) in dams at E15.5 under MO by a margin of nearly 4-fold (Figure 4.2.3.1 
A). Conversely, qPCR assays showed no difference in IL-6 gene expression (p 0.286) in placentas of 
obese dams (Figure 4.2.3.1 B). In addition, detection of IL-6 mRNA in egWAT revealed a 3-fold increase 
compared to control dams that was not statistically significant (p 0.204, Figure 4.2.3.1 D). However, 
weight of the egWAT pad dissected from obese dams was significantly elevated (p <0.0001, Figure 
4.2.3.1 C) and IL-6 protein level detected in egWAT were increased about 2.5-fold (Figure 4.2.3.1 E & 
F), but again without falling below the border of statistical significance (p 0.057). Nonetheless, these 
results suggest that the placenta is not the source of IL-6 production released in the serum and increased 
IL-6 serum level could rather originate from augmented fat pads in obese dams.  
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Figure 4.2.3.1: Interleukin-6 expression level in serum, placentas and egWAT under MO. (A) Serum level of 
IL-6 determined by ELISA in SD (n = 9) and HFD (n = 10) dams. (B) IL-6 gene expression in placental lysates  
(n = 16 from 4 dams in SD and n = 25 from 7 dams in HFD) analyzed by qPCR and normalized to HPRT. (C) Weight 
of dissected egWAT pad, n = 12 for SD and n = 14 for HFD. (D) IL-6 gene expression in egWAT, n = 8 for SD and 
HFD, analyzed by qPCR and normalized to ACTB. (E) Western blot for the detection of IL-6 and HPRT as loading 
control in n = 4 samples of egWAT for SD and HFD. (F) Densitometric analysis of relative IL-6 protein level from 
(E) normalized to HPRT. Graphs show mean ± SEM. The p value is denoted above graphs in the figure, calculated 
using Mann-Whitney test. Figure was published in Kretschmer et al. [81], Figure 3 and was modified. 
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4.2.4 Effect of IL-6 stimulation on placental EC homeostasis 
It has been stated that serum IL-6 is able to pass over the placental barrier and to reach fetal ECs in the 
transfer zone [94, 95]. Furthermore, it was noted that IL-6 also is capable of causing EC activation and 
apoptosis [69], which led us to test the hypothesis that IL-6 can affect placental EC homeostasis 
(proliferation, apoptosis and/or senescence) and tube formation capacity in vitro. To this end, human 
placenta vein endothelial cells (HPVEC) were treated with various concentrations (without IL-6, with  
10 ng/mL or 50 ng/mL) of IL-6 (i.e. hyperIL-6, a bioactive fusion protein of IL-6 and the IL-6R, see 
Methods 3.10.4). To verify the activity of IL-6 in HPVEC cultures, p-Stat3 level as a well-known target 
of IL-6 signaling was assessed, and we found p-Stat3 level to be clearly increased upon IL-6 stimulation 
(Figure 4.2.4.1 A). The effect of IL-6 stimulation of HPVEC on proliferation was determined by BrdU 
assay (Figure 4.2.4.1 B). For quantitation of apoptosis, the Caspase-GLO® 3/7 assay was used and 
senescence was estimated by quantifying senescence-associated beta-galactosidase activity (Figure 
4.2.4.1 C & D). Neither BrdU, nor Caspase-GLO® 3/7 assays showed significant differences after 
treatment with IL-6, indicating no effect of IL-6 on EC proliferation and apoptosis. Conversely, IL-6 
showed a concentration-dependent effect (10 ng/mL, p 0.057; 50 ng/mL, p 0.029) on senescence of EC 
deduced from significantly elevated senescence-associated beta-galactosidase activity (Figure 4.2.4.1 
D). No clear effect was detected for tube formation capacity after IL-6 stimulation (Figure 4.2.4.1 E). 
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Figure 4.2.4.1: The effect of IL-6 stimulation on HPVEC. (A) Analysis of HPVEC after 15 minute-stimulation 
without (-), with 10 ng/mL or 50 ng/mL of IL-6 by western blot. The level of p-Stat3, total Stat3 and ACTB were 
detected. (B) Relative proliferation rates were measured with a BrdU assay after HPVEC were stimulated with 
similar concentrations as in (A) and n = 6 replicates. (C) Relative apoptosis rates were assessed by Caspase-GLO® 
3/7 assay after HPVEC were stimulated similarly to (A) and n = 5 replicates. (D) Relative senescence rates were 
determined with senescence-associated beta-galactosidase activity assays after HPVEC were stimulated similarly 
to (A) and n = 5 replicates. (E) Tube formation capacity was determined after HPVEC were stimulated similarly to 
(A) and n = 5 replicates. Graphs show mean ± SEM. The p value is denoted above graphs in the figure, calculated 
using Mann-Whitney test. Figure was published in Kretschmer et al. [81], Figure 4 and was modified. 
 
4.2.5 No difference in expression of markers for proliferation, apoptosis and senescence, but 
significant reduction in p-Stat3 in placentas of obese dams 
Since increased EC senescence and reduced EC marker expression due to MO were found in 
placentas, molecular marker expression for proliferation, apoptosis and senescence were also assessed 
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in whole placental lysates (Figure 4.2.5.1). Results of western blots and densitometric analyses showed 
no difference for cyclin D1, PCNA (proliferation), γH2A.X (senescence) or cleaved-caspase 3 and PARP 
(apoptosis) expression between placentas of obese and controls dams. However, p-Stat3 was found to 
be significantly reduced in placentas of obese dams. 
 
 
(Figure caption on the next page) 
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Figure 4.2.5.1: Level of markers for proliferation, senescence, apoptosis and IL-6 signaling/transcription in 
placentas at E15.5. (A) Western blotting of placental lysates (SD and HFD: n = 7 placentas, 1 per dam) showed  
p-Stat3, total Stat3, Cyclin D1, PCNA, γH2A.X, PARP, Caspase 3, cleaved caspase 3 and HPRT (loading control) 
protein level. (B) Densitometric analyses of western blots of proliferation markers Cyclin D1 and PCNA normalized 
to HPRT. (C) Densitometric analyses of western blots of the senescence marker γH2A.X normalized to HPRT.  
(D) Densitometric analyses of western blots of apoptosis markers cleaved caspase 3 normalized to total  
caspase 3 and cleaved PARP (~89 kDA) normalized to total PARP (~116 kDA). (E) Densitometric analyses of 
western blots of p-Stat3 normalized to total Stat3. Graphs show median ± interquartile range and * p <0.05, 
calculated using Mann-Whitney test. 
 
4.3 MO impairs trophoblast differentiation, disrupts basement membrane integrity and affects 
cell-cell interactions 
Note: This part of the results section, i.e. “MO impairs trophoblast differentiation, disrupts basement 
membrane integrity and affects cell-cell interactions”, was recently in parts submitted for publication to 
Biology of Reproduction in the article “Maternal, high fat diet-induced obesity affects trophoblast 
differentiation and placental function in mice”. The prospective first author is Tobias Kretschmer and the 
work presented was made possible through the assistance of several others: 
Animal handling and tissue collections was performed by Eva-Maria Turnwald, Marion Handwerk, Sarah 
Appel and Tobias Kretschmer. LCM procedure and protein extraction was conducted by Tobias 
Kretschmer. Quantitation after SP3 lysis was done by the staff of the Cologne Proteomics Facility 
(CECAD), supervised and statistically analyzed by Christian K. Frese. The qPCR assays were prepared 
and performed by Maria Wohlfarth, while data calculation was done by Tobias Kretschmer. Protein 
isolation, detection and densitometric analysis were performed by Tobias Kretschmer. Placenta 
collection by perfusion fixation was conducted by Marion Handwerk and Tobias Kretschmer, while tissue 
embedding and sectioning was done by Mojgan Ghilav. Electron microscopy was performed by Tim van 
Beers and Wilhelm Bloch and observations were interpreted by Wilhelm Bloch and Tobias Kretschmer. 
Histological stainings (IHC, IF, Oil Red O and Stereology) were performed by Tobias Kretschmer, while 
picture processing and scripting for Oil Red O and stereology was done by Peter Zentis and analysis of 
Oil Red O and stereology sections was conducted by Tobias Kretschmer. Cell culture assays and 
analyses (AdipoRed and permeability assays) were performed by Tobias Kretschmer. Data collection 
and statistical analyses were performed by Peter Zentis and Tobias Kretschmer. The project was 
supervised and supported by technical input and advice from Inga-Bae Gartz, Eva Hucklenbruch-
Rother, Jörg Dötsch and Sarah Appel. 
 
4.3.1 The proteomics profile of the Lz is altered regarding cell adhesion and AJ markers in obese 
dams 
LCM was used on cryo-preserved tissue sections of placentas to specifically dissect and collect the Lz 
for the analysis of its proteome profile. Studying the proteomics profile of the Lz permits detection of a 
high number of proteins and can drive a hypothesis-generating approach. In placentas of obese and 
control dams, proteomics profiling revealed two distinct component clusters for each group SD and HFD 
(Figure 4.3.1.1 A) and 1619 proteins were detected. Among these, 126 proteins were significantly 
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different in expression between both groups. For the 126 proteins, q value was below 0.05 and the Log2 
difference was ≤ -0.454 (< 0.73-fold) and ≥ 0.406 (> 1.33-fold) (Appendix 6.2, Table 6.1). These detected 
proteins were put into String database (version 11) and a network of protein clusters was generated in 
which functional pathways and the confidence of protein interactions can be displayed [96].  
 
 
Figure 4.3.1.1: Proteomics profiling revealed altered protein level and clustering under MO. (A) Clustering 
and principal component analysis revealed two different clusters for control (blue, n = 5 placentas, 1 placenta per 
dam) and obese (magenta, n = 4 placentas, 1 placenta per dam) dams. (B) Protein quantitation by proteomics 
profiling of markers for adhesion and cell junction in the Lz from obese compared to control dams. To represent 
halving in expression level, a dotted line was added at a Log2 difference of -1.0. Graphs show mean values.  
(C) String database-generated network of protein interactions in which red-colored nodes (Cdh1, Flot2, Ptk2, 
Lamb2, and Lamc1) are markers of cell adhesion processes, green-colored nodes (Cdh1, Flot2, Iqgap1, Ptk2, and 
Sdc4) are related to adherens junctions, blue-colored nodes (Iqgap1, Rock2, Ptk2, and Sdc4) are related to the 
regulation of cell junction assembly, and magenta-colored nodes (Ptk2, Rock2, Lamb2, and Lamc1) are proteins of 
the KEGG pathway of focal adhesion. The graphic was made in String v11 with the thin lines between nodes 
representing a low interaction and low confidence score (0.150) and the thick lines between nodes representing a 
medium to high interaction and confidence score (>0.400) [96]. All proteins denoted in this figure were significantly 
altered as determined by Student’s t test and Benjamini-Hochberg correction [92] with a q value <0.05. Figure is in 
revision for publication in Kretschmer et al. Biology of Reproduction 2020, Fig. 1 and was modified. 
 
 
From the list of 126 significantly altered proteins, 78 proteins were categorized as protein binding by 
String database, 60 proteins were involved in cellular component organization, 13 were related to cell 
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junctions, and 4 proteins were related to focal adhesion. Among the set of 126 proteins detected in the 
Lz, E-cadherin was found to be the most prominent of the down-regulated cell junction and cell 
adhesion-related proteins (Figure 4.3.1.1 B). According to String database, E-cadherin could share 
protein-interactions with Ptk2, Flot2 and Iqgap1 which are also down-regulated junction and adhesion-
related proteins. Furthermore, two subunits of the major basement membrane protein laminin, i.e. 
Lamb2 and Lamc1, were also found to be significantly decreased in expression (Figure 4.3.1.1 B & C). 
These results suggest altered cell-cell and cell-basement membrane adhesion in placentas of obese 
dams as a consequence of down-regulation of these proteins. 
 
4.3.2 Localization of AJ markers in the Lz 
IHC and IF were used to identify the localization of AJ markers within the Lz and Jz. First, staining for 
β-catenin revealed its intracellular expression in cells of the Lz and Jz. In the Jz, β-catenin was 
particularly present in larger trophoblasts and the staining pattern suggests accumulation primarily at 
the cell membrane boundary and thus the site of cadherin-catenin interaction (Figure 4.3.2.1 A & B). 
Besides, in SynT of the Lz and fetal ECs, β-catenin was also observed (Figure 4.3.2.1 C). In the Lz, 
both E-cadherin and P-cadherin were found (Figure 4.3.2.1 D & G), while in the Jz only P-cadherin was 
weakly stained by IHC and IF (Figure 4.3.2.1 G – I). The transition from Jz to Lz could be well-observed 
by E-cadherin staining which indicates that this cadherin is exclusively and most prominently expressed 
in the Lz (Figure 4.3.2.1 D – F). Using confocal microscopy, the localization of E-cadherin towards the 
SynT cell boundary where cell junctions between SynT layer I and II are present could be highlighted 
(Figure 4.3.2.1 E). Towards the fetal endothelium, there were yellow artifacts of signal overlay. On the 
other hand, P-cadherin expression seemed limited to the apical face of SynT (Figure 4.3.2.1 H).  
VE-cadherin expression was not clearly possible to denote from IHC and IF stains and green staining 
artifacts were observed in fetal blood vessels (Figure 4.3.2.1 J – L). These observations were similar in 
placentas from obese and control dams. 
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Figure 4.3.2.1: AJ marker localization in murine placentas by IF and IHC. Representative images are derived 
from control placentas since HFD had no influence on staining patterns. (A, D, G, J) IHC showed localization of  
β-catenin (A), E-cadherin (D), P-cadherin (G) and VE-cadherin (J) and dotted lines in these panels A, D, G and J 
denote the transition from Lz to Jz. (B, C, E, F, H, I, K, L) IF staining showed β-catenin (B & C, green) in SynT (B, 
vertical arrow heads) and in trophoblasts of the Jz (B, horizontal arrow head) and co-localization to fetal capillary 
CD31-positive (red) ECs (C, arrow head). SynT in the transfer zone were E-cadherin-positive (E & F, green) 
highlighting SynT cell boundaries (E, arrow heads) with minor yellow artifacts (F) towards the endothelial side.  
P-cadherin was localized towards maternal blood sinuses (H & I, green), probably in MTB (H, arrow heads).  
VE-cadherin staining was very poor with green dotted artifacts (K, arrow heads) and indicated no specific IF signal 
and no clear IHC staining pattern (J – L). Scale bars: 50 µm. Figure is in revision for publication in Kretschmer et 
al. Biology of Reproduction 2020, Fig. 2A and was modified. 
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4.3.3 Significant reduction of AJ markers expression under MO at E15.5 
Next, the integrity of AJ was examined by protein quantitation of AJ markers in whole placental lysates. 
We previously reported down-regulation of β-catenin in placentas of obese dams at E15.5 [93], however 
in this work, total β-catenin was down-regulated without reaching statistical significance (p 0.053) in 
whole placenta lysates. The β-catenin phosphorylated at tyrosine 654 (phosphorylated Y654-β-catenin) 
is a marker for reduced E-cadherin to catenin-binding and is observed at ~88 kDa by a fade band in our 
western blots (Figure 4.3.3.1 A) together with a second band at ~92 kDa which is the size of total β-
catenin. Western blot with an antibody specific to total β-catenin confirmed that the 92 kDa band 
detected by the phosphorylated Y654-β-catenin-antibody belongs to total β-catenin. The data showed 
a trend towards up-regulation in placentas of obese dams of phosphorylated Y654-β-catenin, again with 
a certain degree of variability in expression level (Figure 4.3.3.1 A & B). Among the cadherins, E-
cadherin was found significantly reduced, P-cadherin and VE-cadherin showed no clear change in 
expression level compared to controls, but displayed high variability in expression level. Similar to 
observations from western blotting, proteomics profiling specifically of the Lz also showed a significant 
reduction in E-cadherin and a strong tendency for β-catenin down-regulation (Log2 difference -1.2 in 
obese vs. control, q 0.059). On mRNA level, no difference in E-cadherin and VE-cadherin expression 
level were measured in whole placental samples, however, β-catenin expression was strongly reduced 
(p 0.016) when normalized to any of the two housekeeping genes (HPRT and ACTB) in placentas from 
obese dams. P-cadherin expression was only significantly reduced when normalized to ACTB (p 0.031), 
but not HPRT (Figure 4.3.3.1 C). 
 
(Figure caption on the next page). 
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Figure 4.3.3.1: Level of AJ markers on protein and mRNA level in placentas at E15.5. (A) Western blotting of 
whole placental lysates (SD and HFD: n = 7 placentas, 1 per dam) showed phosphorylated Y654-β-catenin (lower 
band at ~88 kDa), total β-catenin (~92 kDa), E-cadherin, P-cadherin, VE-cadherin and HPRT (loading control) level. 
(B) Densitometric analyses of western blots of phosphorylated Y654-β-catenin, total β-catenin, E-cadherin,  
P-cadherin, VE-cadherin normalized to HPRT. Two outliers were excluded from graph, i.e. phosphorylated  
Y654-β-catenin (~88 kDa band, HFD mouse 6) and VE-cadherin (SD mouse 7) indicated by brackets “( )”. Graphs 
show median ± interquartile range and * p value <0.05, ** p <0.01, or p value is shown above graph. (C) Analyses 
of gene expression of AJ markers in placentas by qPCR. Normalization was performed with housekeepings HPRT 
and ACTB and relative expression level of HFD normalized to SD (line at 1.0) are shown in graphs. n = 7 placentas, 
1 per dam, for SD and HFD. Graphs show median ± interquartile range and * p <0.05, calculated using  
Mann-Whitney test. Figure is in revision for publication in Kretschmer et al. Biology of Reproduction 2020, Fig. 2B, 
C and D, and was modified. 
 
4.3.4 MO affects cell homeostasis and cell junctions in the transfer zone and causes lipid 
accumulation in the Lz 
By means of electron microscopy, we aimed to examine ultrastructure and cell junctions in the transfer 
zone of placentas. Control placentas (Figure 4.3.4.1 A – C) displayed a regular phenotype of the transfer 
zone with SynT layer I and II. Both layers shared an undulated cell boundary and had intact cell-cell 
contacts and AJ showing syncytial fusion. Fetal ECs showed ordinary paracellular clefts with AJ and 
tight junctions as well as desmosomes which were identified by higher electron density. Additionally, the 
BM was found regular in thickness and a few segments displayed small deposits of ECM material. In 
SynT, lipid and lipoprotein deposits were rarely seen and their extent was rather small. As a 
consequence, the SynT developed normally and fused which was also evident from SynT II to BM 
contact which was continuous showing no detachments. In stark contrast to controls, placentas from 
obese dams (Figure 4.3.4.1 D – F) displayed major lipid and lipoprotein deposition which could be 
intracellular and extracellular of SynT. The BM was disrupted with excessive lipid and ECM 
accumulation also showing detachment of ECs on one side and SynT on the other side. Besides, both 
ECs and trophoblasts appeared condensed frequently and with irregular nuclei, while the SynT II 
seemed loose from the BM on its basal side. Furthermore, the SynT showed a defective differentiation 
by the absence of a defined cell boundary in electron density which was observed in control placentas. 
Although ECs and SynT showed damaged connection to the BM, there were no apoptotic cells visible. 
On some trophoblasts, entangled membrane deposits and lipoprotein structures were observed in 
placentas of obese dams, but not in control dams.  
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Figure 4.3.4.1: Ultrastructure of the maternal transfer zone of SD and HFD placentas. (A – C) The phenotype 
of control placentas shows the materno-fetal transfer zone with a fetal capillary (FC), endothelial cell (EC) and 
nucleus (n) in addition to the basement membrane (BM, black arrows in A, vertical black arrows in B & C). The 
condensed syncytiotrophoblast layer II (SynT II) and the fused SynT I were observed. The SynT I faces towards 
maternal blood sinus (MBS) on one side and the SynT II on the other side (horizontal white arrow in B). EC showed 
paracellular cleft with cell junctions (horizontal black arrows in B & C), i.e. with AJ and electron dense desmosomes. 
The separating BM between EC and SynT II sporadically showed extracellular matrix deposition (ECM, vertical 
black arrows in B & C). In (B), a small deposit of lipids can be seen (*). (C) A close-up of the framed area in (B).  
(D – F) The ultrastructure in HFD placentas. The BM was disrupted and enriched in ECM deposits (vertical black 
arrows) and ECs and their nuclei appeared condensed. The SynT accumulated high amounts of lipids and 
lipoproteins (*) and seemed undifferentiated and unfused, therefore a second SynT layer could not be observed. 
The connection of ECs and SynT to the BM was disrupted and discontinuous (vertical black arrows in E & F). Cell 
junctions of SynT were barely present (horizontal white arrows in E & F) and entangled cell debris (ß) was observed 
towards the MBS on SynT surface (F). The frame in (D) shows the close-up in (E). In total, 5 different placentas per 
group, 1 per dam, were analyzed and representative images are shown. Scale bar: A & D 5 μm; B, C, E & F 1 μm. 
Figure is in revision for publication in Kretschmer et al. Biology of Reproduction 2020, Fig. 3 A – F and was modified. 
Since extensive lipid deposition was observed in placentas of obese compared to control dams, lipid 
accumulation in the transfer zone was determined by a semi-quantitative approach using Oil Red O 
staining of placental sections. Sections were stained (Figure 4.3.4.2 A – D) and analyzed by pixel 
quantitation which showed a significant increase in Oil Red O-positive area fraction (p 0.004, Figure 
4.3.4.2 E) and thus, a significantly augmented lipid accumulation in the transfer zone of placentas of 
obese dams compared to controls. Red-stained lipid droplets were found in or between SynT which 
indicates a similar pattern of staining to the pattern of deposition observed under electron microscopy 
(Figure 4.3.4.1 A & D). 
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Figure 4.3.4.2: Lipid quantitation by Oil Red O staining of placental Lz. (A & B) In the Lz of SD placentas, small 
clusters of Oil Red O stained lipid deposits (arrows) were observed mostly in trophoblasts of the syncytium (A).  
(C & D) In HFD Lz, the staining pattern was more intense and deposits of lipids appeared larger than in SD, similar 
to what was observed under EM (arrows in D). Each panel shows a different placenta, in total 5 placentas from 5 
dams for SD and 6 placentas from 6 dams for HFD were analyzed. (E) Semi-quantitation of Oil Red O-positive pixel 
area fraction in the Lz of SD and HFD placentas (n = 5 placentas for SD and n = 6 placentas for HFD, 1 placenta 
per dam). Graph shows mean ± SEM, ** p <0.01, calculated using Student’s t test. Figure is in revision for publication 
in Kretschmer et al. Biology of Reproduction 2020, Fig. 3 G – K and was modified. 
 
4.3.5 MO affects placental morphology and impairs Lz development 
We previously reported that vascularization of the placenta was severely affected by MO, as assessed 
by stereology [81]. Further stereological assessment showed that total placental volume was 
significantly increased (p 0.029, Figure 4.3.5.1 A) in placentas from obese dams and Lz:total placental 
volume ratio was strongly decreased (p 0.021, Figure 4.3.5.1 C) under MO. However, there was no 
difference in the volume fraction of the Lz between control and obese dams, while there was a trend 
towards reduction of the Lz:Jz ratio (p 0.150, Figure 4.3.5.1 B). Therefore, the relations between the 
exchange zone for nutrients and oxygen, the Lz, total placental volume and probably Jz volume are 
disturbed which implies an impaired development of the Lz under MO. 
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Figure 4.3.5.1: Stereological assessment of placentas from SD and HFD dams. (A) Representative image of 
a total placenta stained with CD31-IHC to show the different placental zones (Lz = red outline, Jz = orange outline, 
Db = yellow outline). The yellow crosses represent an area of 250,000 µm². Scale bar: 1 mm. (B) Lz to Jz volume 
ratio and (C) Lz to total placenta volume ratio were determined in SD (n = 8 placentas from 8 dams) and HFD  
(n = 7 placentas from 7 dams). Ratios are shown in arbitrary units. Graphs display median ± interquartile range,  
* p <0.05, calculated using Mann-Whitney test. Figure is in revision for publication in Kretschmer et al. Biology of 
Reproduction 2020, Fig. 4 D – F and was modified. 
 
4.3.6 Fatty acid stimulation of BeWo cells reduces β-catenin protein level and affects lipid 
accumulation and cell layer permeability 
The HFD used in this study contains high amounts of fatty acids compared to the SD. Among these fatty 
acids are palmitic acid (PA), oleic acid (OA) and linoleic acid (LA) and these fatty acids were therefore 
used in cell culture studies with trophoblast-like BeWo cells. We aimed to determine the effect of PA, 
OA and LA on protein level of AJ markers, intracellular lipid accumulation and cell layer permeability 
(Figure 4.3.6.1). PA, OA and LA were used at two different concentrations, however, none had an effect 
on E-cadherin protein level. Conversely, stimulation with 1000 µM of LA significantly decreased total  
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β-catenin protein level (p 0.029) and also significantly increased the relative cell layer permeability  
(p 0.029). On the other hand, a significant decrease (p 0.029) in cell layer permeability was found after 
stimulation with 500 µM OA. Furthermore, when BeWo cells were stimulated with OA at a concentration 
of 1000 µM, a tendency towards increased lipid accumulation was observed, however, other fatty acids 
had no such effect. Therefore, isolated LA at high concentrations can affect intracellular β-catenin level 
and BeWo cell layer permeability. 
 
 
Figure 4.3.6.1: Effects of stimulation with fatty acids on AJ marker protein level, cellular lipid accumulation 
and cell layer permeability in BeWo cells. (A) Western blot after 24 hours stimulation of BeWo cells with various 
fatty acids (PA, OA, LA) at concentrations between 100 µM and 1000 µM (as indicated in the graphs). (B) Results 
of densitometric analyses of western blots for proteins E-cadherin and β-catenin normalized to ACTB. Bar graphs 
show median ± interquartile range, * p <0.05, calculated using Mann-Whitney test, n = 4 replicates (1 – 4 as 
indicated). (C) Results of AdipoRed assays showing relative lipid accumulation after 8 hours of stimulation with fatty 
acids at above-mentioned concentrations in BeWo cells. Bar graphs show fluorescence signal [AU], n = 5 replicates 
as mean ± SEM, and the p value for control versus OA 1000 μM is indicated above the graph, calculated using  
Mann-Whitney test. (D) Relative cell layer permeability normalized to control after 24 hours of stimulation with fatty 
acids. Bar graphs show median ± interquartile range, * p <0.05, calculated using Mann-Whitney test, n = 4 
replicates. Figure is in revision for publication in Kretschmer et al. Biology of Reproduction 2020, Fig. 5 and was 
adapted. 
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IF staining for E-cadherin after stimulation of BeWo cells with either fatty acid (PA, OA or LA) or control 
revealed no major differences in staining patterns (data not shown). In these examples, E-cadherin was 
localized to the cell boundary and in several cells, it was also observed diffusely in the cytoplasm. 
 
4.4 Passive transfer is significantly increased across the placental barrier, but glucose transport 
and metabolization rate seem unaltered under MO 
Note: The part under 4.4.1 of the results section, i.e. “Materno-fetal transfer capacity is significantly 
increased under MO”, was recently in parts submitted for publication to Biology of Reproduction in the 
article “Maternal, high fat diet-induced obesity affects trophoblast differentiation and placental function 
in mice”. The prospective first author is Tobias Kretschmer and the work presented was made possible 
through the assistance of several others: 
Animal handling for in vivo studies were performed by Marion Handwerk, Sarah Appel, Heike Endepols 
and Tobias Kretschmer. Placenta and fetus collection after isoflurane anesthesia was conducted by 
Marion Handwerk and Tobias Kretschmer. Positron emission tomography (PET) was conducted by 
Heike Endepols. Data collection and statistical analyses were performed by Heike Endepols and Tobias 
Kretschmer. The project was supervised and supported by Heike Endepols, Jörg Dötsch and Sarah 
Appel.  
 
4.4.1 Materno-fetal transfer capacity is significantly increased under MO 
Since AJ marker level were reduced in mice in vivo under MO and in BeWo cells in vitro after fatty acids 
stimulation, together with ultrastructural defects in the Lz and reduced cell layer permeability in vitro 
after stimulation with LA, we aimed to determine materno-fetal transfer capacity in vivo by means of  
14C-mannitol administration and liquid scintillation. 14C-mannitol is an inert radio-labeled tracer that 
crosses the placenta and reaches the fetal circulation without depending on active transporters and was 
therefore used as a marker of Lz integrity. Materno-fetal clearance (Kmf) was determined after 
accumulation of the non-metabolizable tracer 14C-mannitol in fetal lysates and liquid scintillation. The 
Kmf significantly increased in offspring of obese dams compared to controls (Kmf 166.4 vs 113.5, Effect 
size -52.93, CI -82.92 to -19.93, p 0.002) by a margin of 46.6% ± 14.6% (Figure 4.4.1.1 A). Additionally, 
fetal weight was recorded and significantly decreased by 8.5% ± 2.5% in offspring of obese dams  
(0.362 g vs 0.396 g, Effect size 0.0336g, CI 0.0136 to 0.0536, p 0.001, Figure 4.4.1.1 B), however, 
placental weight was unaltered (Figure 4.4.1.1 C). MO is thus associated with increased materno-fetal 
transfer capacity while offspring develop a growth restriction in utero as shown before in cohort A057 
[93]. 
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Figure 4.4.1.1: Materno-fetal clearance, fetal and placental weight under MO. (A) Materno-fetal transfer 
capacity (clearance) across the placental barrier of radiolabeled 14C-mannitol in SD and HFD dams. n = 39 fetuses 
from 5 dams for SD and n = 41 fetuses from 5 dams for HFD. (B) Fetal weight in SD and HFD offspring, n = 34 
fetuses from 5 dams for SD and n = 42 fetuses from 5 dams for HFD. (C) Placental weight of SD and HFD placentas, 
n equals n under (B). Graphs show mean ± confidence interval, ** p <0.01, calculated using Student’s t test. Figure 
is in revision for publication in Kretschmer et al. Biology of Reproduction 2020, Fig. 4 A – C and was modified. 
 
4.4.2 Glucose transport and metabolization rate are probably unaltered under MO 
The radio-labelled glucose analogue 18F-FDG was used to study glucose metabolization in control and 
obese dams and also to assess glucose transfer to fetuses via the placenta. PET was used to detect 
18F-FDG accumulation in maternal and fetal tissue and the signal in fetal tissues was normalized to the 
injected dose corrected for body weight (SUVbw). The Patlak-approach with a lumped constant of 0.6 
was used to calculate the glucose metabolization rate (GMR). Analyses of PET scans revealed the 
highest signal of 18F-FDG in fetal heart-liver area (Figure 4.4.2.1 A & B). Time-activity curve showed that 
directly after 18F-FDG injection, the signal in the aorta went to a maximum and subsequently plummeted. 
At the same time, the signals in fetal tissue and maternal spinal cord increased up until the end of the 
measurement at 60 minutes (Appendix 6.3, Figure 6.2.1). Based on these values, time-activity-curve 
rations (TAC ratios) were calculated with the signal from fetal tissue normalized to the signal from 
maternal spinal cord. The resulting TAC ratios showed no difference between obese and control dams 
(Figure 4.4.2.1 C). There was no significant difference in the data for relative 18F-FDG signal in fetal 
tissue when displayed as SUVbw (p 0.222, Figure 4.4.2.1 D). However, maternal blood glucose 
concentration significantly correlated with the signal in fetal tissue in control dams (p 0.021, R 0.83), but 
not in obese dams (p 0.25, R -0.63, Figure 4.4.2.1 E). These results indicate that net transfer of glucose 
across the placenta to fetal tissues is similar in obese and control dams. However, the positive 
correlation between maternal blood glucose and glucose supply to fetal tissues is absent in obese dams 
which indicates a disturbed regulation in glucose supply in obese dams. 
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Figure 4.4.2.1: 18F-FDG PET studies in SD and HFD dams. (A) PET scan of an obese dam 60 minutes after  
18F-FDG injection. Heart (H) and bladder (B) accumulated most of 18F-FDG, however, fetuses (F) and placentas (P) 
also accumulated 18F-FDG. The aorta of dams was used to normalize signals for Patlak analysis and calculate 
glucose metabolization rate (GMR). (B) PET scan image showed localization of 18F-FDG to the fetal heart-liver area 
and placentas. (C) Based on normalization of the injected dose (SUVbw) of 18F-FDG, TAC ratios were calculated 
for each dam over a course of 57.5 minutes (arbitrary units, AU). n = 5 dams for both SD and HFD. (D) Quantitation 
of 18F-FDG signal in fetal tissues normalized to SUVbw in SD and HFD dams. n = 5 dams for both SD and HFD. 
Bar graphs show mean ± SEM. The p value is indicated above graphs, calculated using Mann-Whitney test.  
(E) Linear regression of the 18F-FDG signal in fetal tissues normalized to the injected dose depending on maternal 
blood glucose in SD (black) and HFD (gray) dams. n = 7 dams for SD and n = 5 HFD. SD (black) p 0.021, R 0.83; 
HFD (gray) p 0.25, R -0.63, calculated using linear regression analysis. 
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4.5 Dynamics in AJ and EC marker expression during placental development 
Results in this section, i.e. “Dynamics in AJ and EC marker expression during placental development”, 
have not been published or submitted by the time of writing this thesis. The work described hereafter 
was made possible with the help of several others: 
Animal handling and tissue collection were performed by Eva-Maria Turnwald, Marion Handwerk, Sarah 
Appel and Tobias Kretschmer. Protein isolation, detection and densitometric analysis were performed 
by Tobias Kretschmer. Data collection and statistical analyses were performed by Tobias Kretschmer. 
The work was supervised and supported by Jörg Dötsch and Sarah Appel. 
 
4.5.1 Vascular and AJ marker dynamics in placentas of SD and HFD dams from E11.5 to E18.5 
The placenta is a temporary organ which needs to develop in close concert with the embryo and adapt 
to its demands by a dynamic expression pattern of various markers and other factors. Under 4.3.1 and 
4.3.3, it was reported that under MO at E15.5, various markers of the AJ are differentially expressed 
compared to control placentas. To assess the course of AJ marker and CD31 level from mid-gestation 
to shortly before term, E11.5, E15.5 and E18.5 placentas were analyzed by western blot (Figure 4.5.1.1). 
In placentas of obese dams, CD31 level was highest at E11.5 and declined gradually until E18.5 where 
it was significantly reduced (p 0.026) compared to E11.5. In control placentas, there was a trend of 
down-regulation from E11.5 to E18.5 (p 0.093) and further, a significant decrease between E15.5 and 
E18.5 which was not observed in placentas of obese dams. Moreover, VE-cadherin level significantly 
plummeted from E11.5 to E15.5 under both HFD and SD (both p 0.002). Again, a further significant drop 
in expression can be seen in control placentas from E15.5 to E18.5 (p 0.015) which was absent under 
MO, however a trend was still observed. Similarly, Y654-phospho-β-catenin level decreased significantly 
from E11.5 to E15.5 (SD p 0.009, HFD p 0.015) onto E18.5 in both HFD (p 0.026) and SD (p 0.002) 
placentas. Total β-catenin level did not change significantly from E11.5 to 16 or E18.5 under MO, but 
dropped significantly in SD placentas from E15.5 to E18.5 (p 0.004). Conversely, E-cadherin level was 
lowest at E11.5 in placentas of both groups and significantly increased between E11.5 and E15.5 (both 
p 0.002) prevailing on this level until E18.5 (both p 0.002). The expression dynamics of P-cadherin were 
opposite under HFD compared to SD in that the level gradually and significantly increased (p 0.041) 
from E11.5 to E18.5 in HFD placentas, but declined significantly (p 0.041) from E11.5 to E18.5 in SD 
placentas. This suggests that especially towards the end of pregnancy, AJ dynamics are significantly 
altered under MO. 
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Figure 4.5.1.1: Protein level dynamics of EC and AJ markers from E11.5, E15.5 and E18.5 in SD and HFD 
placentas. (A) Western blotting of SD placental lysates (n = 6 placentas, 1 per dam) showing CD31, E-cadherin, 
P-cadherin, VE-cadherin, phosphorylated Y654-β-catenin, total β-catenin and ACTB (loading control) level. (B) 
Densitometric analyses of SD western blots of CD31, E-cadherin, P-cadherin, VE-cadherin, phosphorylated  
Y654-β-catenin and total β-catenin normalized to ACTB. Graphs show median ± interquartile range and * p value 
<0.05, ** p value <0.01, or p value is shown above graph. (C) Western blotting of HFD placental lysates (n = 6 
placentas, 1 per dam) displaying CD31, E-cadherin, P-cadherin, VE-cadherin, phosphorylated Y654-β-catenin, total 
β-catenin and ACTB (loading control) level. (D) Densitometric analyses of HFD western blots of CD31, E-cadherin, 
P-cadherin, VE-cadherin, phosphorylated Y654-β-catenin and total β-catenin normalized to ACTB. Graphs show 
median ± interquartile range and * p <0.05, ** p <0.01, or p value is shown above graph, calculated using  
Mann-Whitney test. 
 
4.5.2 AJ marker level at E11.5 and at E18.5 in SD and HFD dams 
Under 4.3.1 and 4.3.3, it was demonstrated that MO led to a decrease in AJ marker E-cadherin and a 
tendency towards down-regulation of β-catenin at E15.5. Therefore, we tested whether MO also 
influences AJ marker expression earlier (E11.5) and later (E18.5) during gestation. At E11.5, AJ marker 
and vascular marker CD31 expression were similar in placentas of obese and control dams (Figure 
4.5.2.1 A & B). 
Interestingly, at E18.5 the AJ marker E-cadherin and total β-catenin expression were significantly down-
regulated in placentas of obese dams (Figure 4.5.2.1 C & D), which was also reported previously [93]. 
Furthermore, in those placentas, there was a tendency towards decreased EC marker CD31 expression. 
On the contrary, P-cadherin expression was significantly increased in placentas of obese dams at E18.5 
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compared to controls whereas there was no difference between both groups at E11.5. Taken together, 
these results suggest that under MO, placental development is marginally affected until E11.5 regarding 
vascularization and cell junction integrity. However, at the end of pregnancy, there are major differences 
in vascular and AJ marker expression which could translate to placental function under MO. 
 
 
Figure 4.5.2.1: Protein level of CD31 and AJ marker at E11.5 and E18.5 in SD and HFD placentas. (A) Western 
blotting of whole placenta lysates from E11.5 (SD and HFD: n = 7 placentas, 1 per dam) showing CD31, E-cadherin, 
phosphorylated Y654-β-catenin, total β-catenin, VE-cadherin, P-cadherin and HPRT (loading control) level.  
(B) Densitometric analyses of western blots from (A) of phosphorylated Y654-β-catenin, total β-catenin, CD31,  
E-cadherin, P-cadherin, VE-cadherin normalized to HPRT. (C) Western blotting of whole placenta lysates from 
E18.5 (SD and HFD: n = 7 placentas, 1 per dam) showing CD31, phosphorylated Y654-β-catenin, total β-catenin, 
E-cadherin, P-cadherin, VE-cadherin and HPRT (loading control) level. (D) Densitometric analyses of western blots 
from (C) of phosphorylated Y654-β-catenin, total β-catenin, CD31, E-cadherin, P-cadherin, VE-cadherin normalized 
to HPRT. Graphs show median ± interquartile range and * p <0.05, ** p <0.01, or p value is shown above graph, 
calculated using Mann-Whitney test. 
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4.6 Anti-IL-6R antibody therapy under MO causes similar maternal and fetal phenotype to HFD, 
but further increases placental IL-6 level and affects placental AJ and vascular marker 
expression 
Results in this section, i.e. “Anti-IL-6R antibody therapy under MO causes similar maternal and fetal 
phenotype to HFD, but further increases placental IL-6 level and affects placental AJ and vascular 
marker expression”, have not been published or submitted by the time of writing this thesis. The work 
described hereafter was made possible with the help of several others: 
Animal handling and tissue collection were performed by Marion Handwerk and Tobias Kretschmer. 
Protein isolation, detection, densitometric analysis and ELISA were performed by Tobias Kretschmer. 
Data collection and statistical analyses were performed by Tobias Kretschmer. The work was supervised 
and supported by Jörg Dötsch and Sarah Appel. 
 
4.6.1 mMR16-1 or IgG antibody therapy under MO causes similar phenotype as HFD alone in 
dams and offspring, but only mMR16-1 significantly increases placental IL-6 level 
We recently demonstrated that IL-6 serum level are increased in obese dams concomitant with EC 
damage and placental dysfunction [81]. Hence, we aimed to investigate effects of IL-6 signaling 
blockade by anti-IL6R therapy with mMR16-1 or IL-6 knock-out on placental vascular and AJ markers. 
Several of the dams that received HFD ad libitum after weaning and were obese at the time of mating 
(data not shown), were randomly selected after mating for IL-6 antibody therapy, i.e. IgG or mMR16-1. 
HFD dams without antibody therapy served as control together with IL-6-/- that also received HFD after 
weaning and were obese at the time of mating (data not shown). 
For the mMR16-1 therapy, obese dams were treated over a period of 16 days of gestation with 3 
injections of mMR16-1 on E0.5, E7.5 and E14.5 (see Methods section 3.1.2). As control, obese dams 
received an IgG antibody as described for mMR16-1. Similar to dams which received HFD without 
antibody therapy, IgG treated HFD dams had significantly more egWAT at section on E15.5 than SD 
dams. HFD dams that received mMR16-1 had about the same weight of egWAT as IgG and HFD without 
antibody therapy (not significant, but with a strong trend compared to SD, Figure 4.6.1.1 A). However, 
fetal weight was significantly reduced in both mMR16-1 and IgG treated dams compared to SD controls 
(Figure 4.6.1.1 B), as shown for HFD alone. Litter size alive and embryo resorption rate were unaltered, 
however there was a tendency towards increased resorption rates in HFD dams without antibody 
therapy compared to SD (Figure 4.6.1.1 C & D). In a small group (n = 4 dams) of IL-6-/- mice, however, 
there was no resorption of embryos observed at all, whereas litter size was similar compared to SD, 
HFD, mMR16-1 and IgG dams. Fetal weight of IL-6-/- offspring was significantly reduced and dams of 
this group also showed a drastic increase in egWAT weight similar to HFD wild type dams and compared 
to SD dams. These results show that HFD, independent of interventions with mMR16-1, IgG antibodies 
or IL-6-/-, has the strongest impact on maternal and fetal phenotypes. Also, similar to HFD alone, 
offspring of IL-6-/-, mMR16-1 and IgG treated dams developed an IUGR (Figure 4.6.1.1 B). 
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Figure 4.6.1.1: Phenotypic data of dams and offspring from SD, HFD, mMR16-1 and IgG antibody-treated 
and IL-6-/- animals at E15.5. (A) Weight of egWAT pads at section. SD n = 13, HFD n = 15, IgG n = 6, mMR16-1 
n = 5, IL-6-/- n = 4. (B) Fetal weight at E15.5. SD n = 97 (13 dams), HFD n = 115 (15 dams), IgG n = 61 (8 dams), 
mMR16-1 n = 47 (7 dams), IL-6-/- n = 27 (4 dams). (C) Number of alive litters per dam at E15.5. SD n = 14, HFD  
n = 20, IgG n = 8, mMR16-1 n = 7, IL-6-/- n = 4. (D) Ratio of resorptions per dam observed at E15.5. SD n = 14, 
HFD n = 20, IgG n = 8, mMR16-1 n = 7, IL-6-/- n = 4. All graphs show mean ± SEM, * p <0.05, ** p <0.01,  
*** p <0.001, **** p <0.0001, or p value is shown above graph, calculated using one-way ANOVA followed by 
Tukey’s multiple comparisons test. Dotted lines show either SD or HFD values for better orientation. 
 
SAA2 level were measured by ELISA in maternal serum of antibody-injected dams to assess successful 
IL-6 signaling blockade in mMR16-1 treated dams. Median SAA2 level was higher in mMR16-1 injected 
dams compared to IgG controls (p 0.063). From both groups about half of the dams had low level  
(<500 pg/mL) while the other half had higher level (>1500 pg/mL) of serum SAA2 (Figure 4.6.1.2 A) 
indicating no uniform response to either antibody therapy regarding SAA2 expression and/or no 
blockade of SAA2 by mMR16-1. 
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Figure 4.6.1.2: SAA2 concentration and placental IL-6 signaling-related protein level in mMR16-1, IgG and 
HFD dams. (A) SAA2 level in mMR16-1 and IgG treated dams at E15.5. For mMR16-1 n = 7 serums samples from 
7 dams, for IgG n = 8 serums samples from 8 dams were used for the analysis. Graphs show median ± interquartile 
range and p value was calculated using Mann-Whitney test. (B) Western blot of IL-6, p-Stat3, total Stat3, SOCS3, 
pErk1/2, total ERK1/2 and ACTB (loading control) in placentas of mMR16-1, IgG and HFD dams (n = 6 dams per 
group, 1 placenta per dam). (C) Densitometric analyses of protein level from western blots of IL-6, SOCS3 and total 
ERK1/2 normalized to ACTB, as well as p-Stat3 normalized to total Stat3 and pErk1/2 normalized to total ERK1/2. 
Graphs show median ± interquartile range and * p <0.05, ** p <0.01, or p value is shown above graph, calculated 
using Mann-Whitney test. 
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Next, IL-6 protein level were analyzed in placentas of mMR16-1, IgG and HFD control dams together 
with down-stream signaling molecules of the IL-6 signaling pathway (Figure 4.6.1.2 B &C), i.e. p-Stat3 
and SOCS3. The expression of IL-6 in placentas of mMR16-1 injected dams was significantly increased 
compared to IgG (p 0.004) and HFD control (p 0.002) dams. Furthermore, IL-6 was also significantly 
increased (p 0.009) in IgG compared to HFD placentas. SOCS3 protein level remained unaltered while 
p-Stat3 level were significantly reduced in placentas of IgG dams (p 0.041) and also in mMR16-1 without 
reaching statistical significance (p 0.065) compared to placentas from HFD dams. Expression of pErk1/2 
was also significantly decreased in placentas of mMR16-1 treated dams compared to IgG (p 0.015) and 
HFD (p 0.026) dams. Total ERK1/2 level were reduced in mMR16-1 placentas compared to IgG  
(p 0.026) and HFD (p 0.002), as well as in IgG placentas compared to HFD (p 0.004). These results 
suggest that mMR16-1 therapy over gestation increases IL-6 protein level in placentas and that either 
antibody therapy, mMR16-1 or IgG, might have an effect on growth and differentiation compared to HFD 
alone. However, classical readout marker SOCS3 for IL-6 feedback signaling was unaltered after 
antibody therapy over gestation. 
 
4.6.2 Vascular and AJ markers are significantly reduced in placentas after mMR16-1 
administration 
Next, AJ and EC marker protein level were determined in placentas of mMR16-1, IgG and HFD dams. 
CD31 level was significantly decreased in mMR16-1 (p 0.026) and IgG (p 0.041) treated dams compared 
to HFD dams. Furthermore, P-cadherin and VE-cadherin level were significantly reduced (p 0.026) in 
placentas of mMR16-1 treated dams compared to HFD. Protein level of E-cadherin and β-catenin 
remained unaltered in both mMR16-1 and IgG treated dams compared to HFD (Figure 4.6.2.1). Taken 
together, placental vascular development may be altered in dams which were administrated either 
mMR16-1 or IgG antibodies as seen by reduced level of CD31 and VE-cadherin whereas AJ marker 
level were unaffected. 
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Figure 4.6.2.1: Placental EC and AJ marker level in mMR16-1, IgG and HFD dams at E15.5. (A) Western blots 
of CD31, E-cadherin, P-cadherin, VE-cadherin, β-catenin and ACTB (loading control) in placentas of  
mMR16-1, IgG and HFD dams (n = 6 dams per group, 1 placenta per dam). (B) Densitometric analyses of protein 
level from western blots of CD31, E-cadherin, P-cadherin, VE-cadherin and β-catenin normalized to ACTB. Graphs 
show median ± interquartile range and * p <0.05 calculated using Mann-Whitney test. 
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5. Discussion 
 
5.1 Novel insights into maternal and fetal phenotypes under HFD-induced MO 
In this work, we induced an obese phenotype in C57BL/6N mice by feeding a HFD from week 3 of age, 
through adolescence and pregnancy until pregnancy was terminated at various gestation days, E11.5, 
E15.5 and E18.5. Even though feeding this diet rich in fatty acids and calories from fat makes our mouse 
model primarily a HFD-model, this HFD has been shown to induce obesity [93] and can cause a 
compromised glucose tolerance, increased serum leptin and insulin level [77, 97] in these mice, which 
we believe could largely be attributed to its composition. These effects show that we basically generated 
a diet-induced obesity mouse model by HFD nutrition which accompanies the translational character 
and several co-morbidities of obesity from mice to human. These crucial aspects have led to an 
acceptance of HFD in animal models to induce overweight and obesity, study their pathophysiologic 
effects (also during pregnancy) and extrapolate from these effects to humans [98-101]. Hence, in this 
work, HFD dams were synonymously referred to as obese dams. The HFD used in this work comprised 
a significant amount of fatty acids, i.e. saturated and mono-unsaturated fatty acids from palm oil (about 
4.5%) and animal lard (about 30.5%), of C-16:x and C-18:x carbon chain length (Appendix 6.4, Table 
6.2). The total metabolizable energy from these fatty acids together with the remainder of shorter and 
longer chain fatty acids sums up to about 60% [81]. There have been other diets discussed in literature 
to induce obesity, and these may more closely reflect the “western-style” type of diet that is rich in sugar 
and saturated fatty acids, preferably consumed by humans. However, results from animal studies with 
western diets and HFD displayed comparable effects, for example on dam weight and fetal weight [97, 
102-104]. In this work, ad libitum consumption of HFD led to a significantly higher weight-gain compared 
to control mice that received a SD for the same period of time, and typically the HFD dams reached 24 
to 26 g bodyweight by week 12 of age, compared to 20 to 22 g for SD dams [93]. Hence, mating of HFD 
and SD dams took place from week 12 to week 16 of age with already obese HFD dams. At section 
day, HFD dams displayed significantly heavier egWAT “fat pads” which were on average more than 2-
times heavier than in control dams and showed the obese phenotype persisted through pregnancy under 
HFD. Furthermore, offspring of HFD dams in this study developed an IUGR which was signified by lower 
embryo weight at E15.5 compared to offspring from SD dams. Towards the end of pregnancy, at E18.5, 
fetal weight was restored to a similar weight average in HFD and SD dams, indicating a catch-up growth 
during the third trimester of pregnancy under HFD which was mainly attributed to glucose stores of the 
placenta [93]. Conversely, in studies of human pregnancy of overweight and obese women, offspring 
had a higher risk of developing fetal macrosomia termed large for gestational age which was related to 
maternal body mass index (BMI) and gestational weight-gain [38, 105, 106]. Therefore, it seems more 
likely that in mice, HFD impacts on placental function and early fetal development rather than causing 
oversupply in mice offspring which would lead to overgrowth. Indeed, placental insufficiency and 
dysfunction are associated with fetal growth restriction in humans [107, 108], suggesting a primary role 
of the placenta in developing IUGR. Moreover, offspring of HFD dams displayed pathological effects 
early in life regarding body weight, egWAT and serum levels of insulin, indicating long-term effects and 
programming in offspring for obesity-associated pathologies [77]. 
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5.2 Pre-delivery inflammatory events are altered in obese dams 
Investigations on inflammatory events revealed that there is a significant increase in CD45-positive 
immune cell (leukocyte) infiltration, as well as an increased inflammatory marker expression in placentas 
of lean dams shortly before birth. While the increase in inflammatory marker expression was also 
present in placentas of obese dams, leukocyte infiltration was absent. However, there could be other 
relevant immune cells infiltrating the placenta which are not detected by CD45 staining, which suggests 
that further investigations are necessary to elucidate immune cell infiltration in placentas of normal and 
obese dams. Concomitant with the increase in CD45-positive immune cell infiltration in SD placentas 
was a lower anti-oxidative stress gene expression (of glutathione peroxidase and catalase) and an 
increase in oxidative stress, measured by lipid peroxidation, before parturition. This could be relevant to 
initiate birth and shedding of the placenta towards the end of pregnancy. In placentas of obese dams 
however, oxidative stress seemed enhanced compared to control dams at E18.5 since lipid peroxidation 
and pro-oxidative stress markers of the respiratory chain were elevated and occurred simultaneously to 
decreased catalase gene expression. Augmented oxidative stress can cause pre-mature aging and a 
decline in function of the placenta, which has been shown in placentas of obese women, together with 
an exaggerated inflammatory environment during pregnancy [36, 109]. Thus, increased oxidative stress 
in obese dams could harm placental function and might influence the immune cell infiltration observed 
in lean dams to initiate birth and placenta shedding. 
We also studied egWAT in lean and obese dams at E15.5 and E18.5 since its functional unit, the 
adipocyte, produces inflammatory cytokines and chemokines that can reach the circulation [110]. 
Additionally, it was reported that low grade inflammation in adipose tissue of dams is linked to a 
physiological increase in adipose tissue during pregnancy [111]. We could show that on E18.5 (data not 
shown) and on E15.5, obese dams had significantly heavier egWAT than lean mice. In lean mice,  
pro-inflammatory gene expression of a variety of genes (IL-6, TNFα, IL-1β, CXCL1 and 10 and MCP1) 
was significantly increased in egWAT towards the end of pregnancy (E18.5) compared to E15.5. This 
increase was not observed in egWAT of obese dams. These results indicate that the egWAT could play 
a role in the inflammatory response shortly before parturition in lean dams whereas in obese dams this 
response seems hampered. We could even speculate that there is a link between the endocrine roles 
of adipose tissue described by Coelho et al. [112] and the absence of leukocyte infiltration in the placenta 
and a rise in inflammatory markers in egWAT before parturition. However, further studies are required 
to decipher the mechanisms of egWAT and placenta interplay before birth.  
Lastly, the deficient leukocyte infiltration and slight change in pro-inflammatory gene expression in 
placentas of obese dams was accompanied by an attenuated inflammatory response in egWAT and an 
increase in the duration of gestation by about 1 day. Overall, our data suggest that these processes are 
relevant to initiate birth at about E19 in dams. Indeed, in human studies it was reported that obese 
women had prolonged pregnancy and that inflammation seems relevant at the end of pregnancy to 
initiate parturition [113, 114], however the mechanism remains unclear.  
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5.3 Impact of MO on placental EC homeostasis and vascularization 
Maternal BMI is associated with the risk for several pathologies during pregnancy and obesity has been 
reported to affect vascular function and vascular EC homeostasis [115, 116]. Both of these factors have 
direct implications for placental development and function, since the placenta forms around maternal 
blood vessel-invading trophoblasts, is a highly vascularized organ and provides the main interface for 
fetal supply via nutrient and waste exchange from maternal and fetal blood, respectively [7]. Studies in 
rodents have shown that HFD has direct effects on placental function and outcome of pregnancy and 
influences vascularization and hemodynamics in the placenta. These adverse effects include placental 
vasculopathy and EC damage in mice [44], altered placental labyrinth size in rats [117], and reduced 
placental blood flow in primates [62]. Moreover, stereological analysis showed compromised placental 
size and morphology in high-fat high-sugar treated mice [104] which led us to believe that placental 
vascularization and morphology could be altered significantly in our model of maternal obesity. Indeed, 
our stereological analyses of placental vascularization in SD and HFD dams at E15.5 provide evidence 
for a disturbed vascular development of the placenta under MO, and both gene expression as well as 
western blot analyses showed a significant reduction of vascular marker level. One of these vascular 
markers down-regulated on the mRNA-level is Tie-1, an EC specific receptor tyrosine kinase, which has 
been implicated in the maturation of vessels and angiogenesis, the de novo formation of blood vessels 
[118]. Furthermore, in inflammatory diseases like rheumatoid arthritis and atherosclerosis, Tie-1 was 
reported to be up-regulated. Overexpression of Tie-1 is probably capable to induce an inflammatory 
response in ECs and thus, might be a target for anti-angiogenesis treatments in cancer [119, 120]. 
However, in our study, a down-regulation of Tie-1 in placentas of obese dams was found, indicating that 
inflammatory effects observed herein are not mediated by Tie-1. Nonetheless, its down-regulation could 
be related to impaired vascularization observed by stereological analyses and this notion is further 
supported by simultaneous CD31 down-regulation on both mRNA and protein level, another well-known 
vascular marker. 
This work presents evidence that EC homeostasis is significantly affected in the placental transfer zone 
by MO at E15.5, not only by down-regulation of EC markers on protein and mRNA-level, but more so 
due to both ultrastructural changes observed under EM and the increase in EC senescence specifically 
in the Lz. The increased electron density and condensed appearance of EC nuclei may indicate EC 
damage, and there was detachment of ECs from the BM. In certain instances, loss of contact of cells, 
like ECs, from the ECM and the BM lead to a form of programmed cell death, called anoikis [121-123]. 
However, this was not observed in placentas of obese dams in this study and increased cell death by 
apoptosis was also not detected by staining assays conducted in vivo for the Lz or in vitro in placental 
EC (HPVEC). On the other hand, γH2A.X staining suggests a significant increase in DNA-damage [124] 
in ECs in the Lz of obese dams which could explain the observed ultrastructural appearance. Classically, 
γH2A.X is not considered a senescence marker and is found in case of damaged DNA regions, like 
double strand breaks, and was even reported to be increased in proliferating cells [125, 126]. However, 
we investigated proliferation and apoptosis marker in ECs which allows a better estimation of 
senescence by γH2A.X staining [127] and found no changes in proliferation and apoptosis under MO, 
which makes EC senescence more likely. In whole placenta lysates, we evaluated γH2A.X protein level 
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together with markers for apoptosis (cleaved caspase-3 and PARP) and proliferation (cyclin D1 and 
PCNA) by western blot, but reported no differences in protein level between SD and HFD dams. This 
indicates that HFD does not simply cause more apoptosis, proliferation or senescence/DNA-damage 
than SD in the whole placenta and that instead specifically the EC in the transfer zone are affected by 
increased senescence. Hence, analysis of the transfer zone may be particularly relevant to study 
consequences of HFD for placental function rather than evaluating apoptosis, proliferation or 
senescence marker in whole placental lysates.  
We showed that IL-6 serum level were increased under MO in our mouse model at E15.5 and previous 
reports showed that IL-6 can pass the placental barrier and reach the fetus [95, 128]. Therefore, we 
speculate that increased level of IL-6 from maternal serum in obese mice might affect placental EC 
homeostasis and cause the observed increase in senescence as well as alter EC appearance on the 
ultrastructural level. Cell culture studies indeed confirmed that IL-6 is capable to induce senescence, 
assessed in our work by senescence-associated beta-galactosidase activity in HPVEC [81], and others 
showed increased senescence in fibroblasts after IL-6 stimulation [129]. The IL-6R is the target of 
circulating IL-6 and is not expressed by ECs [130], yet IL-6 can still act on cells not harboring the IL-6R. 
In those situations, the cell surface receptor gp130 and IL-6 bound to the soluble IL-6R in the circulation, 
associate with each other and induce signaling. This way of signaling is called trans-signaling of IL-6 
and is the most prominent inflammatory pathway for most cell types without a classical IL-6R [68, 131]. 
Regarding the origin of increased circulating IL-6 in maternal serum, we tested IL-6 mRNA expression 
and protein level in egWAT of obese dams at E15.5 which showed enlarged fat pads on section 
concomitant with weight gain. We found increased mRNA expression, albeit not statistically significant, 
and a strong tendency towards increased protein level of IL-6 in egWAT of obese dams. Mohamed-Ali 
et al. [132] and Coppack [133] reported that white adipose tissue can produce inflammatory cytokines 
and be the origin of circulating IL-6, and increased egWAT could therefore attribute to the systemically 
inflamed state under MO. As a result, we believe that the egWAT in our HFD dams could cause 
increased serum IL-6 level by egWAT hypertrophy and production. Serum IL-6 subsequently can reach 
the placenta and hence, lead to a “WAT - maternal serum - placenta” axis [81] which denotes a possible 
route of MO-induced EC damage in the placenta, propelling placental insufficiency. We aimed to further 
investigate this proposed route by applying an IL-6 signaling antibody therapy as well as an IL-6-/- mouse 
model, which are both discussed further below. 
The formation of blood vessels is paramount for proper placental function and the above mentioned 
placental insufficiency due to EC damage could translate to an impaired placental vascular 
development. We investigated gross morphology and vascularization of the placenta by stereological 
means at E15.5. Placenta weight was similar between obese dams and controls, however total placenta 
volume was larger and the fraction of the Lz, which is the main vascularized part of the placenta, was 
significantly reduced in obese dams. Additionally, fetal vascular surface area and total capillary length 
were reduced under MO while capillary diameter seemed slightly increased. These results strongly 
suggest impaired vascular branching and development and a reduced area for materno-fetal exchange 
of nutrients, oxygen and disposal of waste [11, 24]. As a consequence, the placenta cannot fulfill its 
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function and the fetus might be undersupplied and develop the observed IUGR at E15.5, as there is a 
tight regulation of the three-dimensional development of the placenta and its strata. Indeed, deviations 
from this controlled growth processes were linked to placental insufficiencies and fetal development [11, 
24, 25]. Additionally, a study showed that a reduced surface area in the placental transfer zone and 
decreased materno-fetal transfer could cause fetal growth restriction [83]. Our data further indicate that 
surface area and capillary length of SD placentas closely resemble what others reported for control 
dams at E15.5, while HFD placentas displayed surface area and capillary length at E15.5 which others 
observed at E14.5 in control dams [24]. This further indicates a disturbed development of the transfer 
zone under MO with direct consequences for placental function. 
The catch-up in fetal weight development by E18.5 under MO could be attributed to enhanced glycogen-
storage utilization in the placenta and increased protein level of GLUT1 and GLUT4-transporters [93]. 
These effects may compensate for the decreased relative size of the Lz observed at E15.5 under MO. 
However, further studies on the developmental dynamics of morphology and vascularization by 
stereological techniques before and after E15.5 could generate valuable insight into placental effects of 
MO. In another study utilizing an obesogenic diet, it was reported that fetal weight was also normalized 
around day 19 of gestation after IUGR was present at day 16, and placental transport proteins for 
specific nutrients might contribute to this normalization in fetal growth trajectory, even though placentas 
were smaller and morphologically altered [104]. Nonetheless, these and our results show that the 
placenta is severely affected regarding vascularization and function on a morphological and protein 
marker level by MO.  
 
5.4 Impaired trophoblast differentiation, damaged placental basement membrane and AJ as well 
as lipid accumulation under MO 
Not only did we observe changes in EC homeostasis and vascular morphology, trophoblasts that lie 
opposite of the BM in the placental transfer zone seem also affected by MO at E15.5. Proteomics 
profiling revealed a list of proteins that relate to processes relevant for trophoblasts in the transfer zone 
to be altered. We found significantly reduced E-cadherin level, not only in the proteomics screen of the 
Lz, but also in western blots of whole placenta samples, and could show by immune-staining that this 
protein is exclusively found in trophoblasts of the Lz. Originally, E-cadherin was described on epithelial 
cells before it was also shown to be expressed in human villous trophoblasts [28]. Cadherin proteins 
function as transmembrane molecules that are calcium-dependent for their adhesive properties. By 
homophilic interactions of the extracellular domain of cadherins, they produce dimers which bind to other 
cadherin dimers from adjacent cells. On the intracellular side, cadherins form connections to the 
cytoskeleton via binding to catenin family proteins, for example β-catenin [134, 135]. Furthermore,  
E-cadherin was reported to have an important regulatory function in epithelial barriers and as its 
expression is inhibited, this could lead to epithelial barrier and AJ disruption [135, 136]. In our cell culture 
studies, there was no effect observed on E-cadherin level after BeWo stimulation with isolated fatty 
acids. However, cadherins can be internalized to mitigate their adhesive function which also destabilizes 
AJ structures [137], and this mechanism was briefly touched in our investigation by IF staining of cells, 
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but yielded no conclusive results (data not shown). However, E-cadherin has an important role in 
epithelial-to-mesenchymal transition and trophoblast cell behavior which it thusly regulates [138]. From 
both, mRNA and protein quantitation of E-cadherin and β-catenin it can be deduced that AJ stability is 
negatively affected by MO, specifically in the placental transfer zone, since E-cadherin was exclusively 
detected in the Lz by IHC and IF. Furthermore, proteomics profiling of the Lz revealed significantly lower 
level of E-cadherin and a strong trend towards reduced β-catenin level. Next to E-cadherin, P-cadherin 
and VE-cadherin are part of AJ and regulate cell adhesion, signaling pathways and placental transfer. 
Unfortunately, IHC staining of VE-cadherin and IF staining of VE-cadherin and P-cadherin could not 
precisely show the localization of these cadherins to a specific cell layer within the Lz. However,  
P-cadherin seems to localize to the maternal blood sinus surface of SynT while E-cadherin occurred 
between SynT layers more strongly in the Lz of our samples. This is interesting since E- and P-cadherin 
were reported to occur jointly in embryonic and other tissues and P-cadherin was mentioned to be 
expressed more strongly [139]. Staining patterns were similar between SD and HFD placentas which 
further indicates no tremendous difference in expression pattern or localization. 
The ultrastructure of the placenta in HFD dams at E15.5 showed that SynT homeostasis was affected 
and indicates a defect in SynT differentiation where the formation of two distinctly visible SynT layers is 
absent. This also implies that AJ could not form properly and cell-cell connections are disturbed, again, 
as mentioned above, indicating impaired placental development. Concomitantly, SynT exhibited altered 
cell-matrix interactions, as evidenced by the observed detachment from the BM in ultrastructure analysis 
and reduced level of focal adhesion marker Ptk2 detected by proteomics profiling, which is an important 
regulator of cell orientation and cell-matrix interaction [140, 141]. Furthermore, two subunits of laminin 
(Lamc1 and Lamb2) that were down-regulated under MO in the proteomics profile are relevant for BM 
integrity, further indicating disruption of the BM. These changes may have strong implications for 
permeability and transfer properties of the Lz [142]. Many of the detected proteins in proteomics profiling 
have not been characterized in expression, localization or function in the placenta, including Sdc4, 
Iqgap1/2 and Flot2, making it worthwhile to conduct further studies investigating the role of these 
proteins in the placenta. In the case of some focal adhesion-related proteins, they have already been 
mentioned to be involved in placental and embryonic development [143, 144]. Furthermore, the 
interaction between Ptk2 and VE-cadherin may be relevant for endothelial barrier function, and together 
with negative regulation of E-cadherin by Iqgap1 [141] might, in our eyes, have an effect on placental 
barrier integrity.  
Another major ultrastructural difference in placentas of obese dams compared to controls was the 
accumulation of lipids in the transfer zone at E15.5. EM analysis displayed lipid and ECM depositions 
on the BM, as well as lipid droplets intracellular and extracellular of SynT which could have negative 
effects on the barrier integrity and cell homeostasis. The amount of lipid deposition, as quantified by  
Oil Red O staining, throughout the Lz was significantly higher in placentas of obese dams than controls, 
indicating that the placenta has the capacity to store lipids and these stores are hypertrophic under MO. 
Indeed, other studies reported that, like other non-adipose tissues, the placenta is able to store lipids in 
obese animal models [145, 146]. However, these lipid accumulations may have lipotoxic effects on the 
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placenta and its environment, leading to elevated oxidative stress, inflammation and metabolic effects 
in the fetus [147, 148]. In addition, a trophoblast-like cell line (BeWo) showed a tendency towards 
increased lipid accumulation upon stimulation with the isolated fatty acid OA at high concentration. This 
may suggest that there is a mechanism for certain fatty acids to pile up in placental cells, and consuming 
diets in which fatty acids are present in high amounts could promote accumulation of lipids in the 
placenta. This may have serious implications for offspring developing within a placental environment 
associated with augmented inflammation and fat deposits in the transfer zone, leading to fetal 
programming for obesity and lipid accumulation in tissues and organs later in life [77, 146, 148]. The 
HFD used in this study was, amongst others, enriched with PA, OA and LA from palm oil and animal 
lard (Appendix 6.4, Table 6.2). PA was reported to cause inflammation in placental cells [149] and cell 
death concomitant with impaired invasion of trophoblastic HTR-8/SVneo cells [150, 151]. In addition, in 
western style diets LA is frequently found and has been associated with oxidative and pro-inflammatory 
effects [152, 153]. Furthermore, cell viability was decreased and inflammatory responses as well as 
mitochondrial function in trophoblasts were affected by LA, which could translate to altered placental 
function [154]. Within the last years, we tried to establish a protocol for the isolation of murine 
trophoblasts and EC from placentas of obese dams in order to stimulate these primary cells with 
maternal serum from obese dams to elucidate if and how factors from maternal serum could affect cell 
homeostasis. However, such an isolation protocol is not established to date and in the future we will turn 
to commercially available murine placental trophoblast which recently became available and are isolated 
murine trophoblasts (SM-9) [155, 156].  
Mid-gestation, days E10.5 to E12.5, in mice, where the definitive placenta is functional, has been 
suggested as equivalent to the end of first trimester in human pregnancy at which point organogenesis 
is completed [3]. Interestingly, we found that E-cadherin level in placentas of SD and HFD dams were 
lowest at E11.5, while VE-cadherin and CD31 level were highest at this point in mid-gestation. Lower 
level of E-cadherin early in placental development are associated with a more invasive and less 
epithelialized phenotype, and specific subsets of extravillous trophoblasts retain lower E-cadherin level 
to allow invasiveness [157]. At E11.5, the Lz already contains blood in its vessel system which is not 
observed 2 days prior [158]. From E11.5 to E15.5, E-cadherin level drastically increase and thus, it 
seems likely that trophoblast differentiation occurs, and trophoblasts of the syncytium intermit 
invasiveness. Vascular adhesion mediated by VE-cadherin is somewhat modified, causing a significant 
drop in VE-cadherin level from E11.5 to E15.5 in both SD and HFD placentas. This further supports that 
lower E-cadherin level at E15.5 in HFD placentas are a sign of impaired trophoblast and placental 
development, since E-cadherin expression is “behind schedule” in obese placentas. In line with the 
decrease in VE-cadherin from E11.5 to E15.5 is the decrease in phospho-Y654-β-catenin in both SD 
and HFD placentas. Phosphorylation of β-catenin at this tyrosine residue can lead to a reduction in 
cadherin-β-catenin interaction, increased WNT/β-catenin signaling and could thusly affect AJ stability 
[159, 160]. Similar to junction and focal adhesion markers Ptk2, Sdc4 and Iqgap1/2 mentioned above, 
phospho-Y654-β-catenin has not been functionally characterized in the placenta or trophoblast, making 
interpretations on its role in placental development difficult. However, one could carefully speculate that 
phospho-Y654-β-catenin mediates trophoblast invasiveness by inhibiting cadherin interaction between 
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cells on and before E11.5 to enable trophoblast migration and invasion. Once the placenta is fully 
functional and syncytial fusion has occurred, phosphorylation of β-catenin at Y654 is suppressed. At 
E15.5, phospho-Y654-β-catenin level appeared higher in placentas of obese dams, even with a 
considerable degree of variation between dams which could, nonetheless, support this speculation, 
since ultrastructure analysis showed the defect in syncytial fusion and trophoblast differentiation at 
E15.5. Total β-catenin expression was mildly affected by MO and displayed no change at E11.5 on 
protein level, but was down-regulated on mRNA and by tendency on protein level at E15.5 and on 
protein level at E18.5. These observations further indicate AJ destabilization, as β-catenin is a cadherin-
anchoring protein to the cytoskeleton [30]. Interestingly, we found that the fatty acid LA was able to 
reduce β-catenin protein level in trophoblast-like BeWo cells, suggesting that the HFD might be a 
causing factor for reduced β-catenin level during gestation once blood supply to the placenta is fully 
established. Thus, with maternal blood reaching trophoblasts and fetal EC after E9.5, there is also 
contact of placental cells with nutrients and fatty acids from maternal blood, and these fatty acids might 
then exert their potentially negative effects on cells of the transfer zone leading to observable changes 
at E15.5. However, it might also be relevant to study further gestation days between E11.5 and E15.5 
to elucidate these effects in more detail.  
 
5.5 Impact of MO on placental transfer capacity 
14C-mannitol is an inert, non-metabolizable radioactive tracer that readily crosses the placental barrier 
via passive diffusion and accumulates in fetal tissues, and hence is used to study integrity of the feto-
maternal transfer zone. This form of transfer of molecules across the placenta is responsible for a 
significant quantity of transfer, for example of up to 50% unidirectional flux of ions in humans. 
Consequently, any reduction in passive permeability of the placental barrier to hydrophilic substances 
and nutrients would have a direct consequence on total transfer capacity, and therefore also fetal supply 
and growth capability [83, 161, 162]. Next to hydrophilicity, steric properties of the molecules to be 
transferred are also important, which in the case of mannitol are quite similar to glucose. Additionally, 
morphological characteristics of the placenta are relevant for transfer [83, 104] which we assessed by 
stereological means, i.e. surface area and volume fractions. Results from our in vivo studies showed 
that materno-fetal transfer capacity of 14C-mannitol was significantly increased in obese dams at E15.5, 
even though the Lz:Jz ratio was reduced and Lz development seemed delayed at this stage. This might 
seem counterintuitive and one might expect a smaller Lz and impaired vascularization to lead to reduced 
transfer capacity, however there are possible explanations for the increased transfer capacity. First, it 
was described in our mouse model and elsewhere [83, 93] that in dams with IUGR offspring a catch-up 
growth between E15.5 and E18.5 can occur, which would demand increased transfer of nutrients and 
oxygen to the fetus to enhance its growth. However, not all nutrients are transported by passive diffusion, 
and altered morphology to enhance unidirectional transfer by maybe a margin of 50% can probably not 
solely compensate for fetal demands under IUGR. Therefore, investigation into active transport of e.g. 
GLUT-mediated glucose transport was conducted and revealed similar GLUT1/3 level in placentas of 
SD and HFD dams and slightly elevated GLUT4 level in placentas of HFD compared to SD dams at 
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E15.5 [93]. However, at E18.5 GLUT1 and GLUT4 level were both elevated in placentas of obese dams 
as described above, while GLUT3 level were similar to controls. These finding support the hypothesis 
of increased glucose flux to enable a catch-up growth between E15.5 and E18.5. On the other hand, 
the increase in 14C-mannitol could be a consequence of the disturbed ultrastructure in the transfer zone. 
We observed down-regulation of BM and ECM proteins, e.g. Lamc1 and Lamb2, as well as AJ markers 
concomitant with lipid accumulation, trophoblast differentiation defects and EC damage. These aspects 
could constitute a weakened placental barrier that might be unable to limit diffusion and, as a 
consequence, 14C-mannitol passes more readily from maternal to fetal circulation (Figure 5.4.1). A 
possible mechanism for this increase in permeability was presented by cell culture studies. We could 
show that BeWo cell layer permeability was significantly increased by stimulation with a high 
concentration of LA, a fatty acid found in high levels in HFD. Therefore, trophoblast cell layers in the 
placenta may be more permeable to substrate diffusion as a result of fatty acids from HFD in obese 
dams.  
 
 
Figure 5.4.1: Schematic illustration of the observed changes in the placental transfer zone under maternal 
obesity. The figure illustrates damaged adherens junctions (AJ) and the differentiation defect in syncytiotrophoblast 
(SynT) concomitant with lipid and extracellular matrix (ECM) accumulation, also in the basement membrane (BM). 
Furthermore, endothelial cells (EC) were affected and might show disturbed AJ and increased γH2A.X staining 
which indicates a senescent phenotype. Additionally, stereology showed that the surface area of fetal capillaries 
was significantly reduced (not shown in this figure). These changes in cell homeostasis could lead to placental 
insufficiency and a defective placental barrier with increased materno-fetal transfer of inert hydrophilic substances. 
Trophoblast giant cells which are frequently observed superior to SynT were left out of this figure for simplification 
of the illustration and because they were not observed under EM in our HFD placentas. 
 
Active substrate transport across the placenta was also touched in this work. 18F-FDG is a commonly 
used radioactive tracer in the clinic to assess tumor stages in a variety of cancers by PET scans which 
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are coupled to either computer tomography or MRT for precise tumor localization [163-165]. Moreover, 
PET scans coupled to MRT have also been performed on pregnant women in the past and yielded 
valuable information on 18F-FDG distribution and signal quantitation in placental and fetal tissues [166-
168]. 18F-FDG PET scans have moreover been used in small animals, however studies in pregnant mice 
are very scarce [169]. Therefore, our 18F-FDG PET study is probably unique in that we investigated 
pregnant obese and control dams at E15.5. One challenge of determining accumulation of 18F-FDG in 
fetal tissues is the reference signal from maternal tissue [166]. We chose to apply the Padlak method 
and used maternal aorta as reference. We observed signal progression in the aorta of dams after 
injection into the tail vein and distribution in the circulation (Appendix 6.3, Figure 6.2.1) and normalized 
the signal in fetal tissues to the signal from the aorta. We could not find a significant difference in either 
18F-FDG transfer or glucose metabolization rate in obese dams compared to controls, and regarding 
previous reports [93] might expect altered transfer rather at E18.5 than E15.5. Also, linear regression 
analysis was performed with various parameters and we found a significant, positive correlation of signal 
in fetal tissue and maternal blood glucose in control dams. This correlation was absent in obese dams, 
which showed high signals in fetal tissues even when maternal blood glucose was low. This suggests 
that obese dams have altered glucose distribution and that control dams favored maternal glucose 
supply with glucose over fetal supply when blood glucose level were low. Glucose is also the main 
energy source for the fetus and the placenta harbors glucose transporters, mostly GLUT1 and GLUT3, 
to mediate glucose accumulation [170]. Interestingly, it was reported that placentas under HFD showed 
increased GLUT1 expression at E18.5, but not E15.5 compared to SD placentas, as well as decreased 
glycogen cluster size from E15.5 to E18.5 in HFD placentas [93]. This may suggest that glucose 
accumulation in fetal tissues could be elevated later during gestation and hence, it would be reasonable 
to investigate 18F-FDG transfer capacity around E18.5, as mentioned above. Nonetheless, it has to be 
noted that a catch-up growth, as described, may not only require glucose, but also amino acids and fatty 
acids, and therefore increases in and increased activity of their transporters. Thus, amino acid and fatty 
acid transfer across the placenta need to be studied as well to fully understand fetal growth under MO 
[104]. 
 
5.6 Effect of anti-IL-6 signaling therapy on AJ marker and vascular development 
We reported that IL-6 can induce EC senescence in vitro and proposed that this effect could lead to 
placental dysfunction, since IL-6 mRNA and protein level in egWAT and IL-6 serum level were increased 
and could potentially reach the placenta in obese dams. Hence, we aimed to determine whether IL-6 
signaling blockade has positive effects on placental EC homeostasis and consequently on fetal outcome 
under MO. To this end, obese mice on HFD received either the IL-6 signaling blocking antibody  
mMR16-1 or the control antibody rat IgG and moreover, obese IL-6-/- mice on HFD were generated. 
Similar to HFD dams without antibody therapy, in mMR16-1 and IgG treated, as well as IL-6-/- dams, 
maternal and egWAT weight were significantly increased and fetal weight was strongly reduced at E15.5 
compared to lean controls, showing an IUGR phenotype. Thus, the IL-6 signaling blockade by antibody 
therapy or IL-6-/- seem not to prevent an IUGR under MO. Also, litter size was not influenced by HFD 
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with or without mMR16-1 or IgG therapy or IL-6-/-. However, resorption rates increased by more than  
3-fold on average under HFD alone and mMR16-1 therapy when compared to SD, but this was without 
statistical significance. Nonetheless, absence of statistical significance does not prove absence of an 
effect [171] and hence, there might be an effect of HFD alone and mMR16-1 therapy on fetal resorption 
rate. Interestingly, up until now we could not show resorption of embryos in IL-6-/- dams which, of course, 
has to be interpreted with great care, since this cohort is very small, counting only 4 dams. Contrary to 
this observation is our personal experience and others (personal communication) that IL-6-/- dams 
became pregnant less frequently than HFD dams or antibody treated dams in this study, despite similar 
mating schemes with IL-6-/- males. However, there is some evidence in the literature that maternal 
immune activation modulates fetal development and further, knock-outs of cytokines in animal models 
have shown conflicting results in terms of fertility and pregnancy success, also regarding IL-6 knock-out 
[78, 172, 173]. Therefore, it is not surprising that pregnancy rate is somewhat lower in our IL-6-/- and a 
larger animal cohort might yield additional valuable insight. 
ECs in the placenta can only react to IL-6 by soluble-IL6R (sIL-6R)/gp130-mediated trans-signaling, as 
described above, because they do not express the IL-6R [174]. Inflammatory signaling in ECs is thus 
mainly mediated by sIL6R/gp130 trans-signaling and leads to the activation of JAK/STAT3 and 
PI3K/AKT pathways, which therefore can also serve as read-out pathway when IL-6 trans-signaling is 
blocked [175-177]. To block IL-6 signaling in EC, it is required to e.g. block the IL-6 binding site in  
sIL-6R which is achievable by using an anti-IL-6R antibody, like tocilizumab in humans or mMR16-1 in 
mice [178-180]. The rat anti-murine IL-6R antibody mMR16-1 was used in pre-clinical studies to achieve 
FDA approval for tocilizumab and has been used in various other studies with non-pregnant C57BL/6 
mice [84, 179, 181, 182]. 
Yoshida et al. [183] reported that MR16-1 induced an anti-rat IgG response after repeated administration 
in mice and hence, long-term application of MR16-1 could lead to antibody-mediated neutralization of 
MR16-1 and its effects. Therefore, MR16-1 was modified in the rat IgG1 FC part to generate a rat (Fab)-
mouse FC chimeric antibody, mMR16-1, that should be less immunogenic and remain potent to block 
IL-6R for a longer period [84]. Serum level of SAA2, which is frequently used to evaluate IL-6 signaling 
blockade [84, 184], were not reduced in mMR16-1 treated dams compared to IgG treated dams in our 
study. This suggests that success of blocking IL-6 signaling may not be evaluated by SAA2 level after 
long-term application of mMR16-1 as we performed, or that IL-6 blockade was not successful in our 
setting. Wu et al. [84] showed that 7 days after mMR16-1 application, the SAA2 level returned to baseline 
which is the time-point at which dams in our study received the second injection with mMR16-1. 
Furthermore, it was reported that after 7 weeks of weekly application of MR16-1 (not mMR16-1), SAA 
level were significantly reduced compared to PBS injected mice, but not after 4 weeks of weekly 
application [185]. Thus, it remains unclear how multiple applications of mMR16-1 change expression of 
read-out marker like SAA2. On the other hand, in our model administration of mMR16-1 therapy over 
several weeks showed a significant increase in placental IL-6 level but no increase in SOCS3 level, a 
negative feedback regulator of IL-6 signaling. If elevated IL-6 level led to increased IL-6 signaling, 
SOCS3 level would likely be significantly increased to induce a negative feedback and block IL-6 
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signaling. However, this was not observed in mMR16-1 treated dams, indicating successful IL-6 
signaling blockade and subsequent up-regulation of IL-6 level as compensation mechanism which was 
also reported elsewhere [84]. Moreover, we found suppression of Stat3 activation [182] and we also 
observed lower active p-Stat3 level in placentas of mMR16-1-treated dams. However, IgG therapy had 
a similar effect not only on p-Stat3 level, but also SOCS3 and total Erk1/2, which are also markers of 
JAK/STAT3 and PI3K/AKT pathways, respectively. Especially p-Stat3 remains difficult to evaluate as 
IL-6 signaling and blockade marker in vivo in our obesity model, since IL-6 serum level was elevated in 
HFD compared to SD dams, whereas p-Stat3 level were lower in placentas of HFD compared to SD 
dams (Figure 4.2.5.1). Nonetheless, mMR16-1 caused a strong increase in placental IL-6 protein level. 
We therefore believe that mMR16-1 does indeed block IL-6 signaling in parts, as the antibody is IL-6R 
specific, and suggest that p-Stat3 alone is not a sufficient in vivo marker for documenting blockade of 
IL-6 signaling after long-term mMR16-1 therapy. The use of a relevant control to the mMR16-1 antibody 
therapy is important for the study of mMR16-1-related effects and we chose a rat IgG antibody as control. 
Many other studies that utilized MR16-1 or mMR16-1 over variable time periods treated control animals 
with aqueous vehicles without an IgG antibody [182, 185, 186] or used an IgG similar to ours [84, 181, 
187], making it difficult to compare existing literature and results of others with our work. This 
necessitates further investigation into mMR16-1 and its effects on IL-6 signaling blockade read-out 
markers, other than SAA2 and markers of JAK/STAT3 and PI3K/AKT pathways. 
Administration of mMR16-1 or IgG led to a significant reduction of CD31 level in placentas compared to 
HFD dams without antibody therapy. In mMR16-1 treated dams, VE-cadherin and P-cadherin were also 
significantly decreased in placentas, compared to dams that received HFD without antibody therapy. 
This decrease of CD31 and VE-cadherin level may indicate a defect in placental vascularization that 
might be even further augmented under mMR16-1 therapy, when IL-6 signaling is blocked, than under 
HFD without antibody therapy compared to SD. The reduction in VE-cadherin and P-cadherin level in 
placentas of mMR16-1 treated dams indicates disturbed AJ compared to HFD dams without antibody 
therapy. Interestingly, level of VE-cadherin and P-cadherin in placentas of IgG treated dams seemed 
also reduced compared to HFD dams without antibody therapy, but failed to reach statistical 
significance. This suggests that IgG therapy causes less of an effect on AJ marker than mMR16-1 
compared to the HFD without antibody therapy, possibly due to control IgG not blocking IL-6 signaling 
but inducing other unspecific side effects. As mentioned above, mMR16-1 and IgG therapy caused a 
reduction in placental p-Stat3 level and p-Stat3 has been associated with pre-eclampsia which is a 
pathology associated with vascular defects [188] and seems to regulate trophoblast invasion [189] as 
well as being involved in pregnancy loss in mice [190]. Hence, lower p-Stat3 level in the placenta may 
indicate defective vascular and placental development in mMR16-1 and IgG treated dams. 
Taken together, the administration of either antibody, mMR16-1 or IgG control, in combination with HFD 
probably lead to an impaired placental development, placental dysfunction and fetal IUGR. 
Unfortunately, there is yet no data available on IL-6-/- placentas and level of these markers, together 
with stereological data that can be compared to data of mMR16, IgG and HFD without antibody therapy. 
Especially the stereological data would be particularly interesting, since these could show placental 
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vascularization and morphology under complete IL-6 knockout compared to temporary mMR16-1 
antibody therapy and further elucidate the functional role of IL-6 signaling. Furthermore, IL-6-/- placentas 
could serve to decipher some of the mechanisms that are IL-6-related under MO in the context of 
placenta and fetal development on different gestation days (E11.5 to E18.5) since the IL-6 knockout 
persists constantly before and during pregnancy. However, based on the phenotypical data, it is safe to 
say that HFD was always associated with an IUGR phenotype, independent of IL-6-/- or IL-6 signaling 
blockade by mMR16-1, which probably limits the therapeutic potential of anti-IL-6 signaling strategies in 
obese pregnant patients. Literature on IL-6 antibody (tocilizumab) therapy in human pregnancies is 
scarce and only few case reports and expert opinions exist, and these suggest that tocilizumab should 
best be discontinued before and during pregnancy [191, 192]. 
As mentioned above, IL-6 signaling is required for normal pregnancy [172, 173] and IL-6 and other 
cytokines might play relevant roles in immune and fetal development [78, 172] and placental function 
[75]. Furthermore, Jones et al. showed that IL-6 is capable to up-regulate Stat3 and via this mechanism 
is linked to amino acid transporter increase in the placenta, and suggested that this occurs in 
combination with other pro-inflammatory cytokine signaling and can lead to fetal growth alterations [193]. 
Hence, influencing cytokine signaling, like IL-6, probably alters a spectrum of processes in the placenta. 
Since obesity alone alters inflammatory cytokine expression [79, 194], the combination of anti-IL-6 
signaling therapy and obesity in our dams most certainly affected placental development and function. 
Hence, testing alternative concentrations of mMR16-1 antibody may be consequential, since the ideal 
concentration to allow healthy placenta development by simultaneously blocking negative effects in this 
organ due to increased IL-6 signaling under MO could not be determined herein, and the issue has not 
been addressed in this study. 
 
5.7 Future perspectives 
The impairment in placental development and function by HFD-induced MO was shown in this work, 
and it appears that EC as well as trophoblast homeostasis are affected during placental development 
under MO. Different markers of cell growth, differentiation and homeostasis were found to be altered, 
and ultrastructural changes fit the assumption of a disturbed cellular and extracellular environment. 
However, the ECM and especially the BM and cell-ECM interface were also affected by MO as indicated 
by proteomics profiling, and functional studies on markers of cell-ECM interaction like Ptk2 and Sdc4 
are not discussed in the literature, yet. Therefore, we are currently busy with investigating changes in 
focal adhesion markers in placentas of obese and control dams. Furthermore, the period between E11.5 
and E15.5 is probably very relevant for proper placental function and fetal development, since EC and 
AJ marker level that we investigated were unaltered at E11.5 between obese and control dams, however 
they were altered thereafter at E15.5. It might thus be possible that the placenta is fully functional in the 
first couple of days after first contact with maternal blood, between E9.5 and E11.5, but soon after 
develops insufficiencies and induces compensatory mechanisms. As a consequence, we observe the 
IUGR phenotype at E15.5 under MO, but lack valuable mechanistic insight on changes of placental 
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development that occur between E11.5 and E15.5, a period of 4 days out of about 20 days of total 
pregnancy duration. 
Insights and findings from our murine maternal obesity model can serve as a basis for clinical 
investigations and a better understanding of the human placental health, pathologies and development. 
Over the past 2 years, we have gathered placenta and blood samples from pregnant human patients 
with lean, overweight and obese phenotypes with and without gestational diabetes in cooperation with 
the Gynecology and Obstetrics Department of the University Hospital in Cologne. These samples will 
be used to analyze EC homeostasis, vascularization as well as gene expression and protein level of 
various markers that were altered under MO in our mouse model. Despite morphological and cellular 
differences between murine and human placentas, the mechanisms of placental health and 
development show some astonishing similarities [7]. Hence, we believe that a lot of translational aspects 
of clinical relevance can be obtained from studying murine placentas under various maternal conditions. 
Additionally, serum from our patient cohort can be utilized in in vitro assays for placental cell stimulation 
to further decipher mechanisms of regulation and signaling in the placenta under MO, which might also 
pave the way for novel therapeutic approaches.  
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6. Appendix 
 
6.1 Example of IL-6+/- genotyping 
 
Figure 6.1.1: Example of a genotyping agarose gel after electrophoresis. The left side shows the gene marker 
with 100 bp intervals. Lane 1 is the negative control without genomic DNA. Lanes 2 to 5 show wild type samples 
with bands of approximately 174 base pairs only. Lanes 6 and 7 show two heterozygous IL-6+/- samples with bands 
at approximately 380 base-pairs (IL-6 mutant) and 174 base-pairs (wild type). Compare to example of the Jackson 
Lab at: https://www.jax.org/Protocol?stockNumber=002650&protocolID=22373).  
 
6.2 Proteomics profile  
Table 6.1: List of the 126 significantly altered proteins from proteomics profiling in HFD vs. SD transfer zone. The 
proteins are listed according to their Log2 difference (-1.0 represents fold-change of 0.5; 0 represents fold-change 
of 1; 1.0 represents fold-change of 2). The thick line shows transition from down-regulated to up-regulated protein 
level in HFD compared to SD samples. The q value of <0.05 denotes statistical significance. 
Protein ID Gene names Log2 difference 
HFD vs.SD 
q value 
P07356 Anxa2 -2,6168 0,0333684 
Q9DCN2 Cyb5r3 -2,59906 0,0084 
P50543 S100a11 -2,5607 0,0094 
Q91VB8 haemaglobin alpha 2;Hba -2,17721 0,013375 
P19096 Fasn -1,89499 0,0264419 
Q9ER00 Stx12 -1,78543 0 
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Q8BHN3 Ganab -1,71235 0,0396699 
Q6EDY6 Lrrc16a -1,69647 0,0218485 
P57787 Slc16a3 -1,6913 0,007 
P14733 Lmnb1 -1,63922 0,0454553 
Q99PL5 Rrbp1 -1,61566 0,0346912 
P62192 Psmc1 -1,60362 0,0351379 
Q8JZU2 Slc25a1 -1,58432 0,0266429 
O55111 Dsg2 -1,52494 0,0302222 
O54724 Ptrf -1,47945 0,009 
Q8BH61 F13a1 -1,47331 0,0283725 
P09803 Cdh1 -1,45957 0,0351196 
O54988 Slk -1,44695 0,0355465 
Q91ZJ5 Ugp2 -1,40693 0,0342338 
P51150 Rab7a -1,40441 0,02828 
Q99LC5 Etfa -1,36717 0,0317458 
P16045 Lgals1 -1,33354 0,048063 
Q91YK2 Rrp1b -1,33122 0,0127059 
Q8K4I3 Arhgef6 -1,32215 0,0348854 
E9QAX7 Cse1l -1,30902 0,011625 
Q9Z1T1 Ap3b1 -1,29593 0,0347742 
Q9WTR1 Trpv2 -1,2713 0,0340128 
Q61753 Phgdh -1,21717 0,0145909 
P48678 Lmna -1,19905 0,0454758 
F8VPU2 Farp1 -1,19074 0,023725 
Q3TWV4 Ap2m1 -1,18023 0,0165172 
P97351 Rps3a -1,17537 0,0400625 
Q921G7 Etfdh -1,17352 0,0147895 
Q9D881 Cox5b -1,16998 0,036802 
D3YUP1 Carm1 -1,1574 0,0236579 
Q8VBZ3 Clptm1 -1,15313 0,0362323 
Q6W4W7 Diap2;Diaph2 -1,14764 0 
Q8CH18 Ccar1 -1,14342 0,00763636 
Q3UQ44 Iqgap2 -1,10754 0 
Q6P5E4 Uggt1 -1,08886 0,0337123 
O08553 Dpysl2 -1,08026 0,0218235 
Q3U4W8 Usp5 -1,07322 0,0397547 
O88844 Idh1 -1,07236 0,0341884 
Q61292 Lamb2 -1,07222 0,0217429 
Q5SQG5 Phb -1,0642 0,0338485 
Q9JLV5 Cul3 -1,04271 0,0322931 
Q8VDN2 Atp1a1 -1,03661 0,0461032 
Q6P5H2 Nes -1,03493 0,0452269 
Q8BML9 Qars -1,0222 0,0296923 
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O08749 Dld -1,01181 0,0190323 
G3X971 Ank3 -0,986192 0,01416 
Q60634 Flot2 -0,982782 0,0305273 
E9Q6R4 Arid1b -0,981078 0 
P13707 Gpd1 -0,980603 0,034 
Q9D8N0 Eef1g -0,978909 0,0336716 
Q6P9R4 Arhgef18 -0,956909 0,0349091 
Q64521 Gpd2 -0,95459 0,0334634 
Q920Q4 Vps16 -0,954346 0,0393832 
Q810B6 Ankfy1 -0,941094 0,0386545 
P34152 Ptk2 -0,931865 0,0136154 
Q8VCQ8 Cald1 -0,911643 0,0428696 
Q9D0E1 Hnrnpm -0,909578 0,0328 
P70168 Kpnb1 -0,90501 0,0273673 
Q9JKF1 Iqgap1 -0,901555 0,0339125 
B2RX14 Zcchc11 -0,884978 0,0171667 
Q7TQ95 Lnp -0,856671 0,008375 
Q5H8C4 Vps13a -0,849888 0,0184375 
Q8CGB3 Uaca -0,833469 0,01405 
E9Q616 Ahnak -0,827819 0,0303585 
Q62318 Trim28 -0,817407 0,0341899 
Q9Z1G4 Atp6v0a1 -0,813168 0,0351222 
Q62383 Supt6h -0,802911 0,0340156 
Q3UMF0 Cobll1 -0,788507 0,0366275 
E9Q4K7 Kif13b -0,788062 0,0401333 
O35988 Sdc4 -0,762921 0,0390185 
J3QJX0 Cul4b -0,731063 0,0271875 
G5E898 Ppl -0,730015 0,0349278 
Q8R1K1 Ubac2 -0,721819 0,040018 
Q9Z0K8 Vnn1 -0,720036 0,0351905 
Q8BKG3 Ptk7 -0,718419 0,0342222 
P17156 Hspa2 -0,699641 0,0390092 
Q05793 Hspg2 -0,69063 0,0275111 
Q91V41 Rab14 -0,683975 0,0322807 
Q569Z5 Ddx46 -0,669953 0,03587 
Q8R0G9 Nup133 -0,66988 0,0349895 
Q99KI3 Emc3 -0,666976 0,0340714 
O35379 Abcc1 -0,654475 0,0347363 
Q9WVK4 Ehd1 -0,65194 0,0341231 
Q8C391 Exoc4 -0,651399 0,0336533 
Q9D2R0 Aacs -0,640354 0,0458279 
Q5SVG5 Ap1b1 -0,639239 0,0263404 
Q6PGF7 Exoc8 -0,620831 0,0253659 
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F7BPW6 Sec16a -0,61018 0,0341311 
Q62261 Sptbn1 -0,602572 0,0397404 
Q91V89 Ppp2r5d -0,59464 0,0299821 
Q6TXD4 Dnmbp -0,548996 0,0210541 
F8VPK5 Rock2 -0,546932 0,0339054 
P46460 Nsf -0,546922 0,0450171 
D3YX34 Dctn1 -0,543849 0,026913 
A2AWA7 Rabgap1 -0,513952 0,040177 
F8VQJ3 Lamc1 -0,511355 0,0347419 
Q99MR8 Mccc1 -0,510445 0,0341806 
Q8C8U0 Ppfibp1 -0,508217 0,0446356 
Q91W86 Vps11 -0,497033 0,0359647 
Q9QXZ0 Macf1 -0,476136 0,0430776 
Q6P9Q4 Fhod1 -0,454446 0,0345783 
Q9CYH2 Fam213a 0,406607 0,0353617 
O08677 Kng1 0,524401 0,045525 
P55065 Pltp 0,567094 0,0452562 
E9Q5B6 Hnrnpd 0,583015 0,0338765 
Q922U1 Prpf3 0,614512 0,024 
Q99JY9 Actr3 0,673098 0,0156111 
Q04447 Ckb 0,678408 0,0171071 
Q8BH95 Echs1 0,710599 0,0421754 
Q9DBM2 Ehhadh 0,753224 0,0139565 
Q61233 Lcp1 0,776454 0,045784 
Q3TQP6 Me1 0,822377 0,00933333 
Q3TC93 Hs1bp3 0,822602 0,0364184 
Q99KK9 Hars2 0,847471 0,0100714 
O70310 Nmt1 0,849706 0,0140952 
Q9CY58 Serbp1 0,953535 0,0171111 
P58774 Tpm2 1,10221 0,0277273 
Q61553 Fscn1 1,10559 0,00771429 
P68040 Gnb2l1 1,19011 0,0108462 
Q8K114 Ints9 1,24664 0,0347528 
Q61781 Krt14 1,50661 0,0211389 
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6.3 18F-FDG time activity curve example 
 
Figure 6.2.1: Time activity curve example of 18F-FDG study. The curve shows that first a signal from 18F-FDG is 
detected in the aorta (red curve) of dams directly after injection at minute 0 to 5 where the curve also has its peak. 
After some minutes, the signal increases in fetal tissue (green curve) and maternal spinal cord (blue curve) and 
reaches near maximum in spinal cord after about 10 minutes while the signal continuous to increase in fetal tissue 
until about minute 50. 
 
6.4 Fatty acids found in the HFD 
Table 6.2: Excerpt of the fatty acids found in the HFD used in this study. Table adapted from Kretschmer et al. [81], 
Table S1 and modified. 
Ingredient Unit Content 
Crude fat mg/kg 350,921 
Crude protein mg/kg 204,600 
Saccharides mg/kg 256,291.3 
Metabolizable Energy kcal/kg 5,297.347 
Palmitic acid C-16:0 mg/kg 84,800 
Palmitoleic acid C-16:1 mg/kg 10,401 
Stearic acid C-18:0 mg/kg 48,600 
Oleic acid C-18:1 mg/kg 139,135 
Linoleic acid C-18:2 mg/kg 31,550 
Linolenic acid C-18:3 mg/kg 3,565 
Arachidic acid C-20:0 mg/kg 5,200 
Eicosaenic acid C-20:1 mg/kg 2,595 
Arachidonic acid C-20:4 mg/kg 120 
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